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Ab st r a c t .
CYP3A4 is the most abundant P450 enzyme expressed in the human liver and it is 
responsible for the metabolism of approximately 50% of all clinically administrated 
drugs. The CYP3A4 gene is transcriptionally regulated by xenobiotics and previous work 
has demonstrated the first 300bp of proximal promoter to be the minimal requirement for 
such activation. Several nuclear receptors (CAR, SXR) have been shown to be involved 
in the induction of the CYP3A4 gene. The aim of this work was to further delineate the 
molecular basis of CYP3A4 gene expression.
In vitro DNase I footprinting was carried out using HepG2 nuclear extracts to map the 
sites of DNA-protein interaction within the -301/+7 region of the CYP3A4 gene. Putative 
protein assignment for these sites using in silica analysis revealed the potential binding of 
transcription factors previously shown to be involved in the regulation of other GYP 
genes (Spl, HNF3 and C/EBPa) at the identified protein-DNA interaction sites. These 
regulatory regions were then disrupted by mutagenesis and their functional effect 
assessed by transient transfections of reporter gene plasmids into HuH7 hepatoma cells. 
Statistically significant reductions of reporter gene expression were observed when 
putative C/EBPa and HNF sites were altered, in both the basal and rifampicin (SXR 
ligand) induced states. This finding suggests the involvement of proteins binding at these 
sites in the regulation of the CYP3A4 gene expression.
An examination of the CYP3A4 promoter (-1056/+7) from 11 human DNA samples 
exhibiting a 14.3 fold variability in CYP3A mediated metabolism failed to show the 
presence of mutations. Protein-DNA interaction analysis were carried out within the 
newly identified CYP3A4'^1E and alleles as well as the CYP3A4 allele.
The results implicate the Spl transcription factor in the regulation of the CYP3A4 gene, 
albeit at a more distal binding site.
The findings described in this thesis suggest a substantial involvement of transcription 
factors other than SXR/CAR in expression of CYP3A4, Because of the polymorphic 
expression of several liver- and hormone-dependent transcription factors their role in 
CYP3A4 regulation must be taken into account to understand drug-induction mechanisms 
and assess variability in inter-individual drug response.
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bp Base Pair
BSA Bovine Serum Albumin
CAR Constitutive Androstane Receptor
cDNA complementary Deoxyribonucleic Acid
CYP Cytochrome P450
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mut Mutant
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TCPOBOP 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene
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UV Ultra-Violet
VDR Vitamin D Receptor
WT Wild Type
XRE Xenobiotic Response Element
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Ch a pter  1 -  In tr o d u c tio n
1.1. Cytochrome P4S0 enzymes.
1.1.1. Drug metabolism.
In order to maintain physiological homeostasis, a vast number of exogenous or 
endogenous compounds must be removed from the organism or transformed to modify 
their biological activity. Water-soluble molecules can be readily excreted whereas 
hydrophobic molecules must go through a biotransformation process to increase their 
water solubility. These reactions are called drug metabolism and are divided in two 
phases. Phase I consists of the addition or the umnasking of a functional group (e.g. 
hydroxyl) on the molecule to be excreted. This may be followed by a phase II reaction 
where a conjugate (e.g. glucuronic acid or sulphate) is added to the product (and possibly 
to the substrate) of the phase I metabolism (Gibson and Skett, 1994). The metabolites 
may be further processed, for instance compounds conjugated to glutathione may be 
involved in the biosynthesis of mercapturic acid conjugates (Gibson and Skett, 1994). 
The excretion of the biotransformed compounds may later take place through the kidneys 
(urine), the gastrointestinal tract (bile and faeces), the lungs (exhaled air) and body fluids 
such as sweat and breast milk (Taylor and Reide, 1998).
1.1.2. The cytochrome P450 supcrfamily.
A whole vai'iety of phase I reactions are canied in the presence of NADPH and oxygen 
by the mixed fimction oxidase (MFO) system, which is located in the endoplasmic 
reticulum of the cell and is composed of the NADPH cytochrome P450 reductase, lipids
and cytoclii'ome P450 enzymes (Gibson and Skett, 1994). Cytochrome P450 enzymes are 
the terminal elements of an electron transfer chain and they are haeme containing 
proteins (or haemoproteins) composed of a ferric protoporphyrin IX prosthetic group non 
covalently associated to an apoprotein which binds the substrate and the oxygen 
necessary to the MFO reaction (Gibson and Skett, 1994). They catalyse the 
biotransformation of compounds (RH) into hydroxylated metabolites (ROH) in the 
presence of NADPH and molecular oxygen according to the following stoichiometry: 
NADPH + H"" + O2 + RH NADP"  ^+ H2O + ROH 
Cytochrome P450’s (or CYP) constitute a superfamily of drug metabolism enzymes 
which probably arose 3.5 billion years ago and are found in a vast number of taxa in the 
animal and plant kingdom, filamentous fungi, yeast and bacteria (Nelson et al, 1996). It 
is thought the first CYP enzymes were involved in endogenous compound metabolism 
and that they later were involved in xenobiotic detoxification processes (Lewis et al, 
1998). Because of the increasing number of CYPs identified, a standard nomenclature has 
been agreed. The cytochi’ome P450 enzymes have been grouped in families and 
subfamilies according to the degiee of amino acid sequence similarity (Nelson et al, 
1996). A family contains enzymes with 40 % or greater similarity in the amino acid 
sequence of the apoprotein. The homology is greater within a sub family, where there is a 
protein similarity greater than 55 % (Nelson et al, 1993). For instance CYP3A4 
represents the fourth gene in the A subfamily of the CYP3 family and CYP3A4 is the 
protein. More recently a higher order of nomenclature, the clans, has been proposed 
(http ://drnelson.utmem.edu/Clans. June 2003). A clan contains several families on the 
basis of their structural similarity and for instance the CYP3 clan contains CYP3, 5, 6, 9, 
13, 25, 28, 30 and 45 (Nelson, 1999). The diagram in figure 1.1 shows an example of 
CYP gene clans in animal species.
A depository of CYP data is frequently updated and is available on the Internet (Dr David 
Nelson, Cytochi'ome P450 homepage, http://dmelson.utmem.edu/cvtochromeP450.html. 
June 2003).
Figure 1.1. The cytochrome P450 clans (Taken from Nelson, 1999). Only one member 
gene for each family is represented within a given clan. This diagram represents animal 
CYP genes.
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1.1.3. Major CYP enzymes involved in drug metabolism.
The human CYP enzymes involved in xenobiotic metabolism mainly belong to the 
CYPl, 2 and 3 families (Wrigliton and Stevens, 1992). The CYPl family enzymes 
(CYPlAl, 1A2 and IBl) transform and sometimes bioactivate several environmental 
pollutants especially the procarcinogen polyaromatic hydrocarbons (Nebeit and Russell, 
2002). The CYP1A2 enzymes appear to metabolise 10-20 dmgs, whereas the other CYPl 
family members may not be greatly involved in the metabolism of pharmaceutical 
compounds (Nebert and Russell, 2002). With 13 subfamily and 16 genes in human, the 
CYP2 family is one of the most important in drug metabolism (Nebert and Russell, 
2002). It contains the CYP2C subfamily (CTP2C5, P, 18 and 19) that is, at least partially, 
involved in the transformation of half of the commonly used drugs (Nebert and Russell, 
2002). The CYP2D6 gene encodes an enzyme which catalyses the transformation of a 
large number of dmgs (more than 75, Nebert and Russell, 2002), including the 4- 
hydroxylation of debriquisone. Population studies of debriquisone metabolism revealed 
the existence of a bimodal distribution, which consists in poor (PM) and extensive (EM) 
metabolisers (Gibson and Skett, 1994). Analyses of PM patient livers allowed the 
identification of a genetic polymorphism in PM subjects, resulting in the production of an 
incorrectly spliced CYP2D6 mRNA and consequently in the absence of the CYP2D6 
protein (Gonzalez et al.  ^ 1988). The identification of such mutation provided a molecular 
basis for the observed inter-individual variability. The only member of the CYP2E 
subfamily, CYP2E1, is another important enzyme since it induced by a variety of small 
organic molecules (e.g. ethanol) and that many of the metabolites are more chemically 
reactive than the substrates, creating a possible toxicological risk such as duiing 
carcinogen activation (Wrigliton and Stevens, 1992). Other CYP2 enzymes such as 
CYP2A6, CYP2A13, CYP2F1 and the phénobarbital inducible CYP2B6 are also capable 
of transforming drugs (Nebert and Russell, 2002). The CYP3 gene family has a very 
important role in drug metabolism since its members are known to metabolise at least 120 
frequently prescribed pharmaceutical compounds (Nebert and Russell, 2002) together
with endogenous steroid hormones and bile acids. The four members of the CYP3A 
subfamily are described below (section 1.2).
The three CYP enzyme families described above aie also capable of transforming 
endogenous substrates such as arachidonic acid and its eicosanoid metabolites, which are 
signalling molecules for a diversity of biological processes such as e.g. platelet 
aggregation or disaggregation (Nebert and Russell, 2002).
1.2. Human CYP3A subfamily.
Due to the high amino acid sequence similarity obseived in the CYP3 family, only one 
subfamily {CYP3Â) exists with four different genes having been described so far in 
human: 3A4, 3A5 and 3A7 (Nelson et al, 1996) and the newly identified CYP3A43 
(Domanski et a l, 2001). The CYP3A genes are located on the short arm of cliromosome 7 
(7q21-q22.1) (Nelson et al, 1996) and the locus has recently been mapped (see figure 
1.2) (Finta and Zaphiropoulos, 2000; Gellner et al, 2001). Early reports described 
another CYP3A gene, CYP3A3 (Nelson et al, 1996), however, its existence has now 
been refuted since it appears that it was a pseudogene (CYP3P) (Finta and Zaphiropoulos, 
2000; Gellner et a l, 2001).
CYP3 is a very important family of drug metabolising enzymes because of their 
occurrence and their ability to metabolise a wide range of substrates (Wrighton and 
Stevens, 1992). It is estimated that 60% of all currently used drugs are metabolised by 
enzymes horn this family which represents approximately 30% of the total hepatic CYP 
content in man (see Plant and Gibson, 2003 and references therein).
Figure 1.2. Genomic structure of the human CYP3A locus (drawn to scale and adapted 
from Finta and Zaphiropoulos, 2000; Gellner et al, 2001). The grey arrows represent the 
coding regions of the different CYP3A subfamily members and their relative orientations. 
The black boxes represent two pseudogenes {CYP3AP2 and CYP3AP1).
CYP3A43 CYP3A4 CYP3A7 CYP3A5
20 kb CYP3AP2 CYP3AP1
1.2.1. CYP3A4.
CYP3A4 is found in the majority of individuals and is the major hepatic P450 enzyme in 
healthy adult liver, however, it is not expressed in foetal liver (Lacroix et al, 1997). 
Additionally, CYP3A4 mRNA has been detected using in situ hybridisation in 
extrahepatic tissues such as the stomach, colon, oesophagus and in the mucosa of the 
small intestine segments (McKinnon et al, 1995). This enzyme will be further described 
in section 1.3.
1.2.2. CYP3A5.
CYP3A5 appears to be polymorphically expressed in adults and was found to be 
expressed only in a fraction of the population tested, ranging from 10-20 % in 
Caucasians, 33% in Japanese to 55% in African Americans (Lamba et a l, 2002). This 
polymorphic expression seems to be caused by two mutations in the CYP3A5 coding 
region, teimed CYP3A5'^3 and CYP3A5^6 (Kuehl et al, 2001). These two mutants 
encode mRNA molecules with disrupted splice sites which result in either a truncated 
protein at amino acid 102 {CYP3A5^3) or a missing exon 7 and a truncated protein at 
residue 184 (CYP3A5^6) (Kuehl et al., 2001). The enzyme seems to be able to metabolise 
a lower number of substrates than CYP3A4 (see section 1.2.5), therefore its contribution 
to hepatic drug metabolism may not be significant (Wrighton and Stevens, 1992).
1.2.3. CYP3A7.
CYP3A7 is only present in human foetus and is the major foetal hepatic enzyme 
(Wrighton and Stevens, 1992). Using a polyclonal antibody reacting against CYP3A4 
and CYP3A7 it was found that during development (foetus, newborn, adult) the hepatic 
CYP3A levels remain fairly constant (Lacroix et a l, 1997). However, the relative 
amounts of these enzymes vary, CYP3A7 being the dominant form in foetal liver and
after birth CYP3A4 level rises rapidly and reaches adult hepatic content after one week 
(Lacroix et a l, 1997).
1.2.4. CYP3A43,
Using genetic analysis of the CYP 3A locus (Gellner et al, 2001) and RT-PCR (Domanski 
et al, 2001), the CYP3A43 gene was identified. Messenger RNA from this gene was 
detected in the liver, kidney, pancreas and prostate, the latter organ being the site with the 
highest level of expression. Although the CYP3A43 gene is inducible by rifampicin 
(Gellner et al, 2001) and the enzyme is able to catalyse testosterone hydroxylation 
(Domanski et al, 2001), a classic CYP3A reaction, its role in drug metabolism has yet to 
be established.
1.2.5. Drug metabolism by CYP3A enzymes.
Several studies have identified a degree of variability in the expression level of the 
CYP3A enzymes present in the human liver (reviewed in Lamba et a l, 2002). It is 
therefore important to characterise the relative metabolic capability of each CYP3A 
enzyme in order to determine which enzymes are likely to affect hepatic drug 
metabolism. In a comparative study of CYP3A4, 5 and 7 mediated metabolism, the 
transformation of 10 CYP3A substrates was assessed in vitro (Williams et al, 2002). 
Overall it was found that, for the substrates tested, metabolite formation was lower with 
CYP3A7 compared to CYP3A4 and CYP3A5 and that for several substrates (e.g. 
nifepidine) CYP3A4 was faster (and therefore more efficient at metabolising) than 
CYP3A5. In another study the substrate interaction with the CYP3A enzyme active site 
was assessed by measuring the inhibition of 7-benzyloxy-4-trifluoromethylcoumarin 
(BFC) 0-dealkyIation by diverse compounds (reviewed in Ekins et al, 2003). The results 
presented in table 1.1 demonstrate that for all chemicals used, the Inhibitory 
Concentration 50 (IC50) was the lowest for CYP3A4, which suggests a higher affinity of 
the compounds tested with the enzyme active site. Taken together these studies suggest
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that among the CYP3A subfamily members, CYP3A4 is the most significant in terms of 
metabolic capability, making it the most important enzyme in hepatic drug metabolism.
Table 1.1. Mean IC50 values for inhibitors of CYP3A4,5 and 7 mediated metabolism 
of 7-benzyloxy-4-trifIuoromethylcoumarin (adapted from Ekins et al, 2003).
Test substance CYP3A4 
IC50 (|iM)
CYP3A5 
IC50 (pM)
CYP3A7 
IC50 (pM)
Astemizole 0.59 15 27
Cisapride 0.038 5.4 16.5
Clotrimazole 0.002 0.042 0.046
Cyclosporin A 0.46 35 42
Erytlu'omycin 1.8 7 7
Ketoconazole 0.016 0.1 0.42
Mibefradil 0.006 0.23 0.44
Midazolam 0.46 5.6 24
Nicardipine 0.008 0.14 0.35
Nifepidine 6.6 12 14
Nimodipine 0.62 3 3.6
Terfenadine 1.4 11 29
Troleandomycin 0.36 1.52 8.9
Verapamil 0.12 2.2 9.1
1.3. The CYP3A4 enzyme.
The first CYP3A protein was discovered in the female rat (Lu et al, 1972). This protein 
is inducible and has the same spectral properties as those induced by treatment with 
phénobarbital in rats but has a different substrate specificity. Watkins and co-workers 
(Watkins et a l, 1985) reported the identification of a 52 kDa protein (called Human Liver 
P450 or HLp, now CYP3A4) induced by dexamethasone, phenobarbitone and PCN.
1.3.1. Substrates.
CYP3A4 has a very wide range of substrates and can metabolise environmental 
pollutants, pharmaceutical compounds or endogenous molecules such as testosterone (Li 
et a l, 1995). About 60% of clinically used drugs are metabolised by this enzyme 
(Cholerton et al, 1992). The substrate size varies from acetaminophen (M=151) to 
cyclosporine A (M=1201) (Guengerich, 1999). The various types of reactions performed 
by CYP3A4, as well as examples of substrates are given in table 1.2. Since this large 
number of substrates may compete for the CYP3A4 active site (Shou et a l, 1994) and 
may increase the protein levels (see below) there is therefore a substantial potential for 
drug-drug interactions in man (see section 1.3.3).
Table 1.2. Examples of reactions performed by CYP3A4 (adapted from Li et al, 
1995).
Chemical Use / Occurrence Metabolic Pathway
Acetaminophen
Aflatoxin B1
(Z)-Benzaldoxime
Clonazepam
Cocaine
Rapamycin
Testosterone, Oestradiol 
Zonisamide
Analgesic
Food hepatocarcinogen 
Insect growth regulator 
Anticonvulsant 
Recreational drug 
Antibiotic, Immunosuppressant 
Steroid hormones 
Anticonvulsant
N-oxidation
C-oxidation
Dehydration
Nitroreduction
N-demethylation
O-demethylation
C-hydroxylation
Reductive deamination
1.3.2. Regulation of CYF3A4 enzyme activity.
CYP3A4 substrates are also often inducers, the later being known to influence the 
production of enzyme in an active form. However, several compounds can alter the 
activity of this enzyme by directly interacting with the protein. Binding of molecules to 
the CYP3A4 enzyme and steric interactions between substrates (at least in vitro) can have
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regulatory effects on CYP3A4 catalytic activity (Shou et al, 1994). In another study it 
was found that mifepristone (RU 486) inliibits CYP3A4 by covalent binding to the 
apoprotein (He et a l, 1999) and is therefore a suicide substrate.
1.3.3. Drug-drug interactions and first-pass metabolism.
The levels of CYP3A4 activity may influence drug availability in the organism. If a drug 
is metabolised and inactivated by hepatic or enteric CYP3A4, an equivalent oral dose will 
remain in patients with a low metabolic ability for a longer time than in efficient 
metabolisers, potentially altering the clinical effect observed. Some authors report 
interactions between CYF3A4 inducers, when co-administered with other drugs. For 
instance the rate of cyclosporin A metabolism was altered by the presence of several 
classes of pharmaceutical compounds (e.g. rifampicin or cortisol), in primary cultures of 
human hepatocytes (Pichard et al, 1990). Such a situation may arise in vivo, for instance 
in organ transplant patients where the immunosuppressor drug cyclosporin A may be 
used to avoid an immune reaction against the foreign organ, in conjunction with 
rifampicin which may be administered to treat an infection. This may result in a decrease 
of cyclosporin A concentration in the plasma below the therapeutic level (because of the 
increased drug clearance) and may eventually lead to negative outcomes such as graft 
rejection. Some CYP3A4 protein inducers are also loiown to increase the level of 
intestinal P-glycoprotein which act as drug efflux pumps (Synold et al, 2001). Together 
with other drug transporters (Hall et a l, 1999) these epithelial proteins contribute to the 
elimination of drugs and therefore their induction further increases the clearance of the 
substrate/inducers. This phenomenon, known as first pass metabolism (Hall et al, 1999), 
is of critical importance in dmg therapy.
1.3.4. CYP3A4 gene structure.
The CYP3A4 gene as well as about Ikb of the 5’ flanking region was first described by 
Hashimoto and co-workers (Hashimoto et al, 1993). The gene is approximately 27kb 
long, the coding region is composed of 13 exons and the exon-intron organisation of 
CYP3A4 is very similar to that of CYP3A7 (expressed in human foetus) and CYP3A2
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(rat). There is a 91% similarity between the first Ikb of regulatory region 5’ to the 
transcription start site of CYP3A4 and CYP3A7 (Hashimoto et a l, 1993). More recent 
studies report the cloning of 13 kb of CYP3A4 promoter (Goodwin et a l, 1999) and 8.8 
kb of CYP3A7 promoter (Bertilsson et a l, 2001). Both of these latter groups describe 
functional steroid and xenobiotic receptor (SXR) and constitutive androstane receptor 
(CAR) binding sites within a sequence named the xenobiotic responsive enhancer module 
(XREM, see sections 1.5.3.2 and 1.5.3.3) located approximately 8 kb upstream the 
transcription start. The promoter regions for both CYP3A4 and CYP3A7 share 90 % 
sequence identity up to -8.8kb (Bertilsson et al, 2001). Early in silico analysis of the first 
kb of promoter suggested the presence of several putative binding sites for regulatory 
elements such as p53, HNF5, HNF4, ER (oestrogen receptor), GR (glucocorticoid 
receptor), AP3 (Activator protein 3), octamer 1 (Hashimoto et al, 1993).
1.4. Gene regulation mechanisms in eukaryotic organisms.
Eukaryotic gene expression is a complex process involving the transcription of RNA 
from the DNA template by the RNA polymerase II and the translation of the information 
on the RNA into the amino acid sequence of proteins. Transcription involves several 
steps from chromatin structure alterations which allow transcription initiation to the end 
of translation, all of which are likely to be subject to regulatory mechanisms (Latchman, 
1998). Figure 1.3 provides an overview of the process.
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Figure 1.3. Stages lu eukaryotic geue expression where regulation eau potentially 
take place (taken fi'om Latchman, 1998).
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1.4.1. Transcription activation.
Transcription activation represents one of the initial steps of gene expression and 
therefore its regulation can be critical for the subsequent steps of gene activation. This 
process is characterised by the recmitment of specialised proteins to the regulatoiy 
regions of genes (Tjian and Maniatis, 1994). This involves the assembly of the TATA- 
box binding protein with associated proteins (TFIID) together with another transcription 
factor, TFIIA. This is followed by the binding of more associated factors (TFIIB, F, H 
and E) and finally by the RNA polymerase II which becomes activated upon 
phosphorylation of its C terminal domain (Bmatowski, 1994). The formation of the 
complex is favouied by the binding of transcription factors to regulatory sequences 
situated in various regions surrounding the coding region or even contained within the 
introns (Figure 1.4). These factors are thought to stabilise the transcription machinery 
(Latchman, 1998). The binding of these transcription apparatus proteins is strongly 
influenced by the chromatin structure surrounding the regulatory sites (Bonifer, 1999; 
Latchman, 1998). Chromatin contains the DNA molecules wrapped around histone 
proteins forming nucleosomes (see figure 1.4). This chromatin environment may not 
allow transcription when it is in a compacted form where the DNA is tightly associated 
with the nucleosomal proteins. However, prior to transcription and as part of a range of 
cellular processes, chi'omatin may undergo structural changes allowing access of the 
transcription machinery to the DNA regulatory regions and coding regions. This is 
carried out by ATP driven chromatin remodelling complexes, which bind to nucleosomes 
and modify the interactions between the histones and the DNA (reviewed in Sudarsanam 
and Winston, 2000).
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Figure 1.4. Chromatin structure and potential location of the regulatory sequences.
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1.4.2. Nuclear receptors.
Nuclear hormone receptors form a superfamily of transcriptional regulators involved in a 
variety of developmental and physiological processes (Mangelsdorf et al, 1995). These 
proteins are evolutionary conserved and a schematic representation of the common 
structural features is described in figure 1.5. Briefly, these receptors contain a DNA 
binding domain, a ligand binding domain, together with various other regulatory regions 
which allow for protein-protein interactions or co-activator recruitment (Aranda and 
Pascual, 2001). With the exception of the Constitutive Androstene Receptor (CAR, see 
section 1.5.3.3), which is constitutively active and requires no exogenous ligands to 
activate target genes (Baes et al, 1994), these receptors are ligand activated transcription 
factors which transcriptionally modulate target gene expression upon activation. They 
may act as monomers, homodimers or heterodimers with the retinoid X receptor and bind 
specific DNA response elements or interact with other regulatory pathways for instance 
through protein-protein interactions (Aranda and Pascual, 2001). Nuclear receptors 
interact and form complexes with an array of co-activator and co-repressor proteins 
(McKenna and O'Malley, 2002). The function of these co-regulators vary as they can 
sometimes be phosphorylated by MAP kinases, act as bridging factors between other
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regulatory proteins or possess histone modifying activities (McKenna and O'Malley, 
2002). For instance in an immunoprécipitation experiment using a tagged Peroxisome 
Proliferator Activated Receptor alpha (PPARa), a total of 25 peptides present in nuclear 
extracts from rat liver were found to interact with the liganded receptor (Surapureddi et 
al, 2002). Such proteins often contain a LXXLL motif (where L represents a lysine and 
X represents any amino acid), wltich allows for interaction with the AF2 domain in the C- 
terminal ligand binding domain of the nuclear receptor protein (see figure 1.5). These 
interactions bring further complexity to the gene regulation process (McKenna and 
O'Malley, 2002). In addition to their role in mediating signals from xenobiotic exposure, 
nuclear receptors may mediate the effect of several hormones (e.g. thyroid hormone, 
steroids) or cellular metabolites (e.g. some lipophilic molecules) (Aianda and Pascual, 
2001) providing them with endogenous roles. Some receptors, loiown as ‘orphan nuclear 
receptors’, have no loiown endogenous ligands (Aranda and Pascual, 2001). As for the 
members of the cytochi'ome P450 superfamily, the increasing number of nuclear 
receptors identified prompted researchers to adopt a nomenclatuie system based on 
protein sequence homology (Nuclear Receptor Nomenclature Committee, 1999). The 
diagi'am in figure 1 .6  shows an example of phylogenetic tree representing the sequence 
homology between 65 nuclear receptors from different families. For clarity the usual 
protein names will be used in this report instead of the nomenclature name.
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Figure 1.5. Schematic representation of a nuclear receptor (taken from Aranda and 
Pascual, 2001). The DNA binding domain (region C) is involved in the recognition of 
specific DNA sequences (response elements). The region E and F contain the ligand 
binding domain as well as a dimérisation surface. Those two domains are connected by a 
linker domain (D). The ligand independent AF-1 transctivation domain is located in the 
NH2 terminal region (region A/B) and the ligand dependent AF-2 transctivation domain 
is contained within the COOH-terminal of the receptor
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Figure 1.6. Phylogenetic tree connecting 65 known NR genes (taken from Nuclear 
Receptor Nomenclature Committee, 1999). The sequences clustered here are from 
vertebrate, arthropod and nematode species. The boxed numbers represent the bootstrap 
values for each subfamily.
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1.4.3 CYP gene regulation.
1.4.3.1. Potential levels of CYP gene regulation.
Cytochrome P450 enzyme activities may vary in order to adapt to the organism 
physiological needs and/or environmental stimuli. A number of CYP genes are expressed 
constitutively but their basal level of expression may be altered following exogenous or 
endogenous signals (e.g. presence of a xenobiotic inducer or hormone). This therefore 
allows a rapid response to the change in chemical levels within the body. The inducibility 
of CYP genes may involve regulatory mechanisms at several levels of the gene 
expression process as described above (figure 1.4):
-at the transcriptional level (gene activation or repression),
-at the post-tianscriptional level (inRNA splicing, transport, stabilisation, translocation), 
-at the protein level (stabilisation of the protein without increase in mRNA).
1.4.3.2. An example of CYP gene regulation: induction of the CYPlAl gene.
Although some regulation may take place at the post-transcriptional level, most of the 
CYPlAl gene induction by aromatic hydrocarbons takes place at the transcriptional level 
(Denison and Whitlock, 1995). The diagram shown in figure 1.7 summarizes the 
induction process. The aiyl hydrocarbon receptor (Ah receptor) is a cytosolic protein 
associated with heat shock protein 90 in the inactive state. It is activated upon binding of 
the inducer (e.g. 2,3,7, 8  tetrachlorodibenzo-p-dioxin or TCDD) and following 
heterodimerisation with the Ah receptor nuclear translocator (Arnt protein) the receptor is 
translocated into the nucleus, where it binds the Xenobiotic Response Element (XRE) 
and activates gene transcription (Denison and Whitlock, 1995; Fujii-Kuriyama et al,
1992). Post translational modifications of the protein, such as phosphorylation may also 
alter the transcriptional effect of AhR (Mimura and Fujii-Kuriyama, 2003). Studies of the 
CYPlAl gene promoter revealed that c/i'-acting DNA elements other than the XRE might 
be active. For instance, it appears that the induction and expression of the CYPlAl gene 
is modulated by several other transcription factors such as the zinc finger protein Spl
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(Fujii-Kuriyama et al, 1992). More recent work suggests that the local chromatin 
environment is modified by the liganded AhR, which allows other proteins such as Spl to 
bind the promoter (Mimura and Fujii-Kuriyama, 2003). Among the various AhR gene 
targets, including detoxification enzymes such as other CYPl family members or the 
phase 2 enzyme UDP glucoronosyl transferase, a protein called Ah Receptor Repressor 
(AhRR) is also involved in the regulation process. It associates with the 
heterodimerisation partner Arnt, limiting the interactions with AhR, and also binds to the 
XRE acting as a repressor (Mimura and Fujii-Kuriyama, 2003) thereby creating a 
negative feedback loop.
Figure 1.7. Mechanisms of transcriptional activation by AhR and negative feedback 
regulation of AhR by AhRR. See text for a detailed discussion, (taken from Mimura and 
Fujii-Kuriyama, 2003)
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1.5. Regulation of the CYP3A4 gene.
1.5.1. CYP3A4 is transcriptionally activated.
CYF3A genes are known to be induced by a variety of compounds including the synthetic 
glucocorticoid dexamethasone, the antibiotic rifampicin and pregnane compounds such as 
pregnenolone 16a carbonitrile (Gonzalez et a l, 1993). Using nuclear run-on assays it has 
been reported that CYP3A1 is transcriptionally induced in immatuie rat livers (Telhada et 
al, 1992). Together with a substantial body of evidence (Honkakoski and Negishi, 2000), 
this suggests that the CYP3A4 gene induction is transcriptionally regulated. Although the 
induction mechanism has not been completely elucidated, some of the major regulatory 
proteins have been identified (see below).
1.5.2. CYP3A4 regulatoiy regions.
Following the cloning of CYP3A4, the gene structure within the genomic context has 
been analysed and descriptive studies of the promoter were reported (see above section 
1.3.4) (Hashimoto et a l, 1993). The CYP3A4 proximal promoter region was established 
to be an important regulatory region by reporter gene assay and sequence analysis 
revealed the presence of putative binding sites for several transcription factors such as the 
octamer binding protein (Oct 1), activator protein 3 (AP3), progesterone receptor / 
glucocorticoid receptor (PR/GR), hepatocyte nuclear factor 4 and 5 (HNF4 and 5), 
oestrogen receptor (ER), p53 and CCAAT-binding protein (CP-1) (Hashimoto et al,
1993). A distal enhancer (XREM) located from -7836 to -7607 in the 5’ flanking region 
was later discovered which contains several functional binding sites for members of the 
nuclear receptor superfamily (Goodwin et a l, 1999). The diagram presented in figure 1.8 
represents the putative binding sites in the proximal promoter and the enhancer of the 
CYP3A4 gene (Gibson et a l, 2002). It should be noted that the HNF5 factor was later 
found not to exist (Schiem et a l, 2002) and that some of the sequences claimed to be 
similar to common response elements are not similar to consensus sequences (personal 
observation), such as those found in the Transfac database (see section 2.9.8.).
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Figure 1.8. The CYP3A4 promoter structure and putative transcription factor 
binding sites, as predicted by bioinformatic analysis (taken from Gibson et al, 2002)
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P53
consensus sequence recognized by the gene-activating factor, activating 
protein 3
basal ti'anscription element involved in maintenance of the basal level 
of transcription in many genes, possible tlii’ough the BTE-binding 
protein (BTEB) in the liver
consensus sequence present in many genes and binds the liver-specific 
protein C/EBP (CCAAT enhancer-binding protein) and the ubiquitous 
transcription factor CPI (CCAAT-protein-1 ), has a major role in 
determining the efficiency of the promoter
located upstream of the CAAT box and is thought to be involved in 
transcriptional activation; known to bind the transcription factor Spl 
a direct repeat with n bp spacing (AGTTCA-N3-AGTTCA) that binds 
PXR:RXR heterodimers and activates CYP3A-responsive genes 
receptor-response elements with similar consensus sequences; binding 
of the ER, PR and GR receptors involved in both positive and negative 
regulation of gene transcription in response to oestrogens, progestogens 
and glucocorticoids
two everted copies of the AG(G/T)TCA motif, separated by six 
nucleotides; binds the PXR:RXR receptor complex and activates 
xenobiotic-dependent gene transcription in CYP3As; also locus of 
CAR binding
regulatory motifs (hepatocyte-specific, nuclear ti'anscription factors) 
that bind liver-specific transcription factors HNF-4 and HNF-5; also 
involved in the I'egulation of CYP2B genes (HNF-4) and transferin gene 
(HNF-5)
conserved octamer motif present in many genes (including CYPl Al), 
binding members of the octamer factors family, resulting in the 
up/down regulation of responsive genes.
found in all eukaryotic genes and essential for transcription; recognized 
by the TATA binding protein (TBP).
consensus sequence that binds the tumoui' suppressor protein, p53_____
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1.5.3. Regulation of the CYP3A4 transcriptional activation by nuclear receptors
It is becoming increasingly evident that nuclear receptors are involved in the regulation 
of CYP genes. Additionally CYP enzyme products can in turn become nuclear receptor 
ligands and activate other genes (Honkakoski and Negishi, 2000). As will be shown 
below the regulation mechanisms can be direct or indirect and also allow for the 
coordinate regulation of several genes, producing a whole body of response to xenobiotic 
exposure.
1.5.3.1. The glucocorticoid receptor (GR, NR3C1).
In vivo and in vitro work on rat P450 revealed that the isoform initially identified as 
inducible by the antiglucorticoid PCN (Lu et a l, 1972) was also stimulated by 
glucocorticoid exposuie (Schuetz and Guzelian, 1984) especially by dexamethasone. This 
P450 enzyme was in fact the product of a gene belonging to the CYP3A subfamily 
(Nelson et al, 1993; Nelson et al, 1996) and several of the subfamily members were 
found to be inducible by glucocorticoids in various cell models (Schuetz et al, 1993). 
Early attempts to provide a molecular mechanism for the induction process aimed to 
demonstrate the involvement of the glucocorticoid receptor (GR). Firstly two studies on 
the rat CYP3A1 and CYP3A23 promoters (Quattrochi et al, 1995 and Huss et a l, 1996) 
failed to demonstiate a direct binding of the GR to the promoters. It should be noted that 
although these two genes have not been shown to be the same, their 5’ regulatory regions 
are identical (Quattrochi and Guzelian, 2001) and therefore CYP3A1 and CYP3A23 are 
likely to be the same gene. Secondly it was attempted to involve the GR by 
demonstrating its activation by the non-steroidal CYP3A inducer rifampicin (Calleja et 
al, 1998). However, subsequent attempts to corroborate this finding were unsuccessful 
(Herr et al, 2000; Jaffuel et a l, 1999). Examination of GR loiock-out mice revealed that 
the presence of the receptor is not essential for cyp3all induction by glucocorticoids 
(Schuetz et a l, 2000). In this study the authors do not report whether the expression of 
other receptors is affected by the loss of GR, therefore compensation mechanisms 
between different regulatory pathways may take place and the role of GR cannot be ruled 
out by this experiment. Although co-transfection experiments with a GR expression
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plasmid support the hypothesis of GR involvement (El Sankary et a l, 2000; Ogg et al,
1999), induction kinetic studies show that CYP3A activation does not resemble that of the 
tyrosine aminotransferase gene, a classical GR target (Schuetz and Guzelian, 1984) (also I
discussed in section 5.4). Together with the fact that the induction is not suppressed but |
enhanced by the addition of the anti-glucocorticoid RU486 (Williams et a l, 1997), this I
suggests the existence of an alternative regulatory pathway,
1.5.3.2. The steroid and xenobiotic receptor (SXR, NR 112)
The pregnane X receptor (PXR), a nuclear orphan receptor, was first discovered in the 
mouse in 1998 (Kliewer et al, 1998). Three groups subsequently reported the discovery 
of this protein in human (Lehmann et a l, 1998: hPXR; Blumberg et a l, 1998: Steroid 
and Xenobiotic Receptor, SXR; Bertilsson et al, 1998: Pregnane Activated Receptor,
PAR). For the purpose of clarity the term SXR shall be retained for the rest of this thesis.
It has been shown that SXR can bind a wide variety of know CYP3A4 inducers including 
rifampicin and dexamethasone (Lehmann et a l, 1998). Northern blot analysis revealed 
that SXR is highly expressed in the liver and the small intestine (Lehmann et al, 1998), 
where most of CYP3A4 is expressed (Guengerich, 1999). Reporter gene assays using 
various inducers show that mPXR (the mouse SXR) and SXR are not activated to the 
same degree by compounds, providing a possible explanation for the inter-species 
variability in CYP3A induction (Kliewer et al, 1998; Lehmann et a l, 1998). Similarly, 
the activation profile of SXR, GRa and ERa vary in the presence of various steroid and 
xenobiotic ligands (Blumberg et al, 1998).
Following activation by a ligand, SXR binds as an heterodimer with RXRa to a response 
element in the CYP3A4 promoter (Bertilsson et a l, 1998; Blumberg et a l, 1998; Kliewer 
et a l, 1998). This element, called everted repeat 6  (ER6 : TGAACTcaaaggAGGTCA), is 
situated in the 5’ region about 150bp upstream of the transcription start site. Additionally 
the receptor also binds to a direct repeat sequence (DR3: TGAACTtcaTGAACT) and can 
activate the rat CYP3A23 gene (Lelimann et a l, 1998).
Various endogenous and synthetic steroids, such as corticosterone and diethylstilbestrol, 
can bind to this receptor (Bertilsson et al, 1998; Blumberg et al, 1998; Kliewer et al.
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1998; Lelimann et al, 1998). However, the physiological concentrations of these steroids 
may be too low for activation (Kliewer et al, 1998). Therefore questions aie raised about 
whether SXR is a general steroid sensor or if it has a specific endogenous ligand 
(Blumberg et a l, 1998). However, recent evidence point towards a role of SXR as a 
sensor for the levels of bile acid and bile acid metabolites. Indeed litocholic acid and 3- 
keto litocholic acid were shown to bind the receptor and to induce cyp3all genes in mice 
(Staudinger et al, 2001; Xie et al, 2001).
The contribution of the SXR in gene activation by RIF, clotrimazole and RU486 has also 
been reported for CYP3A7 (Pascussi et al., 1999), which has a regulatory region very 
similar to the CYP3A4 promoter (91 % similarity in the first 1 kb). Indeed a functional 
ER6  was found in the promoter region of the liver specific CYP3A7 (Pascussi et al, 
1999). The effect of SXR on other genes has recently been demonstrated. For instance the 
MDRl gene, which codes for the P-glycoprotein efflux transporter, was shown to be 
induced by various SXR ligands including the anticancer drug Paclitaxel (Taxol) (Synold 
et a l, 2001). A study using cDNA and oligonucleotide microarrays with RNA from 
primary human hepatocytes demonstrated that several CYP genes involved in drug 
metabolism were induced by rifampicin, with CYP3A4 being the most extensively up- 
regulated (Rae et al, 2001). Whether SXR has a significant effect on genes not directly 
involved in drag metabolism still remains to be established.
It is also thought that SXR can be involved in xenobiotic mediated CYP3A4 repression 
(Takeshita et al, 2002). The anti-fungal drug ketoconazole was found to inhibit SXR- 
mediated transcription by corticosterone of a CYP3A4 promoter reporter gene construct. 
The authors suggest the mechanism may be due to a decreased SXR interaction with the 
coactivator SRC-1 and the repressor SMRT (Takeshita et al, 2002).
The structure of the human SXR ligand binding domain (LBD) has been determined by 
crystallography (Watkins et al, 2001). It appears that the ligand binding domain is larger 
in SXR than in most other nuclear receptors studied so far (e.g. Estrogen Receptor, ER) 
and that it is mainly lined with hydrophobic amino acids ( 2 0  out of 28 amino acids) with 
a few polar residues (4 out of 28 amino acids). Using site directed mutagenesis it was 
shown that the species-specific activation profile of the SXR could be affected by 
changing only four amino acid residues (Watkins et al, 2001). The mouse SXR can be
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activated by the synthetic steroid 5-pregnen-3p-ol-20-one-16a-carbonitrile (PCN) but not 
by the human SXR ligand SRI2813, whereas the human SXR cannot be activated by 
PCN. Following the mutation of four amino acids in the LBD of the mouse SXR into four 
polar amino acids known to interact with the high affinity ligand SRI2813 in the human 
SXR, the mouse SXR was activated by SRI 2813 by not by PCN in reporter gene assays. 
This data suggests that species specificity in SXR activation profile may be caused by 
only a few residues. Studies of the SXR LBD in the presence of ligands (SR12813 and 
hyperforin, the active ingredient of Saint John’s Wort) revealed the high degree of 
flexibility of the protein structure in order to accommodate structurally diverse 
compounds (Watkins et al, 2003; Watkins et a l, 2001). It was also shown that the ligand 
SRI2813 could interact with the SXR LBD in three different positions (Watldns et al, 
2001). Taken together these results shed light onto the mechanisms by which CYP3A 
genes can be activated by a wide range of chemicals though SXR and how the receptor 
can act as a broad chemical sensor.
1.5.3.3. CAR (NR1I3).
CAR is predominantly expressed in the liver and was found to constitutively transactivate 
(i.e. without xenobiotic ligand binding) retinoic acid response elements, controlling the 
expression of retinoic acid receptor |32 and alcohol dehydrogenase 3 (Baes et al, 1994). 
Like other members of the nuclear receptor superfamily, this Constitutively Active 
Receptor binds to direct repeat hexamers with variable spacers. It was initially shown that 
CAR could activate CYP2B6 thiough a phénobarbital response element (PBRE) located 
in the promoter, in response to phénobarbital and other xenobiotics (Sueyoshi et al,
1999). However, this response, as well as the constitutive activation, is inhibited by the 
addition of 3a androstenol, a steroid sex honnone metabolite, hence the alternative name 
for this receptor is Constitutive Androstane Receptor (Sueyoshi et al, 1999).
The role of CAR in the induction of the Cyp2hlO gene was demonstrated in vivo using 
loiock out mice, where loss of CAR expression resulted in the abolition of Cyp2bl0 
induction by phénobarbital (PB) and l,4-bis[2-(3,5-dichloropyridyloxy)] benzene 
(TCPOBQP) (Wei et al, 2000). Pharmacological experiments also demonstrated that
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wild type animals were more resistant to zoxazolamine-induced paralysis (a Cyp2bl0 
substrate) than the CAR-deficient animals, following pre-induction of the metabolising 
enzymes with PB and TCPOBOP (Wei et al., 2000). The latter findings show that in the 
absence of CAR the xenobiotic metabolising enzymes could not be activated and 
therefore failed to protect the organism from the effect of the muscle relaxant 
zoxazolamine.
1.5.3.4. Retinoic X Receptor a  (RXRa, NR2B1).
RXRa is an heterodimerisation partner for several nuclear receptors such as the vitamin 
D receptor and the thyroid hoimone receptor (Kliewer et al., 1992), as well as CAR and 
SXR as shown above, but can also bind DNA response elements as a homodimer, 
although poorly. Experiments in genetically modified mice where the expression of this 
receptor was suppressed (Wan et al, 2000) resulted in the disruption of many hepatic 
gene functions (e.g. CYP3A1 and CYP2B10 gene expression, cholesterol homeostasis). 
Cellular amounts of RXRa may strongly influence the binding with their 
heterodimerisation partners to the regulatory sequences of the target genes. The role of 
RXRa in the xenobiotic response of the organism is crucial since it is an 
heterodimerisation partner for PPARa (CYP4A regulation), CAR and SXR {CYP2B and 
CYP3A regulation) (Waxman, 1999).
1.5.3.5. Hepatocyte nuclear factor 4 (HNF4, NR2A sub-family).
Several experiments report a role for this tissue specific factor in the regulation of the rat 
CYP3A23 gene (Huss and Kasper, 1998; Huss and Kasper, 2000). A functional binding 
site was identified using DNase I footprinting and transfection assays. An HNF4-like 
protein was identified which bound to the CYP2C2 gene promoter and HNF4 trans­
activated constructs containing the binding site (Chen et al, 1994). A very recent report 
identified a functional binding site for HNF4a in the distal enliancer element (XREM) of 
the CYP3A4 gene, both in cell line and animal models (Tirona et al, 2003). This receptor 
is thought to enhance the CAR- and SXR- mediated regulation of the gene both at the
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basal and drug induced level (Tirona et al, 2003). Therefore members of the HNF family 
seem to play a role in the liver specific expression of CYP genes. Additionally it was 
shown that hepatocyte nuclear factors plays a direct role in promoting SXR expression, 
since the nuclear receptor was not detected in HNF4a knock out mice, together with 
various other factors specific to matuie liver metabolism (Li et al, 2000).
1.5.3.6. Nuclear receptor cross talk.
Using trans-activation assays and electromotility shift assay (EMSA), Xie and co­
workers demonstrated that the human CAR is also involved in the regulation of the 
CYP3A4 gene, where it is constitutively active and further activated by its ligands (Xie et 
al, 2000a). This latter study indicates that SXR is also involved in the up-regulation of 
CYP2B genes via an element known as phénobarbital response element (PBRE), which 
contains a DR4 motif for nuclear receptor binding (direct repeat with 4 spacers). A 
similar obseiwation was reported in a different experimental system (Smirlis et al, 2001). 
Using primary hepatocytes and in vivo liver transfection (using particle mediated 
delivery) it was shown that SXR can mediate the induction of the mouse Cyp2b and 
CypSa genes by synthetic steroids and that CAR could mediate the phénobarbital 
induction of both Cyp genes (Smirlis et al, 2001). This phenomenon was also observed 
in transgenic mice expressing a (3-galactosidase reporter gene construct, where the 
induction of a CYP3A4 promoter constiuct by CAR was further confirmed in vivo 
(Goodwin et al, 2002). The fact that CAR and SXR bind the same response element 
demonstrates the existence of a cross talk between nuclear receptors involved in the 
xenobiotic response and suggests the presence of cellular regulatory networks. It is 
thought that these receptors act as part of a ‘metabolic safety net’, which has evolved to 
defend the organism fiom chemical insult (Xie et a l, 2000a).
A recent study demonstrates that this cross talk results in the induction of several drug 
metabolism genes by both receptors (Maglich et a l, 2002). Using ligands specific for 
either CAR or SXR, together with knock-out animals for each receptor, an overlapping 
set of genes coding for phase I and II enzymes as well as for drug transporters, was found 
to be co-regulated by the receptors. The results also indicate that some genes are only
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induced by only one of the receptors, suggesting that CAR and SXR also have specific 
target activation patterns (Maglich et al., 2002).
1.6. Polymorphic expression of CYP3A4 and contribution to inter- 
individual variability in drug metabolism.
It has been estimated that two human genomes chosen at random within the population 
will differ at approximately 2.5x10^ sites (Alberts et al, 2002). This means that a Single 
Nucleotide Polymoiphism (SNP) may be found once every 1300 nucleotides in the 
genome (Alberts et a l, 2002), with potential effects on the phenotype of the individual. 
There is extensive evidence that all cytochrome P450 genes involved in drug metabolism 
are expressed polymoiphically (reviewed in Cholerton et al, 1992; Daly et al, 1998; 
Ingelman-Sundberg, 2002). Genetic polymorphisms may affect the coding region 
(information) or the regulatory region (expression of the information) of a gene. In the 
first instance, the protein structure and function may be affected and in the latter case the 
amount of gene expression at the basal and drug induced state may vary between 
individuals (e.g. Lamba et a l, 2002). As discussed above for the CYP2D6 gene (section
1.1.3), population variations in the expression and sequence of CYP genes will result in 
the variability of the metabolic rates for the enzyme substrates (e.g. Gibson and Skett,
1994). This can lead to negative effects such as adverse drug reaction (ADR) or lack of 
therapeutic drug effect (Ingelman-Sundberg, 2002) if the plasma level in P450 enzyme 
substrate is too high or too low.
Various studies report a high inter-individual variability in CYP3A4 phenotype (enzyme 
level and activity) (e.g. reviewed in Lamba et al, 2002). Because CYP3A4 is 
ti'anscriptionally regulated, variations in the sequence of the regulatory region of the gene 
could possibly be an explanation for this inter-individual variability. The fact that, unlike 
other CYP enzyme activities such as CYP2D6-mediated drug clearance (see section
1.1.3), CYP3A-mediated drug clearance seems to be unimodal rather than bimodal in the 
population suggests that several genetic polymorphisms or several environmental factors 
may influence the inter-individual variability (Lamba et al, 2002). A meta-analysis study
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suggests that the genetic component of CYP3A4 variability ranges from 6 6  to 98%, with a 
median value of 83%, which provides an indication of the high importance of genetics in 
the variability in CYP3A4 expression (Ozdemir et al, 2000).
Rebbeck and co-workers were the first group to report a mutation in the 5’ region of 
CYP3A4 (CYP3A4V, now called CYP3A4"^IE), which consists of a substitution (A to G) - 
290 bp upstream of the transcription start (figure 1.9) (Rebbeck et a l, 1998), situated in 
what was identified as the nifepidine response element, NFSE (Hashimoto et al, 1993).
Figure 1.9. The CYP3A4V mutation {CYP3A4^'1B) located in the NFSE motif.
CYP3A4 wild type: 5 ’-AGGGCAAGAG-3 ’
CYP3A4V: 5 ’-AGGGC AGG AG-3 ’
The presence of the CYP3A4V genetic variant was found to be associated with prostate 
cancer tumour grade in North American Caucasian patients (Rebbeck et a l, 1998). The 
homozygous polymorphism was present in 9.6% of the population studied. The A to G 
substitution was not detected in any of the 128 DNA samples fiom Japanese volunteers 
(Ando et al, 1999). Another group reported the association between this polymorphism 
and the therapeutic outcome of patients undergoing chemotherapy with the anti-cancer 
drug epipodophyllotoxin (Felix et al, 1998). Individuals carrying CYP3A4V were less 
likely to suffer from de novo leukaemia caused by the genotoxic metabolites of the latter 
chemotherapeutic agent (Felix et al, 1998). In both prostate cancer and treatment 
induced leukaemia studies, the authors explained their finding by an altered expression of 
CYP3A4 which in turn would affect the metabolism of endogenous compounds (Rebbeck 
et al, 1998) or xenobiotics (Felix et al., 1998).
Although the presence of the polymorphism has since been confirmed in multiple studies, 
no gi’oup has yet confirmed any association between the CYP3A4V genotype and 
CYP3 A4 enzyme activity or levels.
To assess CYP3A4V functionality, the genotype of 22 males and 24 females was 
established and CYP3A4 activity was measured as testosterone 6 p hydroxylation 
(Westlind et al, 1999). This study revealed a high inter-individual variability and no 
correlation between genotype and activity was found. Gel shift assays revealed the low
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significance of the polymorphism in terms of difference in cytosolic protein binding to an 
oligomer probe representing the wild type and the mutant sequence of the NFSE. Several 
other studies reported no significant correlation between this polymoiphism and the 
metabolism of the CYPSA substrates alprazolam and trazodone (von Moltke et al, 2000), 
nifepidine (Ball et al, 1999) and cyclosporin (Rivory et al, 2000).
Two further mutations in the coding region of the CYP3A4 gene, in exon 7 and 12, were 
reported at the time of this study (Sata et a l, 2000). The mutation in exon 7, termed 
CYP3A4*2A, was present in 2.7% of the Caucasian volunteers and was found to have a 
functional effect as it caused a decrease in nifepidine oxidation kinetics.
The three mutations described above were the only genetic variants in the coding and 
regulatory regions identified for CYP3A4 at the time this work was carried out. A more 
recent review reports a total of five mutations in the regulatory region of CYP3A4 
(Lamba et al, 2002). A database of CYP gene mutations is frequently updated and is 
available on the Internet (httt)://www.imm.ki.se/CYPalleles/).
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1.7. Project aims.
Previous work in our laboratory had focused on elucidating the mechanisms of induction 
of the human CYP3A4 gene by hormonal and xenobiotic stimuli using reporter gene 
assays. The importance of a Ikb region within the proximal promoter was established for 
the drug response (Ogg et al, 1999). Using co-transfection experiments with expression 
plasmids coding for GR and SXR, the role of both receptors in CYP3A4 expression was 
experimentally confirmed (El Sankary, 2000; El Sankary et al, 2001; El Sankary et al,
2000). Additionally, a T>C transition -190bp from the transcription start was identified 
and this mutation significantly reduced the trans-activation of the promoter in response to 
dexamethasone and hydrocortisone (GR ligands) but did not affect the response to 
rifampicin (SXR ligand) (El Sankaiy, 2000).
This work raised several questions which were experimentally examined here.
- Is the ER6  the only cw-acting region of the CYP3A4 promoter and by extension are 
SXR/CAR the only regulators of CYP3A4 expression?
To identify fiirther components of the regulatory network involved in the basal 
expression and drug-induced expression of CYP3A4, the transcription factor binding to 
the regulatory regions was examined by DNase I footprinting and computer analysis.
- Can the inter-individual variability in CYP3A4 expression be explained by the presence 
of genetic variations within the proximal promoter, which could provide a molecular 
basis for this phenomenon?
By screening eleven phenotyped liver samples for which CYPSA activity has previously 
been assessed using an enzyme assay, the presence of further mutations was investigated 
within the 5’ flanking region of the CYP3A4 gene (about Ikb), using PCR and 
sequencing. The binding of transcription factors to newly identified genetic variants 
(Hamzeiy et al, 2002) was assessed in order to investigate the possible mechanisms 
responsible for the inter-individual variability.
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- Are the putative transcription factor binding sites identified above (by DNase I and 
bioinformatics) functional and relevant to the CYP3A4 basal and drug-induced 
expression?
The putative binding sites were mutated and the functional transcriptional effect assessed 
by reporter gene assay. The effect of the functional -190bp mutation on nuclear protein 
binding was also investigated.
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Ch a pt e r  2 -  M aterials a nd  M eth o ds
2.1. Materials.
2.1.1. General chemicals and plasticware.
Cell culture chemicals were purchased from Invitrogen. All other chemicals and reagents 
used in this work were of the highest purity available and were purchased from Sigma (St 
Louis MO) unless otherwise stated. The suppliers of all additional materials are listed 
below in table 2.1. Some specific molecular biology kits and instruments are described in 
the relevant areas of this chapter.
All work involving radiochemicals was carried out in accordance with the guidelines set 
out in the ‘Local Rules for Protection Against Ionising Radiations’ published by the 
University of Surrey Safety Office. Whenever possible all glassware and plasticware 
were autoclaved and solutions were autoclaved or filter sterilised. All nucleic acid work 
was earned out using DEPC treated water (0.1%).
2.1.2. Plasmids.
Maps of plasmids used in this work showing key restriction sites and functional features 
are presented in Figures 2.1 to 2.6. The plasmids contain the ampicillin resistance gene 
(p-lactamase) in order to enable selection for colonies containing the constructs during 
culture. The human SXR expression plasmid (liPXR-pSG5) was a gift from Dr Steven 
Kliewer (GlaxoSmithKline, Research Triangle Pai'k, NC, USA). The reporter gene 
plasmids (pSEAPpro2 and pSEAP2basic vectors) were purchased from Clontech. The 
pSEAP pro2 plasmid (with an insert from the -301/+7 region of the CYP3A4 promoter) 
was engineered by Dr Wafaa El Sankary, University of Surrey. The pSEAP2-Basic 
plasmid DNA with a 300 bp insert from the CYP3A4 XREM region (-79727-7673) as 
well as the same plasmid with an added 1141 bp (-12017-61) of the CYP3A4 promoter
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were kind gifts from Dr Hossein Hamzeiy, University of Surrey. The pSEAP2-Basic 
plasmid DNA with a 300 bp insert from the CYP3A4 XREM region (-7972Z-7673) and 
the -301/+7 region of CYP2A4 promoter is hereafter termed pWT.
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Table 2.1. Suppliers of items used in this study.
Item or chemical Supplier
Bacterial agar, phosphate buffer saline (PBS) tablets, Tryptone,
Yeast extract Oxoid
Agarose Boehi'inger Mannheim
y-^ ^P ATP triethylammonium salt (370 MBq/ml, approx. 110 Amersham
TBq/mmol) Biosciences
DNA oligomers for PCR and EMSA MWG Biotech
DH5a or Topi OF’ E. coli competent bacterial cells Invitrogen
Sequencing kits Promega and USB
Restriction and other modifying enzymes and DNA size
markers Promega
Transformer site directed mutagenesis kit, mutS E. coli cells and
High Fidelity polymerase PCR kit, plasmids (pSEAP pro2 and
pSEAP2-basic) Clontech
PSG5 plasmid Stratagene
0.22 pm filters Nalgene
96 well Optiplates Canberra Packard
Microbiology plasticware and cryovials Greiner
Kits for DNA gel extraction, plasmid extraction (mini- and
maxiprep) Qiagen
Disposable pipette tips Alpha Laboratories
Microcentrifuge tubes Scotlab
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Figure 2.1. Map of the human SXR expression plasmid (hPXR-pSG5).
SV40
b-globin intron
T7
pSG5-hPXR
5684 bp
Ampr
hPXR
Poly Aon
SV40: SV40 promoter, b-globin intron : p-globin intron, T7: T7 promoter, hPXR: cDNA 
coding for the human SXR gene, ori: origin of replication. Amp r: lactamase conferring 
resistance to ampicillin, fl : origin of replication of the filamentous phage f l .
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Figure 2.2. Map of the pSEAP2-promoter plasmid, an alkaline phosphatase reporter
gene plasmid.
Acc 651 (2) 
/ B g l n (37)
SV4D promoter
Amp r pSEAP2-Promoter4869 bp
SEAP
pUC ori
Xha I (1794) 
SV40 polyA 
Eco 47in (2188)
SV40: SV40 promoter, SEAP: secretory endothelial alkaline phosphatase, pUC ori: 
origin of replication. Amp r: lactamase conferring resistance to ampicillin. Important 
restriction enzyme cutting sites are also shown with their position (bp).
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Figure 2.3. Map of the pSEAP2-promoter plasmid with the -301/4-7 insert from the
CYP3A4 proximal promoter.
Acc 651 (2)
-301/+7 from CYP3A4 
Bgl n  (320)
SV40 promoter
pSEAP2-Promoter -301/+7
5152 bp ■
pUC ori Xba I (2077) 
SV40 polyA
Eco 47m  (2471)
SV40: SV40 promoter, SEAP: secretory endothelial alkaline phosphatase, pUC ori: 
origin of replication. Amp r: lactamase conferring resistance to ampicillin. Important 
restriction enzyme cutting sites are also shown with their position (bp).
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Figure 2.4. Map of the pSEAP2-basic reporter gene plasmid with the distal CYP3A4
gene enhancer XREM.
XREM from CYP3A4
7fmdm(343)
^EcoR I (357)
pSEAP2-basic with XREM
4 9 6 6  bp
Sal I (2159) 
Eco 47m  (2285)
Important restriction enzyme cutting sites are shown with their position (bp).
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Figure 2.5. Map of the pSEAP2-basic plasmid with the XREM insert and the
301/4-7 insert from the CYP3A4 promoter (pWT).
XREM from CYP3A4 
H indlU  (343)
-301/4-7 region of CYP3A4 
EcoR I (661)
pSEAP2-basic XREM -301/+7
5270 bp
Sal I (2463) 
Eco 47III (2589)
Important restriction enzyme cutting sites are shown with their position, (bp)
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Figure 2.6. Map of the pSEAP2-basic reporter gene plasmid with the distal 
enhancer XREM insert and the -1201/-61 insert from the CYP3A4 gene promoter.
XREM from CYP3A4
-12D1/-61 region ofCYP3A4
pSEAP2-basic XREM -1201/-6
6099 bp
Eco 47m (3418)
S ill (3292)
Important restriction enzyme cutting sites are shown with their position (bp).
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2.2. General microbiology techniques.
2.2.1. Transformation of bacteria.
20 to 50ng of plasmid or DNA fi*om a ligation reaction were transformed into competent 
DH5a or Top IGF’ E. coli bacterial cells. A tube containing the frozen cells, stored at 
-80°C, was placed on ice for 5 minutes to thaw the suspension, DNA was added and the 
suspension was stirred gently using the pipette tip. The mixture was incubated on ice for 
30 minutes and heat shocked at 37°C (DH5a) or 42°C (TopiOF’) for 30 s. LB broth was 
added and the tube was shaken at 225 rpm, 37°C for 1 hour. The bacteria were then 
spread on a LB agar plate containing ampicillin and incubated at 37°C or the volume of 
the suspension was made up to 5 ml with LB broth-ampicillin and shaking was resumed 
(in both cases the antibiotic concentration was 100 pg/ml). The cells were grown for 12- 
18 hours.
2.2.2. Preparation of glycerol stocks.
150)0,1 of sterile glycerol were added to 850jol overnight cultures in LB media containing 
100p,g/ml ampicillin. The tube was briefly vortexed to ensuie complete mixing and the 
stocks were frozen at -80°C.
2.2.3. Growth of bacterial cultures.
Transformed bacteria (from a glycerol stock or a tiunsformation reaction) were spread on 
a LB agar plate containing ampicillin and grown at 37°C for 12-18 horns. A single 
colony was picked using a toothpick and inoculated into 5ml LB with 100 pg/ml 
ampicillin. This mini-culture was placed in a rotary incubator (37°C, 225rpm) for 12-18 
hours. For a maxi-culture, 250ml LB containing 100 pg/ml ampicillin were inoculated 
with 250pl of the overnight culture then incubated (37°C, 225rpm) for 12-18 houi's.
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2.3. General molecular biology techniques.
2.3.1. Agarose gel electrophoresis.
DNA samples (-500 ng) were mixed to 5x loading buffer (50 % glycerol, 49 % nuclease 
free water and 1 % w/v Orange G dye) and run in 1 % w/v agarose gel made in TAB 
buffer at about 5 V/cm. Gels were pre-stained with ethidium bromide (0.5 p-g/ml). DNA 
was tlien visualised under UV light and photographed (Polaroid films or Image Master 
imaging system fr om Pharmacia Biotech)
2.3.2. DNA extraction from agarose gel.
For salt sensitive applications such as sequencing or DNase I footprinting, DNA 
fragments (following amplification by PCR) were gel purified, to remove dNTPs and/or 
non-specific amplicons. The entire PCR reaction was run on a 1 % low melting point 
agarose, pre-stained with ethidium bromide, the band of interest was excised using a 
sterile scalpel and the DNA fragment was extracted using a gel extraction kit (Qiagen) 
following the manufacturer’s instr uctions. Briefly, 3 volumes of buffer GQ (solubilisation 
buffer) were added to one volume of the excised band and incubated until dissolution of 
the gel Augment was complete (typically 10 minutes at 65°C). One volume of 
isopropanol was added to increase the yield except for fr agments of size raging from 500 
to 4000 bp where this step has no effect. The mixture was applied to a QIAquick spin 
column and centrifuged for 1 minute. In order to remove traces of agarose, 500 p,l of 
buffer QG were added and the column and centrifuged. The bound DNA was washed 
using 750 fj,l of buffer PE. In order to achieve a higher DNA purity (e.g. for sequencing) 
the buffer was incubated for 5 minutes at room temperature. Finally 30 to 50 pi water 
were added on the column, incubated at room temperature for 5 minutes and centrifuged.
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2.3.3. DNA quantification.
The concentration of DNA preparations (e.g. purified PCR products, plasmids) was 
assessed spectrophotometrically with a Genequant II (Pharmacia Biotech). An aliquot 
was diluted in water and the absorbance at 260nm was measured against appropriate 
blank (water or TE buffer).
2.3.4. Restriction digest.
A typical restriction digest reaction consisted of 0.2 to 2 pg DNA (depending upon 
downstream application), 10 U of enzyme and the appropriate restriction enzyme buffer. 
For sensitive applications (probe labelling, site directed mutagenesis) BSA was added at 
a final concentration of 0.01 mg/ml. The reaction was incubated at 37°C for 2 houi’s.
2.3.5. Ethanol precipitation.
A typical ethanol precipitation consisted of the addition of 2 volumes of absolute ethanol 
to the sample which was then left for 5 to 30 minutes either at room temperature or in the 
cold (on ice, at -20°C or -80°C). The variety of conditions represents a compromise 
between the need to achieve high DNA recovery and the presence of salts which could 
co-precipitate at low temperatures. The DNA was pelleted by centrifugation, washed with 
70 or 80% ethanol, air dried and resuspended in water. In some cases, DNA was also 
precipitated by adding 0.7 volumes of isopropanol, incubating the tube at room 
temperature and proceeding as for a classical ethanol precipitation.
2.4. Cloning.
2.4.1. PCR cloning.
Wlien the ends of a DNA insert do not contain the suitable restriction sites for the 
fragment to be ligated at the desired location in a plasmid, those sites can be generated
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using PCR. In this technique the PCR primers contain the recognition sequence of the 
relevant enzymes in their 5’ ends. The primers were +7B (BcoRI) and -301A (Hind III) 
and they are described in table 2.5. PCR fragments were generated under normal 
amplification conditions (see section 2.10.3 and table 2.6) and prepared for the ligation 
by digesting them using the relevant enzymes (EcoRI and Hindlll) in the appropriate 
buffers followed by gel purification.
2.4.2. Ligation.
Recipient vector was linearised using restriction enzyme(s) compatible with the insert 
DNA and gel purified. A ligation reaction contained 3U T4 DNA ligase, ligase buffer (30 
mM Tris-HCl pH 7.8, 10 mM MgCl2, 10 mM DTT and 1 mM ATP), plasmid vector (40 
ng) and insert DNA. The following equation was used to calculate the amount of insert to 
add to the ligation reaction:
vectoring) x size(kb)insert insert . _ ..--------------------------------X-------- (mol) = ng o f insertsize(kb)vector vector
In order to ensure a high proportion of plasmids with inserts, the molar ratio of 
insert/vector used was set at around 20-25. The ligation reaction was then left overnight 
at 14°C. An alternative ligation protocol was also used, where the temperature cycled 
overnight between the optimal DNA ligase temperature (30°C, for 30 s) and a lower 
temperature (10 °C, for 30 s) more suitable to promote ligation of DNA ends (modified 
from Lund et al^ 1996). The ligation reactions were then used to transform E. coli as 
described in section 2.2.1 and the bacteria plated on LB agar plates.
2.4.3. Selection.
In order to check individual colonies for the presence of plasmids with an insert, a quick 
and simple screening technique was used. Several colonies were picked with a toothpick 
and used to inoculate small volumes (200|.tl) of LB medium with ampicillin in a 96-well
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plate. The bacteria were grown for 5 hours in a rotary incubator (37°C, 225rpm). Next 
40p,l of culture was mixed with an equal volume of phenol-chloroform and centrifuged 
(10000 xg for 2 minutes). The supernatant, consisting of the aqueous phase with all 
bacterial nucleic acids, was mixed with loading dye and run on a 1% agarose gel. The 
plasmid size was compared to that of a control transformation reaction containing the 
empty vector and any culture with a larger plasmid (i.e. migrating more slowly) was 
flirther studied by miniculture, restriction digest and sequencing.
2.4.4. Sequencing.
Fidelity of all constructs generated in this study was confirmed by sequencing using an 
ABI 373 automated sequencer (SBLS core facility. University of SuiTey). Alternatively 
they were sequenced manually using a Thenno Sequenase™ cycle sequencing kit (USB) 
or fimol (Promega), following the manufacturer’s instiuctions with minor modifications 
(see section 2,9,4 for protocol description).
2.5. Plasmid preparation.
Plasmid DNA was extracted from bacterial cultures (prepared as described above in 
section 2.2.3.) using Qiagen miniprep or Endofiee maxiprep kits following the 
manufacturer’s instructions.
2.5.1. Minipreps.
Samples (1.5 to 5 ml) of overnight mini-cultures were spun in a microcentrifuge tube to 
collect the bacteria. The supernatant was removed and the cells resuspended in 250 j.il 
buffer PI. Following addition of 250 \x\ buffer P2 the tube was mixed by inversion 5 
times and the solution became clear and viscous. 350 jal buffer P3 were added and the 
tube was spun for 10 minutes at 10000 xg. The supernatant containing the plasmid DNA 
was applied to a QIAprep column and centrifuged for 1 minute. To increase yields the 
supernatant was sometimes re-applied to the column and spun a second time. The flow-
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through was discarded and 750 jid of buffer PE were applied to was the column. In order 
to achieve higher plasmid purity (e.g. for sequencing) this buffer was incubated on the 
column for at least 5 minutes prior to column centrifligation. The flow-thiough was 
discarded and the tube was fiirther centrifuged for 1 minute to remove residual traces of 
wash buffer. The column was then placed in a sterile microcentrifuge tube, water (30 to 
100 |.il) was applied and column was spun for 1 minute at 10000 xg. In order to increase 
the yields the water was sometimes incubated at room temperature for 5 minutes before 
centrifugation.
2.5.2. Eiidofree maxiprep.
A larger (250 ml) volume of overnight culture was centrifiiged (6000 xg for 15 minutes 
at 4°C) to collect the bacterial cells, which were then resuspended in 10 ml buffer PI. 
Buffer P2 (lysis buffer) was added (10 ml) and the tubes were mixed by inversion 5 
times. Following a 5 minute incubation at room temperature, 10 ml of chilled 
neutralisation buffer P3 were added and the tube was mixed by inversion. The lysate was 
poured into a QIAfilter cartridge, incubated for 10 minutes at room temperature and 
filtered into a collection tube where 2.5 ml of buffer ER were added. The tube was 
incubated for at least 30 minutes on ice in order to remove bacterial endotoxins which 
may impair the DNA transfection process. The lysate was transfened to a QIAGEN-tip 
equilibrated by the addition of 10 ml buffer QBT and the column was allowed to empty 
by gravity flow. The plasmid DNA bound to the column was washed twice with 2 x 30 
ml buffer QC and eluted with 15 ml buffer QN. 10.5 ml isopropanol were added and the 
precipitated DNA was collected by centrifugation (6000 xg for 1 hour). The pellet was 
washed with 70% endotoxin-ffee ethanol, air dried and resuspended in 500 to 750 p.1 
water.
2.6. General cell culture techniques.
2.6.1. Culture conditions.
Human hepatoma cells HepG2 (ECCAC No. 85011430) and HuH7 (a gift from Dr Steve 
Hood, GlaxoSmithKline UK) were grown in 75 cm  ^ flasks with vented lids (Nunclon 
surface from Nalge Nunc International) in 5 % CO2 in air at 37°C. HepG2 cells were 
cultured in 15ml Minimum Essential Medium (MEM), supplemented with 10 % (v/v) 
foetal calf serum, 1 % (v/v) non essential amino acids, 2 mM L-glutamine and 1 % (v/v) 
gentamycin. HuH7 cells were cultured in 15ml Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10 % (v/v) foetal calf serum, 1 % (v/v) non-essential amino 
acids, 2 mM L-glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin. The cells 
were subcultured every 3-5 days (-90% confluence) depending on the growth rate. The 
passage number was initially 78 for the HuH7 cells and they were subjected to a 
maximum of 10 further passages.
2.6.2. Subculture of cells.
When the cells reached more than 80% confluence, the medium was removed by 
aspiration, the cell layer washed with PBS and 1 ml trypsin-EDTA was added. The cell 
culture flask was gently rocked to ensure coverage of the cells by the protease and was 
either incubated at 37®C (HepG2 cells) or at room temperature (HuH7 cells) for 2-3 
minutes. The cells were detached by tapping the sides of the flask and then 9 ml of 
medium added to dilute out enzyme activity. Usually 0.5 to 1 ml of this suspension was 
added to ft esh media in a final volume of 15 ml in a new flask.
2.6.3. Storage and recovery of cells in liquid nitrogen.
HepG2 or HuH7 cells from near confluent flasks were trypsinised and spun at 1300 xg 
for 5 minutes. The resulting pellet was washed with PBS, the cells were resuspended in 
91 % FBS and 9 % DMSO (concentration % 4 xlO^ cells/ml) and aliquoted into cryovials.
49
The suspensions were frozen at -80°C for 1 houi' and stored in liquid nitrogen. Upon 
recovery the tubes were thawed at 37°C for 5 minutes, the cells pelleted by centrifugation 
(5 minutes at 1300 xg) the supernatant removed, medium (MEM or DMEM) added and 
the cells were transferred to cell culture flasks
2.7. Nuclear protein extract preparation.
Nuclear proteins were extracted from HepG2 cells grown as described in section 2.6.1.
2.7.1. HepG2 nuclear protein extraction.
The method used was derived from Dignam and co-workers (Dignam et al, 1983). 
Briefly, HepG2 cell suspensions were obtained by trypsinisation of approximately 90 % 
confluent cells at passage 5 to 9. Cells were pelleted by centrifugation (1300 xg for 5 
minutes) and washed in PBS. After another similar centrifugation, the cells were 
resuspended in 5 packed cell volumes (PCV, the volume of the cell pellet) of PBS and 
spun (1300 Xg for 5 minutes). After removal of the supernatant, a suspension was made 
in 2 PCV of cold buffer A (10 mM Hepes-KOH, pH 7.9, 1.5 mM MgCL, 10 mM KCl 
and 0.5 mM DTT) and the cells were left to swell on ice. After 10 minutes, the cells were 
disrupted using 10 strokes of a Dounce homogeniser. The homogenate was then 
centriftigated at 2000 xg for 15 minutes. The difference between the volume of the 
supernatant and the initial volume was called the packed nuclear volume (PNV). The 
pellet was resuspended in 0.5 volumes of ice cold buffer C (25 % glycerol, 20 mM 
Hepes-KOH, pH 7.9, 1.5 mM MgCh, 0.2 mM EDTA, 20 mM NaCl, 0.5 mM DTT, 0.5 
mM PMSF) and 0.5 PNV of buffer C high salt (buffer C containing 1.2 M NaCl) was 
added dropwise and with swirling. The suspension was homogenised using 10 strokes of 
Dounce homogeniser and then spun at 16000 xg for 30 minutes. The supernatant (nuclear 
proteins) was aliquoted and stored at -80°C.
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2.7.2. Protein electrophoresis and Coomassie staining.
In order to assess the integi’ity of the extracted nuclear proteins, 10 p,l of each sample 
were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- 
PAGE) and stained with Coomassie blue. The samples were mixed to an equal volume of 
loading dye and denatured at 95 °C for 5 minutes. They were then loaded on a 6 % SDS- 
polyacrylamide gel and run in an SDS containing buffer for 40 minutes at 200 V. After 
electrophoresis the gel was stained for 2-4 hours in Coomassie blue and destained 
overnight (10 % methanol and 10 % acetic acid).
2.7.3. Protein quantification.
Protein concentration was measured using a modification of the Lowry assay (Stoscheck, 
1990). Duplicate aliquots (10 |o,l) of the extracted nuclear proteins were diluted in 390 pi 
water and mixed with 400 pi of freshly prepared 2x Lowry reagent (1 ml 2 % CuSO^, 1 
ml 1 % Na,K tartrate, 13 ml 10 % NazCO], 5 ml 1 % SDS and 5 ml 1 M NaOH). The 
solution was mixed by vortexing and incubated at room temperature for 10 minutes. After 
incubation, 200 pi of 0.2 N Folin-Ciocalteu’s phenol reagent was added slowly, while the 
sample was vigorously vortexed. The solution was left at room temperature for at least 30 
minutes and the absorbance at 750 nm was determined using a Kontron 
spectrophotometer (Uvikon). Using the same method, a standard cui"ve was generated (0, 
25, 50, 75, 100 pg BSA in duplicate) and was used to calculate the unknown protein 
concentration by interpolation. The variability between duplicates was generally lower 
than 5 %. All extracted nuclear protein concentrations were found to be within the same 
order of magnitude (2.5 to 4.0 pg/pl).
2.8. Electro mobility shift assay (EMSA).
Two protocols were used to investigate DNA:protein interactions. The initial EMSA 
study was designed to carry out a general investigation of protein binding to a large 
region of promoter -301/4-7 (described in 2.8.1). The second EMSA study aim was to
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assess the effect of mutations in short DNA oligomers on the binding affinity of HepG2 
nuclear proteins (described in 2.8.2).
2.8.1. Electro mobility shift assay with the -301/4-7 CYP3A4 proximal promoter 
fragment.
2.8.1.1. Probe preparation.
One hundred pmol of -301A primer (see table 2.5) was labelled at the dephosphorylated 
5’ end with 2 pi ^^ P ATP (7.4x10^ Bq) to generate -301*, using 10 U of T4 
polynucleotide kinase (Promega). The reaction was incubated at 37°C for 60 minutes and 
to denature the enzyme, 80 pi TE buffer were added and the temperature was raised to 
68°C for 10 minutes. The labelled primers were then used in a PCR reaction (described in 
section 2.10.3) with non-labelled 4-7B primers to generate a single strand labelled 
-301*/4-7 probe. The product of the PCR reaction was then purified by ethanol 
precipitation or through a Qiagen spin column.
Attempts were made to generate labelled 4-7B primers. However, the incorporation 
efficiency was significantly lower than for the -30IB primer. Hence this procedure was 
discontinued.
2.8.1.2. Binding reaction.
The binding reaction was carried out at room temperature (22 °C) and consisted of 10 pi 
of 2x binding buffer (40 mM Tris-HCl, pH 7.9, 100 mM NaCl, 20 % glycerol and 0.2 
mM DTT), 1 pg of poly-dI:dC, 1-10 pi of protein extracts (representing 4 to 40 pg 
nuclear proteins) and the volume made up to 20 pi with nuclease-free water. After a 10 
minute incubation, 2 pi of -301*/4-7 probe were added and the reaction was fluther 
incubated for 30 minutes.
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2.8.1.3. Gel electrophoresis.
2 pi loading buffer (0.5x TBE, 10 % glycerol, 0.25 % bromophenol blue and 0.25 % 
xylene cyanol FF) were added to the binding reaction and 5 pi of the mixture were loaded 
on a 4-6 % polyacrylamide gel, run for 2-4 hours at 200-600 V. To circumvent problems 
due to the presence of unwanted smears in the lanes, various electrophoresis conditions 
(gel concentration, running time and loading buffer with no dye) were initially examined. 
A competition experiment was carried out, using adding Ix, lOx and lOOx excess 
unlabelled -301/+7 probe, in order to test if the binding was specific and reversible. The 
DNA was added in a concentrated form and the final reaction volume remained at 20 pi.
2.8.2. Gel shift assay to determine the effect of DNA mutations on nuclear protein 
binding.
2.8.2.1. Probe preparation.
Single stranded DNA oligomers (from MWG-Biotech) were annealed by heat 
dénaturation of 100 pmol of both the sense and antisense strand in Ix annealing buffer 
(lOmM Tris-HCl pH 8.0, 10 mM MgClz, 50 NaCl, lOpl final volume) for 2 minutes at 
95°C followed by a decrease of temperature at the rate of 0.1 °C per second down to 4°C. 
The concentration of the resulting double stranded oligomer was adjusted to Ipmol/pl 
with DEPC-water and 3.5pmol were 5’ labelled in Ix Idnase buffer (70 mM Tris-HCl pH
7.6, 10 mM MgClz and 5 mM DTT) with 5 to lOU of T4 polynucleotide kinase and Ipl 
[y^^Pj-adenosine triphosphate (-10 TBq/mmol, Amersham Pharmacia Biotech, UK) for 
30 minutes at 37°C. The resulting probe was diluted to 35 finol/pl using TE buffer and 
stored at -20°C. It could be used for several weeks following labelling.
The oligomers used are described in table 2.2. Their length was kept to a minimum in 
order to avoid non-specific binding or binding of adjacent transcription factors.
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Table 2.2. Oligomer sequences for the EMSA studies (the exact complementary 
nucleotide sequence was used for the opposite strand). The letters in underlined bold font 
represent the bases which differ between the wild type and the mutant oligomers.
Oligomer name Sequence
CYP3A4^1B wt 5 ’-GAGACAAGGGCAAGAGAGAGGCGAT-3 ’
CYP3A4^1B (-392 A ^G 5 ’-GAGAC AAGGGCAGGAGAGAGGCGAT-3 ’
transition)
CYP3A4^1EvA 5’-TTAATAGATTATTTTGCCAATG-3’
CYP3A4HE (-369 T-»A 5 ’-TTAATAGATTATTATGCCAATG-3 ’
transversion)
CYP3A4^1F vA 5 '-GTGTACAGC ACÇCTGGTAGGG AC-3 ’
CYP3A4VF (-747 C-^G 5 ’-GTGTACAGCACGCTGGTAGGGAC-3 ’
transition)
Wild-type (pWT) 5 ’-TTGATTGAGTTGTTTATGATACCT-3 ’
Mutant (pMUT) 5 ’-TTG ATTGAGTTGCTTATGATACCT-3 ’
2.8.2.2. Binding reaction.
5-20pg nuclear proteins from DMSO or rifampicin treated HepG2 cells and l-2pg 
polydlrdC were incubated in the presence or absence of various concentrations of 
unlabelled competitor probe (1 to 30 fold excess of either the wild type or mutant 
sequence) in binding buffer A (4% glycerol, ImM MgClz, 0.5mM EDTA, 0.5mM DTT, 
50mM NaCl, lOmM Tris-HCl (pH 7.5)) or B (5% glycerol, ImM MgClz, O.lmM EGTA, 
40mM KCl, 25mM Hepes-NaOH (pH 7.9), 4% Ficoll 400) in a final reaction volume of 
10pi. After 15 minutes on ice 3.5fmol of end-labelled double stranded DNA probe 
(representing the wild type sequence) were added to each tube and the incubation was 
carried out for a further 25 minutes.
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2.S.2.3. Electix)phoresis.
The binding reactions were resolved on a 4% non-denaturing polyacrylamide gel in 0.5x 
TBE at 150V for 25 minutes. The gels were exposed to Kodak X-Omat film overnight 
and quantified using video-based computerized densitometry on an MCID image analysis 
system (Imaging Research, Ontario, Canada). In some instances, additional experiments 
were carried out to demonstrate the interaction observed was indeed a DNA protein 
interaction. The proteins were tr eated with 30 micrograms proteinase K or heat denatured 
(90°C for 1 minute) before addition of the probe.
2.9. In vitro footprinting assays.
2.9.1. Overview of the method.
An overview of the tliree procedures used is given is described in Figure 2.7. Thiee 
methods were used, while attempting to carry out the in vitro footprinting of the proximal 
part of CYP3A4 promoter (-301/+7) but only the final protocol (Figure 2.7. protocol 3) 
was used for the promoter analysis. Briefly this technique consists in incubating a single 
end labelled DNA probe with nuclear proteins, DNase I is then added and randomly 
produces single strand cuts except in the regions protected from the enzyme by proteins 
bound to the DNA. After purification, the DNA is run on a denatuiing polyacrylamide gel 
and the band pattern compared to that of a control lane of DNA digested in the absence of 
nuclear extracts. The protected areas can be observed because of the absence or faintness 
of the band pattern (footprint) indicating the presence of DNA binding proteins at a 
specific binding site.
After several unfruitful attempts using protocols described by Garabedian and co-workers 
(Garabedian et u/., 1993) to carry out copper-phenanthi'oline (Figure 2.7, protocol 1) and 
DNase I (Figure 2.7, protocol 2) footprinting with a PCR labelled probe, a Promega Core 
Footprinting system was purchased. The experiments were carried out following the 
manufacturer’s instr uction. Later all solutions were made in the laboratory, following the 
protocol (Figure 2.7, protocol 3).
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Figure 2.7. Outline of the various in vitro footprinting procedures used.
1: In-gel footprinting 2: Initial DNase I 3: Final protocol
protocol
Label PCR primer Label -301/+7 probe
4  ^ ^
PCR with one labelled and one unlabelled primer. Restriction digest of one
^  end
Single end labelled probe
4^
Incubation with nuclear 
proteins
4^
Non-denaturing 4/
electrophoresis (EMSA)
4/
Cut out the retarded bands 4*
4
Chemical DNA cutting DNase I digestion
^  4
Extraction of the DNA 
fragments
4
Denaturing gel
electrophoresis
4
Autoradiography
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2.9.2. Probe preparation.
Four DNA probes (301/+7, -388/-S3, -240/+69 and -388/+69) were amplified by PCR 
(as described in section 2.10.3) and gel purified. The primer sequences contained 
restriction sites towards their 5’ ends and are described in table 2.3 (the added restriction 
sites are shaded). The PCR conditions were the same as described in table 2.6 for 
-301/+7, except the annealing temperature were 56°C for -388Z-83, 62°C for -240/+69 
and61°Cfor-388/+69.
Table 2.3. PCR primers used to generate the DNA probes for DNase I footprinting. 
Primer Sequence
-30\h{Acc65 r) 5’-GGGGTACCCCAGACAAGGGCAAGAGAGAGG-3’
+7B {Bgl II) 5 -GAÀGATCTTGCACAGCAGTGATTCAGTGAGG-3 ’
-388A (EcoRI) 5 -CCGGAATTCCACAGGCACACTCCAGGCAT-3’
-83B (BamHI) 5 -CGCGGATCCTCTGCCTGCAGTTGGAAGAG-3’
-240A (EcoRI) 5 -CCGGAATTCCTGATAAGAACCCAGAACCC-3’
+69B (BamHI) 5 ’-CGCGGATCCTCTTCCTTTCAGCTCTGTGT-3 ’
The amplicons were labelled using 1 pi ^^ P (3.7x10^ Bq) and 10 U T4 polynucleotide 
kinase for 30 minutes and an extra 10 U PNK were added for another 30 minutes. One 
end of the probe was then removed by digestion for one hour, using 40 U of the 
appropriate restriction enzyme (Bgl II or BamHI for the sense strand and Acc65I or EcoRI 
for the anti sense strand). The single end labelled probe was extracted using an equal 
volume of phenol/chloroform, then another volume of chloroform, ethanol precipitated 
and resuspended in TE buffer.
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2.9.3. In vitro footprinting.
An incubation reaction was set up with 25 pi 2x binding buffer (50 mM tris-HCl pH 8.0, 
12.5 mM MgClz, 1 mM EDTA, 20 % v/v glycerol, 1 mM DTT and 25 or 100 mM KCl 
depending on whether the buffer had a low or high salt content), 5 pi DNA probe 
(approx. 7 kBq), nuclear proteins (5 to 80 pg) and water up to 50 pi. The mixture was left 
on ice for 10 minutes. Then 50 pi of Ca ’^*'/Mg^ '^  buffer was added (5 mM CaClz and 10 
mM MgClz), incubated at room temperature for 1 minute and tiie DNA digested with 
0.15 U DNase I for 1 minute. The reaction was stopped by the addition of 90 pi of warm 
(37°C) stop solution (200 mM NaCl, 30 mM EDTA, 1 % w/v SDS and 9 pg tRNA). 
DNA fragments were then purified by phenol-chloroform extraction and ethanol 
precipitated. The resulting pellet was washed in 70 % ethanol and resuspended in loading 
dye (95 % formamide, 20 mM EDTA, 0.05 % xylene cyanol and 0.05 % bromophenol 
blue) before denaturing gel electrophoresis (described in section 2.9.6). An alternative 
loading dye (1:2 0.1 M NaOH:formamide v/v, 0.1 % xylene cyanol and 0.1 % 
bromophenol blue) was also used and gave equivalent results.
Positive control reactions were carried out using a 342 bp DNA probe, representing the 
SV40 (Simian virus 40) promoter region (with a Hind ///end), which was incubated with 
2 pi of recombinant AP2 protein (Promega). This DNA probe contains a consensus 
binding sequence for AP2 (CCCCAGGC).
2.9.4. Sequencing reactions.
In order to be able to identify the base sequence of the protected region during the gel 
analysis, sequencing reactions were run alongside the DNA samples. These sequencing 
reactions were carried out using a Theimo Sequenase™ cycle sequencing kit (USB), 
following the manufacturer’s instructions with minor modification. Briefly, a primer 
(-301A or 4-7B depending on wliich strand the footprinting analysis was applied to) was 
labelled using 1 pi ^^ P (3.7x10^ Bq) in the presence of 10 U T4 polynucleotide kinase for 
30 minutes and four sequencing reactions were set up for each DNA template Each tube 
contained a different chain terminating dideoxynucleoside triphosphate (ddA, ddC, ddT 
or ddG) in the presence of deoxynucleoside triphosphate (dNTP). Thermo Sequenase
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DNA Polymerase in reaction buffer was added and the tubes were placed on a thermal 
cycler (denatured at 95°C for 2 minutes, then 95°C for 30 seconds (dénaturation), 42°C 
for 30 seconds (annealing), 70°C for 1 minute (extension) for 30 to 40 cycles). Loading 
buffer (lOmM NaOH, 95% formamide, 0.05% bromophenol blue, 0.05% xylene cyanol) 
was then added and the reactions kept at -20°C for up to 2 weeks.
2.9.5. Cerenkov counting.
Preliminary experiments revealed the importance of an equal radioactivity loading 
between each well, to ensuie the most accurate detection of the protected areas, which are 
deduced by the comparison of band intensities between different lanes of the gel. The 
method used here allows an indirect measuiement of high-energy p-emitters such as ^^ P.
The Cerenkov effect is the generation of photons when a charged particle (e.g. electron) 
passes through a dielectric medium (e.g. air) (Parker, 1974) and was measured by placing 
a tube containing the radioactive sample dissolved in loading dye, in a scintillation vial. i
The activity was then semi-quantitatively assessed using a Wallac 1410 scintillation I
counter. Preliminary experiments revealed that the response (luminescence) was linear |
and very well and significantly correlated (r^=0.97, p<0.0001) to the amount of 
radioactivity measured, within the range of activities used for a DNase I footprinting 
experiment (data not shown).
2.9.6. Denaturing gel electrophoresis.
The samples and the sequencing reactions were loaded on at the same time, following 
heat dénaturation (95°C for 2 minutes) and 2 minutes in ice. Electrophoresis (45W 
constant power, 1600-2000V) was carried out in 6 % polyacrylamide gels containing 7 M 
urea in 0.5xTBE and pre-run for about one hour prior to loading.
2.9.7. Autoradiography.
After electrophoresis the apparatus was dismantled, the gel was transferred to a 
Whatmami filter paper and wrapped in cling film. It was then opposed to Kodak film for
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1-2 days (with intensifying screen) or 3-7 days (without intensifying screen) at -80°C to 
stop diffusion.
2.9,8. Binding site analysis.
Computer analyses were performed to identify potential transcription factors binding sites 
corresponding to DNase I protected areas of the -301/+7 region of the CYP3A4 promoter. 
Matlnspector 2.2 (available at transfac.gbf.de/cgi-bin/matSearch/) and AliBaba2 
(wwwiti. cs .uni-magdeburg. de/-grabe/alibaba21 were used to interrogate the Transfac 4 
database and searches were made using various levels of similarity to the consensus 
sequences to gain the most useful information.
2.10. Mutation detection in 11 human liver samples.
2.10.1. Liver samples used in this study.
The eleven human liver samples used were a gift ft om Dr D. Moore (Hoffman La Roche, 
Nutley, NJ, USA) and were obtained ftom Keystone tissue bank (PA, USA). They had 
previously been phenotyped for CYP3A and among the donors (5 males and 6 females), 
there was a 14.1-fold difference in midazolam metabolism (Table 2.4).
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Table 2.4. Human liver samples used in this study.
Donor code Age Ethnicity Gender CYP3A4 activity *
HL 02 24 Caucasian Male 350
HL 03 21 Caucasian Male 286
HL 13 11 African-American Female 626
HL 14 12 African-American Male 442
HL 15 28 Caucasian Female 759
HL 16 45 Aft'ican-American Female 1873
HL17 27 Caucasian Female 286
HL 18 48 Caucasian Female 183
HL 19 36 Caucasian Male 518
HL 20 40 Caucasian Male 133
HL21 61 Caucasian Female 746
*: The CYP3A4 activity was measured using a midazolam hydroxylation assay (CYP3A 
specific) and the results are expressed in pmol metabolite/min/mg.
2.10.2. Genomic DNA extraction from human liver.
Some DNA samples had previously been extracted by Dr Wafaa El-Sankary (University 
of Suirey). Gel electrophoresis and PCR were used to assess the integrity of the genomic 
DNA. Missing DNA samples, or samples of unsuitable quality were re-extracted ftom the 
human liver samples, using a QIAamp DNA mini kit (Quiagen), following the 
manufacturer’s instructions.
2.10.3. Polymerase Chain Reaction (PCR).
The primers for PCR were obtained from MWG Biotech (Milton Keynes, UK) and are 
described in Table 2.5. For CYP3A4 promoter region analysis they were designed using 
Vector NTI 4.0 (Informax, USA) whereas for the exon 7 analysis, sequences were 
obtained ftom the literature (Sata et al., 2000).
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Table 2.5. PCR primers used iu the mutation detection study. Subsequent inspection 
of the sequences revealed that primer +7B actually goes up to +9 in its 5’ region and that 
-301A reaches -300 bp only. The highlighted sequences represent the added restriction 
sites and the +7B (EcoRI) and -301A {Hind III) were used for subsequent cloning of the 
PCR products (see section 2.4.1).
Primer* Sequence
+7B 5 ’-C AC AGC AGTG ATTC AGTG AGG-3 ’
-301A 5 -AGACAAGGGCAAGAGAGAGG-3’
+7B {EcoRI) 5 -CCGGAATTC CACAGCAGTGATTCAGTGAGG -3’
-301A {Hind im 5’-CCCAAGCTTAGACAAGGGCAAGAGAGAGG-3’
-609A 5 ’-TAG ACTATGCCCTTG AGG AGC-3 ’
-556B 5 ’-TGTTTCC ACGCCTGTTTCCC-3 ’
-1086A 5’-ATCATTGCTGGCTGAGGTGG-3’
Exon7A 5’-CCTGTTGCATGCATAGAGG-3’
Exon7B 5 ’-G ATG ATGGTC AC AC ATATC-3 ’
* A: sense primer, B: antisense primer.
The Clontech Advantage® HF and HF-2 kits, which contain a high fidelity polymerase, 
were used. Each reaction mixture contained 40 to 200 ng genomic DNA, 100 pmol of 
each primer, 5 pi of lOx dNTP mix, 5 pi of lOx reaction buffer, 1 pi of HF polymerase 
and the volume was adjusted to 50 pi using nuclease free water. The PCR reactions were 
performed in a PTC-200 thermal cycler (MJ Research). The cycling conditions are 
described in Table 2.6.
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Table 2.6. Cycling conditions for the PCR reactions.
Fragment Dénaturation Annealing Extension
-301/+7 94 °C for 10 s 60 °C for 30 s 72 °C for 30 s
-609/+7 94 °C for 10 s 60 °C for 30 s 72 °C for 40 s
-1086/-556 94 °C for 10 s 65 °C for 30 s 72 °C for 45 s
Exon7A/B 95 °C for 30 s 55 °C for 30 s 72 °C for 60 s
Prior to cycling the tubes were incubated at 94 or 95 for 1 minute to fully denature the 
DNA template. Following 30-35 cycles, a final extension step was earned out (72°C for 5 
minutes).
2.10.4. Sequencing.
2.10.4.1. CYP3A4 promoter region.
Automated DNA sequencing was performed by Rachel Anderson (GlaxoSmitliKline) on 
an ABI prism 377 (Applied Biosystems). 200 to 400 ng of template DNA (purified PCR 
product) were mixed with 3pmol of the appropriate foiward or reverse primers (described 
in Table 2.5.). An additional internal primer was used for the reverse sequencing of the 
-609/-234 region inhe -609/+7 fragment (-234B: 5’-CTTATCAGAAACTCAAGTGG- 
3’).
2.10.4.2. Exon 7.
Automated DNA sequencing was performed by Ms D. Robillard (Endocrinology research 
group. University of Surrey), using a Thermo Sequenase’"'^  Cy"""" 5 dye terminator kit 
(Amersham Pharmacia Biotech) and read with a Long Read Tower™ system V 3.1, by 
Visible Genetics.
Some of the coding region analysis was carried out by Ms Donna McGowan (MSc 
Toxicology, 1999-2000) as part of her research thesis.
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2.10.5. Sequence analysis.
The sequences were then aligned against one of the published CYP3A4 sequence 
(Goodwin et al, 1999), available on the Internet at NCBI under accession number 
AF185589 (http ://www.ncbi .nlm.nih. gov/entrez/). The alignment analysis was carried out 
using ClustalW available on the Internet server of the Pasteur Institute, Paris 
(http://bioweb.pasteur.ff/seqanal/interfaces/clustalw-simple.html).
2.11. Site Directed Mutagenesis.
Two methods were used in order to modify the -301/+7 fragment of CYP3A4 promoter 
cloned into pSEAP plasmids using the unique site elimination method (Deng and 
Nickoloff, 1992). Briefly, the plasmid is denatured to separate both DNA strands and two 
oligomers are then annealed: one mutagenic primer containing the desired SDM 
modification and one selection primer mutating a unique restriction site within the 
template plasmid. The oligomers are used as primers for the DNA strand synthesis 
reaction containing a DNA polymerase and ligase. The plasmids which sequence has 
been altered are then amplified using DNA repair deficient bacteria and selected using 
the fact that non modified plasmids can be linearised by restriction digest at the unique 
restriction site and have a very low transformation efficiency compared to uncut 
supercoiled mutated plasmids with a mutated unique restriction site. Initially a Clontech 
Transformer site directed mutagenesis kit was used and the procedure was mainly carried 
out using manufacturer’s instruction (section 2.11.1) using pSEAP pro2 with a -301/+7 
insert as a template plasmid. Then, due to the lack of success in generating certain 
mutations with this method, a new protocol was developed (section 2.11.2) using 
pSEAP2-basic with XREM and -301/+7 insert as a template. The mutated promoter 
fragments generated in the pSEAP pro2 vector were then cloned into pSEAP2-basic with 
an XREM insert (procedure described in section 2.4). During cloning of the -301/+7 
fragment it was noticed that an insert contained a T->C substitution located at position -  
193 disrupting a putative HNF3 binding site. This was most likely to be a PCR artifact. 
This fr agment was called WT* and it was decided to investigate the effect of the SDM
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generated modifications in this vector in comparison to mutants generated in the true wild 
type (WT) plasmid (i.e. possible interactions between the mutations). A diagiam 
presented in chapter 5 (figure 5.6) describes all the constructs generated in the SDM 
experiments, they are also listed in the two bottom rows of table 2.9.
The mutagenic and selection primers are described in Table 2.7 and Table 2.8. Before use 
1 pg or 10 pg of oligomer was phosphorylated using 10 U of T4 polynucleotide kinase, 1 
mM ATP in kinase buffer (70 mM Tris-HCl pH 7.6, 10 mM MgCl2 and 5 mM DTT) in a 
final volume of 20 pi at 37°C for 60 minutes. The enzyme was heat denatured at 65°C for 
10 minutes.
Table 2.7. SDM mutagenic primers. The letters in underlined bold font represent the 
bases which are altered by the mutagenesis.
Putative 
site altered Sequence
Alteration
(WT*^mut)
ER6 CATAGAATATGTTCTCAAAGGAGAACAGTGAGTGG
Sp 1 GGAGAAGCCTCTTTT AACTGC AGGC AG
HNF3 GATTGATTGAGTTGTGGATGATACCTCATA
C/EBP GTGTGTGTGATTCGAGGCCACTTCCAAGG
M - ^ ï ï  and 
GT-»AA 
CC-»TT 
TT>»GG 
TTT-»GAG
Table 2.8. SDM selection primers.
Name (vector mutated) Restriction Sequence
site modified
Selection 1 (pSEAP2-pro Eco47 III 
and pSEAP2-basic)
Selection2 (pSEAP2-pro) Xba I 
Selection3 (pSEAP2- Sal I
basic)
GTGCCGGCACTAGTCTTCCGCTTC
CCCGGGTTACTCACGTGTCGGGGC
AAGGATCCGTATACCGATGCC
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2.11.1. Initial SDM protocol.
Gel purified WT* or WT plasmid (100 ng) was added to amiealing buffer (20 mM Tris- 
HCl, pH 7.5,10 mM MgCli and 50mMNaCl) and lOOng of both selection and mutagenic 
primer. The volume was adjusted to 20 pi with water. The annealing reaction was then 
heated for 3 minutes at 100°C and immediately transferred to an ice water bath for 5 
minutes. After the tube was spun down, T4 DNA ligase (2-4 units) and T4 DNA 
polymerase (2-4 units) were added to synthesis buffer (proprietary composition, contains 
a nucleotide mixture in Tris-HCl, pH 7.5) in a final volume of 30 pi. The synthesis 
reaction was incubated at 37°C for 2 hours. The DNA was then digested using 5-10 units 
of the appropriate restiiction enzyme (see table 2.8) with 0.01 pg/ml BSA in a final 
volume of 50 pi at 37°C for 2 hours and DNA repair deficient tww/S E. coli cells were 
transformed with 10 pi of the reaction (equivalent to 20 ng plasmid DNA from the initial 
reaction). After overnight culture in LB ampicillin the plasmid DNA was recovered by a 
miniprep procedure and 100 ng were digested again with the same restriction enzyme. A 
25 ng ftaction of the digest was used to transform Topi OF’ bacteria as described in 
section 2.2.3. The transformation reaction was plated on LB agar with ampicillin and the 
mutant selection was carried out by growing individual colonies in LB ampicillin, 
extracting the DNA (miniprep) and digesting the plasmid with the restriction enzyme 
which unique recognition site is modified by the selection primer. Positive (uncut) 
constructs were sequenced and it was found that the fraction of false positive (with a 
modified restriction site but with no mutation in the CYP3A4 promoter fi*agment) varied 
greatly between experiments. In order to increase the mutation efficiency of certain 
primer combinations, the amount of mutagenic primer was increased ft om 100 ng to 1 pg 
in order to achieve a 10-fold excess compared to the amount of selection primer 
(Hutchinson and Allen, 1997). This procedure only worked for the generation of the WT* 
mutants in the initial stages of the project.
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2.11.2. Second SDM protocol.
A second method was developed in order to generate mutations in the WT fragment and 
this proved more efficient at generating mutations. It is a combination of the Clontech 
Transformer site directed mutagenesis kit and Promega Altered sites II system and is 
described below. The plasmid template was initially denatured before the annealing. This 
was done by incubating 2.5 pg DNA with 400 mM NaOH (final volume 20 pi) for 10 
minutes at room temperature. The reaction was neutralised by the addition of 4 pi 3 M 
NaOAc (pH 4.8). The plasmid was ethanol precipitated, washed in 70 % ethanol and 
resuspended in 20 pi water. A sample was mn on a 1 % agarose gel to assess the DNA 
concentration.
The annealing reaction consisted of Clontech annealing buffer (20 mM Tris-HCl, pH 7.5, 
10 mM MgCli and 50mM NaCl), 75 ng selection primer, 1 pg mutagenic primer and 100 
ng denatured DNA. The reaction was heated at 75°C for 5 minutes and cooled down to 
room temperature at the rate of l°C/s using a theimal cycler. The synthesis reaction was 
then carried out using Promega ligase buffer (30 mM Tris-HCl pH 7.8, 10 mM MgCl2, 10 
mM DTT and 1 mM ATP), 10 U T4 DNA polymerase, 3 U T4 DNA ligase, 0.5 mM 
dNTP in a final volume of 30 pi for 2 hours at 37°C. The enzymes were denaturated at 
70°C for 5 minutes then digested using the appropriate restriction enzyme. A fraction of 
the digest representing 20 ng of DNA was used to transform ?nutS E. coli cells and the 
remainder of the protocol was carried out as described above (section 2.11.1). It was 
found that the second protocol generated a higher proportion of mutant plasmids than the 
first one used (about 10 times more efficient). It should be noted that in spite of the 
differences in procedure or selection primers, the resultant plasmids were identical apart 
from a few bp located in the unique restriction site used for mutant selection and these 
were specifically located on the opposite end of the plasmid to the CYP3A4 promoter 
fragment of interest. These mutations should therefore not interfere with DNA:protein 
interactions within the promoter region or affect the coding region for the reporter gene 
product.
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2.11.3. Generation of competent Æco/f BMH 71-18 mutS bacterial cells.
The cell stock was streaked on a LB agar plate containing 50 pg/ml tetracycline and were 
grown overnight at 37°C. A single colony was picked and giown overnight in LB broth 
(50 pg/ml tetracycline). 1ml of this miniculture were then used to inoculate 100 ml of LB 
broth in a sterile flask and the cells were grown at 37°C until the OD at 600 nm of the 
suspension reached 0.5+0.03 (usually 3 hours post inoculation). The flask was chilled on 
ice for 20 minutes and cells were then collected by centrifugation (1200 x g for 5 minutes 
at 4°C) and resuspended in ice cold 10 ml TSS (Transformation and Storage Solution : 
85% LB medium, 10% w/v PEG molecular weight 8000, 5% DMSO and 50mM MgClg 
(pH6.5)). The competent miitS E. coli were then used for a transformation reaction 
(described in section 2.2.1) or aliquoted in sterile tubes and stored at -80°C for later use 
up to 2 months after preparation.
2.12. Transient transfection protocol for the reporter gene assay.
The protocol was taken from Dr Hossein Hamzeiy (Hamzeiy, 2002) with minor 
modifications.
2.12.1. Plasmids.
Following preliminary transfection experiments all -301/+7 promoter fragments 
generated by SDM in pSEAP2-pro were cloned into pSEAP2-basic containing the 
XREM (distal enhancer) insert. Briefly, in this system it was found that inducibility of the 
reporter gene construct was only seen in the presence of the XREM when cloned next to 
the promoter of interest. During preliminary experiments a comparison of the induction 
profile was carried out between the -1201/-61 region of CYP3A4 promoter versus the 
“301/+7 region in plasmids containing the XREM element (-1201/-61 is described in
6 8
(Hamzeiy et a l, 2002)). The plasmids used in this study are listed in table 2.9 and a 
general map of the vector is described at the begimiing of this chapter (figure 2.5).
Table 2.9. Plasmids used in the transient transfection experiments.
Reference plasmid Test plasmid
WT -1201/-61
WT* pER6*, pSpl*, pHNF*, pCEBP*
WT pSpl, pHNF, pCEBP
e.g. pER6* represents the pSEAP2-basic vector with XREM insert, containing the 
“301/+7 insert of promoter (WT* version) modified with the ER6 mutation described in 
table 2.7. The corresponding reference plasmids contain the wild type -301/+7 insert 
(WT) or the -301/+7 insert with the -193 T>C substitution (WT*).
2.12.2. Cell seeding.
Near confluent (-90%) HuH7 cells were hai’vested by trypsinisation as previously 
described. The suspension was spun for 5 minutes at lOOOrpm, the supernatant removed 
by aspiration and the pellet washed in 5ml PBS. The cells were resuspended in 5ml 
DMEM and counted using a haemocytometer. The suspension was then diluted using the 
appropriate amount of DMEM to a concentration of lO^cells/ml. The cells were seeded in 
a 96 well plate (120pl/well, equivalent to 12000 cells/well), avoiding the use of the 
outside wells because of the presence of an edge effect caused by evaporation detected in 
preliminary experiments. The outside wells were filled with PBS (120pl/well). The plates 
were incubated in a humidified container for 48 hours at 37°C.
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2.12.3. Transfection.
Previous transfection protocols in our laboratory relied on the calcium phosphate 
precipitation method to achieve transfer of the plasmid DNA into cells, (e.g. Ogg et al, 
1999). In this work Fugene 6 Transfection Reagent (Roche) offered a more efficient 
alternative and was used following manufacturer’s recommendations. The components of 
the incubation mixture were added to a sterile microcentrifuge tube and incubated for at 
least 30 minutes at room temperature. The order of addition was critical (based on the 
manufacturer’s instructions) and was as follows; serum free DMEM (for a final volume 
of lOOpl), 10 pi of Fugeneô (care was taken to minimise contact between plastic surfaces 
and undiluted reagent), 2 pg of plasmid DNA, 1.5 pg of hPXR expression plasmid. After 
incubation 5 ml of semm free DMEM were added. The amounts of reagent and DNA 
were adjusted proportionally to this final volume of medium according to the needs of the 
experiments.
The DMEM from the HuH7 seeded plates was removed by inverting and shaking the 
plates in order to avoid disruption of the cell layer by the pipette tips. The transfection 
mixture was then added to the cells (120pl/well) and the plates incubated at 37°C for 24 
hours. It is worth noting that during initial experiments it was found that a shorter (6 
hours) incubation period could also be used as this was sufficient to produce good levels 
of transfected cells as determined by the SEAP levels on day 1.
2.12.4. Dosing of the cells with rifampicin (day 1 and day 3).
During preliminary experiments it was found that the different mutated plasmids, as well 
as plasmid from different maxipreps, varied in terms of transfection efficiency. In order 
to assess this phenomenon, a lOpl sample was taken from each well to measure the levels 
of alkaline phosphatase on day 1 (prior to drug treatment) and this value was used to 
noiTnalise the reporter gene levels obseiwed in day 3. It was assumed the measurement of 
SEAP production in the medium by the transfected constructs reflects the amount of
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plasmids in the cells of a given well. It also takes into account any endogenous activation 
(e.g. endogenous SXR ligands). This was preferred to the use of co-transfection with 
another plasmid (e.g. p galactosidase) because upon xenobiotic treatment the 
transcription levels of the latter may be altered and the induction of the two plasmids may 
not be relative. Additionally the transfection efficiency of the two plasmids may differ. 
The remaining medium was removed by inverting and shaking the plates and replaced 
with fresh medium containing various concentrations of xenobiotic dissolved in DMSO 
(usually 0.5 to lOpM rifampicin). The solvent concentration was kept constant between 
treatments to 0.1%. The plates were incubated at 37°C for 48 hours and lOpl samples 
were taken to measure the levels of alkaline phosphatase on day 3 in order to assess 
induction of the constructs caused by rifampicin treatment.
2.12.5. Chemiluminescent detection of SEAP protein activity.
The levels of alkaline phosphatase secreted in the cell culture medium were assessed 
using a chemiluminescent alkaline phosphatase assay (Aurora kit, ICN Pharmaceuticals) 
with minor modifications to the manufacturer’s protocol. Eighteen microliters of Ix 
dilution buffer were added to lOpl of medium in each well of a 96-well optiplate 
(polystyrene microplates). The mixture was incubated at 65°C for 30 minutes in order to 
remove any endogenous alkaline phosphatase activity and then cooled on ice to room 
temperature. 24p.l of assay buffer were added and the plates were incubated for 5 minutes 
at room temperature. Then 24pl reaction buffer (containing the substrate) were added and 
the plates were incubated at room temperature for 20 minutes. The plated were read on a 
Lumicount plate reader (Packard) with an optimal gain and photomultiplier settings 
automatically determined by the machine after screening the plate for the maximum and 
minimum luminescence values.
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2.12.6. Data analysis of the reporter gene assay.
The day 1 and day 3 values were corrected for gain difference by multiplying the day 3 
value by the ratio of the gain on day 3 / gain on day 1. The values were then corrected for 
transfection efficiency (value on day 3 / value on day 1) and averaged (n=6 ).
The induction was modeled using the following hyperbola equation (GraphPad Prism’’'^ , 
version 2 .0 0 ):
Y=Imax*X/(EC50+X)
where Y is the induction, X the xenobiotic concentration, I^ax the maximal induction 
and EC5 0  the concentration of ligand required to reach half-maximal induction. The 9 5 % 
confidence intervals for the variables was calculated using the software. Following non­
linear regression analysis, r^  values ranged from 0.40 to 0.85, meaning that by using this 
model, 40 to 85 % of the induction was explained by the increasing amounts of 
rifampicin. In order to fuither investigate the effect of the mutations, individual data 
points were compared between constructs transfected in cells exposed to similar 
rifampicin concentrations. The data normality was first confirmed by a Kolmogorov- 
Smirnov test and the comparisons were made using an unpaired t-test with Welch 
correction.
72
C h a p t e r  3 - C h a r a c t e r is a t io n  o f  D N A :p r o t e in
INTERACTIONS IN THE CYP3A4 PROXIMAL PROMOTER.
3.1. Introduction.
In order to elucidate the molecular mechanisms of CYP3A4 gene regulation it is 
necessary to identify which proteins may bind to the regulatory regions to ftirther 
determine the factors driving expression (e.g. hoimone specific and tissue specific 
signals). Several reports have demonstrated that the first 300 bp of CYP3A4 proximal 
promoter may act as a basal transcription unit confen'ing responsivity to several classical 
CYP3A4 inducers in reporter gene assays (Barwick et al, 1996; El Sankary et al, 2002). 
Within this region an everted repeat (ER6) was identified as the binding site for the SXR, 
an important regulator of CYP3A4 induction (Lehmann et al, 1998). To date this is the 
only c/s-acting element that has been experimentally defined within the proximal 
promoter.
In addition to the proximal promoter a second region with an important role in CYP3A4 
expression has previously been characterised. The distal enhancer (XREM) was shown to 
be located fiom in the 5’ flanking region of the transcription start (-7836 to -7607) and 
nucleai' receptor binding sites for SXR as well as possible binding sites for other 
transcription factors were identified with DNase I footprinting and reporter gene assays 
(Goodwin et al, 1999).
To further examine DNA:protein interactions within the proximal promoter it was 
decided to carry out a mapping study to determine other cw-acting elements apart from 
the ER6 within this important regulatory region. As the hepatoma cell line HepG2 had 
successfully been used in reporter gene assays in our laboratory (El Sankary et al, 2002; 
El Sankary et al, 2001; El Sankary et a l, 2000; Ogg et al, 1999) it was hypothesised the 
transcription factors necessary for CYP3A4 regulation are expressed within this cell line 
and nuclear extracts were prepared. DNA:protein interaction were first confirmed using
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EMSA and HepG2 nuclear. Following this the nature of these interactions was examined 
using DNase I footprinting and bioinformatics analysis.
3.2. Results.
3.2.1. Electrophoretic motility shift assay for the proximal promoter (-307/+7 
region).
The photograph in figure 3.1 (panel A) shows a typical EMSA gel where the -301/+7 
DNA probe was incubated with varying amounts of HepG2 nuclear extract. Tlnee 
retarded bands were observed with higher molecular weight complexes being observed 
with the highest protein concentrations. It should be noted that for in the lanes with the 
highest protein amounts some of the probe was left in the wells where the samples were 
loaded and did not fully enter the gel. A competition experiment carried out using 
unlabelled -301/+7 as a competitor shows that the binding is reversible following the 
addition of lOOx excess cold probe (see panel B in figure 3.1).
3.2.2. Fooprinting analysis.
In order to identify the protein binding pattern in each DNA-protein complex seen in the 
EMSA experiments, in vitro copper-phenanthroline footprinting was attempted (see 
figure 2.7, protocol 1). This technique consists in the chemical digestion of DNA from 
individual bands cut out fiom a polyacrylamide gel. However, as several attempts to 
carry out this assay were unsuccessful this procedure was discontinued and DNase I 
footprinting was carried out as an alternative. The results presented below were generated 
using a method adapted from a commercial kit (figure 2.7, protocol 3)
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3.2.2.1. Positive control using recombinant AP2 and SV40 enliancer element.
A protected area was observed when the single end labelled SV40 probe was incubated 
with a recombinant AP2 protein and digested with DNase I (data not shown). This proved 
the protocol used allowed for the identification of protein binding sites in the test DNA 
sequence.
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Figure 3.1. Autoradiograms of EMSA experiments. A: a radiolabelled -301/+7 
DNA probe was incubated with increasing amounts of HepG2 nuclear protein. B; the 
same labelled probe was incubated with increasing amounts of HepG2 nuclear protein 
and the same reaction containing 40 pg proteins was spiked with increasing amounts of 
unlabelled probe to compete the binding. This experiment was carried out four times and 
was reproducible.
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3.2.2.2. Optimisation of in vitro DNase I footprinting of the -301/+7 fragment.
An experiment was carried out in order to optimise DNase I cutting with a range from 
0.05 to 0.60 U of enzyme (data not shown) and the final DNase I activity chosen was 
0.15U. In several subsequent experiments binding buffers containing high and low salt 
concentration were used (25 and 100 mM KCl), as well as various amounts of nuclear 
proteins in order to investigate the effect of these two variables on the protected area 
pattern on both DNA strands. It also appeared that varying the electrophoresis time 
allowed for a better detection of protected areas located towards the extremities of the 
probe (i.e. longer electrophoresis for the larger fragments and short electrophoresis for 
the small fragments). The initial methods included the use of poly-dI:dC, which prevents 
non-specific binding of proteins to DNA. However, the binding buffer in the Promega 
Core Footprinting kit purchased did not contain any poly-dI:dC. In an experiment using 
the optimised assay conditions, 50pg of protein and 3pg poly-dI:dC were included in a 
footprinting reaction and the presence of this compound did not appear to affect the 
protection pattern. Hence poly-dI:dC was not included in further experiments.
3.2.2.3. Footprinting of 3 overlapping fragments and composite model of nuclear protein 
binding to the CYP3A4 -301/+7 proximal promoter fragment.
A representative DNase I footprinting experiment using the -301/+7 probe is shown in 
figure 3.2. Comparison of the digestion pattern in the presence or absence or proteins 
allowed for the identification of several DNArprotein interaction sites within the 
fragment. Suiprisingly all footprinting experiments failed to demonstrate any protein 
concentration-dependent effect on the binding pattern in contrast to what was suggested 
by the presence of several complexes (states of binding) obseived in the EMSA 
experiment (see section 3.2.1). Also footprinting experiments using nuclear extracts from 
rifampicin or dexamethasone treated HepG2 cells failed to reveal any qualitative change 
in the binding pattern (not shown). Protected areas near to the ends of the probe could not 
be assessed because the bands were too faint or the pattern was not found to be 
reproducible. Because of the lack of resolution on the edges of the DNA fragment it was 
decided to amplify 2 overlapping probes fr om genomic DNA and to carry out the DNase
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I footprinting protocol. Fragments representing the -388/-S3 and -240/+69 regions of the 
CYF3A4 promoter were processed as described for the -301/+7 fragment. Unexpectedly 
the protein binding pattern from those 2  new probes did not exactly match that of the first 
probe. It was then decided to generate a model representing the protein binding site 
pattern in agreement with at least 2  of the DNA probes used. Following footprinting 
experiments on both strands, a composite diagram of protected areas was constructed 
(figure 3.3). Putative transcription factor binding sites were assigned using the Alibaba2 
search programme to inteiTOgate the Transfac 4.0 database, with assignment based upon 
liver specificity of transcription factors or known involvement in CYP3A gene regulation. 
It can be noted that some binding regions are far wider than the putative binding sites 
suggesting the presence of multiple overlapping regulatory sites. It is interesting to note 
that the site containing the previously identified T>C mutation (-190 bp from the 
transcription start, see chapter 5) was protected, indicating the binding of one or several 
types of HepG2 nuclear proteins to this region. According to this model the potential 
tianscription factor binding sites were the ER6  (where CAR, SXR may bind) as well as 
response elements for Spl, Octl, HNF3, AP2 and C/EBPa.
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Figure 3.2. Typical autoradiogram of an in vitro DNase I footprinting experiment on
the -301/+7 region of the CYP3A4 gene. The end-labelled probe was incubated with 
increasing amounts of nuclear proteins from HepG2 cells. This experiment was repeated 
four times and was reproducible.
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Figure 3.3. Composite model of the protein binding to the -301/+7 region of the 
CYP3A4 gene using in vitro DNase I footprinting on the -301/+7, -388/-83 and -  
240/+69 promoter fragments.
AGACAAGGGC AAGAGAGAGG C G A T T T A A T A  G A T T T T A T G C  C A A TG G C T C C  
T C T G T T C C C G  T T C T C T C T C C  G C T A A A T T A T  CTAA A A T AC G  GTTA C CG A G G
■1 - 2 5 0A C T T G A G T T T  C T GA T AA G A A  C CC A G A A CC C  
T GAACTCAAA G A C T A T T C T T  G G G T C T T GG G
G AT TG A G TT G TTTJAT(TATAC CTCIATAGAAT
TTGI GACTCCC CAGT| AACATT 
A A c k l ^ G A & G G  fexICATTGTAA 
A P 2  C / E B P a
a i t g a a c t C A A  A G G A G G T C A G
C T AACT CAA C A A A ^ A d f A T G  G A G T A T C T T A  T T T 5 A(5 T T T i  Ô T C C A 6 TC
HNF3 C / E B P a Oct-1 ER6
TGAGTGGTGT G T GTG T G A T T X T T T GCCAAC T TC C AA G G T G GAGAAGCCTC
A CT CA C CA C A CACACA ÜTAA GAAA CGG TTG A A G G T TC C AC C T CT T C G G A G
HNF3-C /EBPa
TTCCAA a Gg c a g AGCA CAG G TG G C CC
AAGGTT GÀÙÔ f t C G T t f TCGT G T C C A C CG G G
spl spl
TATA box
g ' c C C T G C C T C  C T T C T C T A G C  APTATAAA 
CGGGACGGAG G AAGA GATCG T A t A T T f  
spl  - sp l
A CT GC T GT G C 
TGACGACACG 
t ranscription s ta r t
TGC|TACTG|GC 
ACG A'i’G A c  CG
G CT CC A
JCGAGGT
CAA
G T T
T CC AA C AG C C T C AC T G A A T C  
A G G T T G T C G G  A G T GA CT T A G
: protected regions.
The transcription putative binding site (underlined) are described in the text and were 
assigned using the Alibaba! programme to interrogate the Transfac 4.0 database.
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3.3. Discussion.
3.3.1. Electrophoretic motility shift assay for the proximal promoter (-307/+7 
region).
This experiment was carried out to confinn that under the experimental conditions 
examined HepG2 nuclear proteins could interact in vitro with the CYP3A4 promoter 
fragment. The results indicate that nuclear proteins do bind to this regulatory region and 
that this binding seems to be influenced both quantitatively and qualitatively by the 
protein concentration. Indeed thiee retarded bands in total were obseived, suggesting the 
presence of at least thiee different DNA-protein complexes. The molecular weight of 
each type of complex is inversely proportional to the distance of migration and heavier 
DNAiprotein complexes were obseived for increasing amounts of protein in the binding 
reaction. The nuclear proteins bind with high affinity because some of the complexes 
started disappearing in the presence of a 1 0  fold molar excess of unlabelled oligomer and 
were completely competed out with 100 fold excess unlabelled probe. This therefore 
demonstrates the specificity of the observed DNA:protein interactions.
3.3.2. In vitro DNase I footprinting of the -301/+7 fragment: method optimisation 
and technical considerations.
Buffer salt concentration (IC^  at 25 or 100 mM) did not seem to have an effect on the 
protection pattern (data not shown). This is surprising since the ionic strength of the 
buffer should modify the protein binding kinetics and the affinity (Garabedian et al, 
1993).
There is a certain lack of correlation between the EMSA and footprinting results since no 
concentration effect was seen on the protein binding in the latter assay. Addition of 
increasing amount of proteins had no qualitative or quantitative effect on the apparent
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binding. The reason(s) for this discrepancy are unknown. It could be because the 
differing assay conditions may favour alternate interactions.
The protection pattern showed little binding at both extremities of the -301/+7 fragment. 
Such an effect may be as a result of several reasons. Firstly DNA:protein interactions 
may not be stable near the termini of the fragments, preventing full DNase I protection. 
Secondly technical considerations such as compression at the top of the gel and diffusion 
(resulting in weaker signal) near the bottom of the gel may make identification of 
protected regions more difficult. Due to this it was decided to examine three overlapping 
fiagments and combine the protection patterns seen in the centre of each fragment to 
obtain an overall pattern
3.3.3. General footprinting pattern analysis of the 3 overlapping fragments and 
composite model of nuclear protein binding to the CYP3A4 proximal promoter.
The lack of concordance in the protein binding between the three fragments tested 
(-3887-83, -3017+7, -2407+69) was unexpected since the regions of overlap between the 
probes contain the same DNA sequences and therefore should be recognised by the same 
factors. Besides the fact that this phenomenon could be due to a technical error, this result 
may possibly reflects protein-protein interactions occuning within the CYP3A4 promoter. 
The binding of a given factor may require, or be enhanced by, the presence of other DNA 
binding proteins. For example, members of the C/EBP family can interact with other 
transcription factors such as NF-icB via their leucine zipper motif (LeClair et al, 1992) 
and hence influence their binding to DNA. Wlien comparing the different probes used in 
this study it may be that some of the binding sites occupied in one fragment may be 
unoccupied in the others because some DNA sequence necessary for the binding of an 
interacting protein is absent in that particular fragment. To circumvent such potential 
problems DNArprotein interactions were only assigned if they were present in two of the 
thiee fragments tested (i.e. they showed a high confidence of being real).
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The footprinting pattern shows large footprints covering several putative transcription 
factor sites (figure 3.3). This suggests the presence of composite binding sites due to 
association of several factors. The high degree of binding to this region is not surprising 
since its importance in trans-activation assays has been shown to be critical (Hashimoto 
et al, 1993) and it also confers responsiveness to many CYP3A4 inducers in primary 
hepatocytes and hepatoma cell lines (e.g. Barwick et al, 1996; El Sankary et al, 2002). 
The fact that several of the putative binding sites are recognised by factors from the HNF 
and C/EBP families is consistent with the liver expression of these factors (Xanthopoulos 
et al, 1991). In fact a link has been suggested between the low cytochiome P450 content 
and the low abundance of liver enriched transcription factor in de-differentiating 
hepatocytes and cell lines (Rodriguez-Antona et a l, 2002).
In concordance with the published literature for the XREM region (Goodwin et al, 
1999), the observed binding pattern to the 300 bp 5’ of the transcription start was not 
changed by the use of nuclear extracts fiom xenobiotic treated HepG2 cells. Footprinting 
patterns of the rat CYP3A1 promoter with extracts from rat liver from control and 
dexamethasone-treated animals were also found to be identical (Quattrochi et al, 1995), 
suggesting this may be a general phenomenon of CYP3A proximal promoters and not a 
species specific effect. Because the drug concentration and cell treatment were similar to 
conditions where a CYP3A4 promoter construct can be trans-activated in a reporter gene 
assay (El Sankary et al, 2000; Ogg et a l, 1999), it can be hypothesised that all 
transcription factors necessary for promoter activation are present within the nuclear 
extracts. This could suggest either that this technique is not suitable for measuring 
quantitative changes in receptor association with a promoter or that the receptor 
association is not altered by xenobiotic exposure and instead other regulatory proteins 
interact with the co-associated protein to increase their ability to activate transcription. 
The former hypothesis is confirmed by work described in chapter 5 where a single base 
pair mutation which had an effect on glucocorticoid mediated activation of a -301/+7 
construct did not cause any noticeable change on the nuclear protein binding pattern in 
footprinting experiments. Instead the change in affinity could be measured by EMSA in a 
competition assay with unlabelled competitor probes (El Sankary et al, 2002). The latter
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hypothesis may also be valid in this situation since nuclear receptors are known to recruit 
co-activators upon ligand binding and to interact with repressor proteins when inactive 
(e.g. Jenster, 1998). Indeed following xenobiotic activation SXR has been shown to 
recruit the SRCl co-activator protein in a concentration dependent fashion (Kliewer et 
al, 1998). Additionally SXR has been shown to interact with the transcription repressor 
protein SMRT (Silencing Mediator for Retinoid and Thyroid receptors) (Takeshita et al,
2002). The fact that SXR (and potentially other transcription factors) associates with 
repressors but may still bind to promoters in the basal state and thereby inhibit the 
transcription machinery is also suggested by experiments in SXR knockout mice. 
Homozygous knockout mice expressed cypSall at a higher level (~4 fold higher) than 
the wild type animals (Staudinger et a l, 2001) suggesting that removal of SXR may 
actually increase transcription levels in some circumstances. However, in another study 
on PXR knock-out mice (Xie et a l , 2000b) ablation of the receptor was not reported by 
the authors as being the cause for an up regulation of the cypSall gene. However, closer 
inspection of the Northern blot data from this paper suggests up-regulation may be indeed 
occurring (figure Ic in Xie et a l, 2000b). Alternatively the discrepancy between the 
papers could be explained by differences in the choice of sequence used to target and 
disrupt the SXR gene, although this is unlikely.
3.3.4. Transcription factors potentially binding to the CYP3A4 promoter region.
Based on an assessment of the current literature and the data presented above the 
following factors have been selected as potential candidate transcription factors involved 
in CYP3A4 regulation.
3.3.4.1. Specificity protein 1 (Spl).
This transcription factor is part of the Sp-protein family which mainly binds to GC/GT 
boxes in the promoters of several genes (Suske, 1999). Spl is involved in the regulation 
of cell cycle regulated or hormonally activated genes and has been shown to be crucial in
the developmental process (Suske, 1999). Indeed disruption of Spl binding to the 
promoter of genes involved in the development by thalidomide is a candidate mechanism 
for this compound toxicity (Stephens et a l , 2000). This transcription factor has also been 
found to interact with Pit-1 with both having the ability to bind to their overlapping 
binding sites (Schaufele, 1990).
Spl recognises sequences in the proximal promoter and the enhancer (PBRE) of the 
CYP2B1 gene (Muangmoonchai et a/., 2001). Experiments in rat hepatocytes have 
demonstrated that this factor enhances the basal activity of the CYP2B1 proximal 
promoter and also increases both the basal and phenobarbital-induced activation in the 
PBRE regulatory region (Muangmoonchai et al, 2001).
Spl and Sp3 could both bind a NF-KB-like response element in the promoter of the 
CYP3A7 gene (GGCAAGTCCC) (Saito et al, 2001). However, this would not occur in 
the same region of the CYP3A4 promoter (GTCAAGTCCC) due to a 1 bp change in 
sequence. This element is located at approximately 2300bp away from the transcription 
start of CYP3A7 but does not exclude that closer putative binding sites may be functional. 
Indeed, using gel shift assays with unlabelled competitors and specific antibodies, Spl 
was found to bind to the BTE region of the CYP3A5 gene and to activate reporter gene 
constructs (Iwano et al,, 2001), Also in the same study the authors claim proteins from 
the Sp family also binds to the same BTE element of the CYP3A4 and CYP3A7 genes 
(unpublished data in Iwano et a l, 2001). This contradicts findings from this study since 
the model in figure 3.3 does not indicate any binding to this site.
3.3.4.2. Hepatocyte Nuclear Factor 3 (HNF3) and members of the HNF family.
HNF3 is a transcription factor involved in the tissue specific expression of numerous 
genes (e.g. Darlington, 1999). Therefore HNF3 and other members of the HNF family are 
likely to play a role in the expression of the CYP3A4 gene.
HNF4 is another member of the HNF family and it has been shown to be involved in the 
regulation of the rat CYP3A23 gene (Huss and Kasper, 2000) and members of the CYP2C 
gene sub-family (Chen et al, 1994). Using adenoviral vectors coding for antisense HNF4 
RNA resulted in a loss of receptor protein and a decrease in the expression of CYP3A4
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and various other CYP genes (Jover et ah, 2001). If HNF4 is not directly involved in 
CYP3A4 regulation, data from HNF4 knock out mice indicate that this transcription 
factor is involved in maintaining mouse PXR expression (Li et al, 2000), which in turn 
would have an effect on CYP3A target genes.
It is interesting to note that some reports have proposed a role for HNF4 as a possible 
mediator of the effects of nitric oxide (NO) on cytochrome P450 gene expression. This 
molecule is involved in signalling during inflammation or infection. Reporter gene assays 
demonstrated that CYP2D6 gene down regulation following NO treatment was caused by 
the loss of protein binding at an HNF4 site (Hara and Adachi, 2002). It was suggested 
that this could take place through S-nitrosylation of cysteine residues at the level of the 
DNA binding domain thereby reducing the DNA binding activity of the receptor (Vossen 
and Erard, 2002).
3.3.4.3. CCAAT/enliancer binding protein alpha (C/EBPa).
As with the members of the HNF family, C/ EBPa is part of a gene family involved in 
the regulation of liver specific gene expression (Darlington, 1999). It is mainly expressed 
in the liver but is also expressed in adipose tissue (Lekstrom-Himes and Xanthopoulos, 
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C/EBPa is generally thought to be involved in the control of genes involved in energy 
homeostasis. Mice lacking C/EBPa were found to die within 8  houi’s of birth due to their 
inability to store glucose through down-regulation of a number of key genes including the 
neoglucogenic enzyme phosphoenolpyruvate carbokinase (PEPCK) (Wang et al, 1995). 
C/EBPa has been reported to increase the activity of the -169/4-11 fragment of the 
CYP3A4 promoter together with another liver specific element (D element binding 
protein) (Ourlin et al, 1997), However, because this efiect was cell line dependent it 
cannot be excluded that the activation observed was due to increased production of 
another CYP3A4 regulating transcription factor whose expression was dependent on 
C/EBPa. It should be noted that in the same study a construct containing the CYP3A7 
regulatory region was not activated by the D element binding protein. This could 
constitute a molecular basis for the developmental pattern of CYP3A gene expression.
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A very recent report suggests the presence of two functional binding sites for C/EBPa in 
the -350/-311 and -628/-608 regions of the rat CYP3A1 gene promoter (Rodrigues et al,
2003). Although the rat and human CYP3A regulatory sequences are different it is not 
umeasonable to assume that they may share a certain degree of resemblance in terms of 
the transcription factors affecting the proximal promoter activity, thus strengthening the 
case for the involvement of C/EBPa in the regulation of CYP3A genes
3.3.4.4. Factors binding to the everted repeat 6  (ER6 ).
As expected from previous experimental evidence (e.g. reviewed in Honkakoski and 
Negishi, 2000) the ER6  site of the CYP3A4 promoter was occupied by nuclear proteins 
from HepG2 cells. However, this is the first time this binding has been obseiwed within a 
sequence larger than the ER6  element itself, taking into account potential interactions 
within the promoter that might affect this binding.
Two of the nuclear receptors occupying this site are most likely to be CAR and SXR, 
since both have been shown to bind to the ER6 , as heterodimers with RXR, using 
transfection assays and EMSA (Xie et a l, 2000a) and were also shown to bind several 
CYP3A4 inducers (Moore et al., 2000). This cross talk between the two nuclear receptors 
is well documented and it is now known that SXR can activate what were thought to be 
CAR target genes and vice-versa CAR can activate what were known to be SXR target 
genes (Smirlis et al, 2001).
Recent research has shown that the ER6  sequence is also a functional binding site for the 
vitamin D receptor (VDR). The earliest report demonstrates a dose dependant induction 
of CYP3A4 mRNA by the natural VDR ligand la,25 dihydroxyvitamin Dg (l,25-(OH2)- 
D3) in the intestinal Caco2 cell line(Schmiedlin-Ren et a l, 1997). The vitamin D 
analogue 19-nor-la, 25 dihydroxy vitamin D2 was later shown to cause an induction in 
this cell line although this was to a lesser extent (Thummel et al, 2001). CYP3A catalytic 
activity and protein content, as well as CYP3A4 mRNA were induced by 1,25 dihydroxy­
vitamin D3 in another colon cell line (LSI80), a pancreas derived cell line (HPAC) and 
human hepatocytes. However, the liver (HepG2) and stomach (Hs746T) cell lines did not 
support induction (Schmiedlin-Ren et al, 2001). Experimental evidence suggests a role
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for the VDR since this receptor binds to the ER6  sequence in vitro and in a reporter gene 
assay exposure to l,25-(OH2)-D3 was shown to activate an ER6  construct in the presence 
of a VDR expression plasmid but not in the presence of a PXR expression plasmid 
(Thummel et al, 2001). Using antisense RNA technology the role of VDR was further 
established as the induction was suppressed in Caco2 cells failing to express the receptor 
(Hara et a l, 2002).
VDR is also involved in the regulation of other CYP genes such as CYP2C9 and CYP2B6 
through response elements that were previously shown to be transactivated by CAR and 
SXR (Drocourt et a l, 2002). In addition to inducing CYP3A4, CYP2C9 and CYP2B6 
mRNA in primary human hepatocytes, l,25-(OH2)-D3 transactivated the xenobiotic 
response element of all three genes in a reporter gene assay. Gel shift assays provided a 
molecular basis for this observation since recombinant VDR was shown to specifically 
interact DNA probes representing the three response elements. The VDR-dependent 
induction of CYP3A4 was found to be influenced by the phosphorylation state of the 
receptor in that transcription can be modulated via protein kinase C and tyrosine kinase 
(Hara et a l , 2002).
Experiments with SXR knock out mice demonstrate the in vivo relevance of the above 
obseiwations (Makishima et a l, 2002). Besides the VDR was found to bind lithocholic 
acid and its metabolites and upon receptor activation the cyp3all gene was induced in 
the liver and intestine. This is thought to be a protective mechanism to detoxify the 
organism from the effects of potential hepatotoxins and enterocarcinogen bile acid 
metabolites.
In conclusion HepG2 cells may not provide a suitable cellular environment for the 
observation of this phenomenon (Schmiedlin-Ren et al, 2001) and VDR may not be 
present in the protein complexes binding to the ER6  sequence in the -301/+7 fragment 
but VDR appears to have an emerging role in CYP3A4 regulation.
8 8
3.4. Conclusion.
In this chapter the binding of nuclear protein extracts on the CYP3A4 proximal promoter 
was investigated for the first time. A model of protein binding sites in the -301/4-7 region 
was produced in order to speculate on the nature of the transcription factors regulating the 
transcriptional activation of this gene. As expected the model suggests the presence of 
nuclear receptors binding to the ER6  region as well as a role for several types of liver 
specific transcription factors. The observations from the DNase I footprinting experiment 
are corroborated by a wealth of information describing the involvement of the putative 
factors described above as regulators of CYP gene activation and basal activity.
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C h a p te r  4 - N a t u r a l  P o ly m o rp h ism s W ith in  T h e CYP3A4 
G ene.
4.1. Introduction.
Insights into the mechanisms of gene regulation can be gained from the discovery of 
genetic variants in the population. Mutations which result in a measurable effect on the 
phenotype can be informative within the context of mechanistic studies since they 
highlight a region of the genome involved in a qualitative or quantitative manner with the 
phenotypic variable measured. In addition the relationship between altered genotype and 
phenotype may provide a clue on the in vivo relevance of the mechanisms studied.
Owing to their importance in drug metabolism, inter-individual differences in CYP3A 
expression have been well documented (e.g. reviewed in Lamba et a l, 2002). For 
instance in a recent study the hepatic CYP3A content was foimd to vary by a factor of 
approximately 40 fold (Lin et a l, 2002).
Because CYP3A genes are transcriptionally regulated (Telhada et al., 1992), efforts have 
focused on the analysis of the 5’ flanking region of the gene. The first identified mutation 
reported was an A>G transversion located 290bp upstream of the transcription start site 
(Rebbeck et al, 1998) and was thought to be related to the incidence of prostate cancer as 
the mutation was found to be statistically associated with men suffering from tumours of 
a higher clinical grade. This mutation was also shown to be statistically associated of a 
higher incidence of treatment related leukemia (Felix et al, 1998). However, such 
associations are only speculative as no mechanistic information was provided to link 
CTPJvf^-mediated effects with these disease states. Indeed CYP3A activity or protein 
levels were not assessed in either study.
At the time the work in this study was earned out, no further variants in the promoter 
region had been reported but two new mutations in the coding region had been identified 
(Sata et al, 2000). CYP3A4^2 is the most significant allele reported in this study in terms 
of effect and incidence. It caused a serine to proline change at position 222 of the amino
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acid chain in exon 7 and exhibited an altered nifepidine metabolism but no statistically 
significant change in testosterone metabolism was observed (Sata et ah, 2000).
The work presented in this chapter firstly aimed to identify novel mutations in the 
CYP3A4 proximal promoter (-1086/+7) and exon 7 of the CYP3A4 gene, within a panel 
of 11 liver samples known to exhibit variability in CYP3A content and catalytic activity. 
Secondly, oligomers representing a previously identified (Rebbeck et a l, 1998) and two 
novel (Hamzeiy et al, 2002) genetic variants in the CYP3A4 regulatory regions were 
used to assess the effect of these mutations on the DNA binding of nuclear proteins from 
HepG2 cells.
4.2. Results.
4.2.1. Mutation detection.
4.2.1.1. Sequencing of the CYP3A4 promoter region (-1086 to +7bp).
Alignment of the tlnee CYP3A4 5’flanking region sequences available online at the time 
of this study (see section 2.10.5) revealed some variations in the first kb between the 
sequences reported by Hashimoto (Hashimoto et al, 1993), Goodwin (Goodwin et al,
1999) and Amirimani (respectively under accession number D11131, AFl 85589, 
AF181105) and they are described in Table 4.1. These errors were either due to 
sequencing errors or mutations in the donor DNA, since they were not in the 11 eleven 
liver samples used in this study (unless all donors in tliis study were carriers of the same 
mutation).
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Table 4.1. Variation in 3 reported promoter sequences and comparison with the 11 
liver samples from the current study.
Consensus from 2 sequences Nature and position of the Sequence obseiwed in
sequence variation. the 11 liver samples
•A at -502bp in Hashimoto G at -502bp in Goodwin A at -502bp
and Amirimani
•ACAT at -715/-718bp in CATA at -715/-718bp in ACATat-715/-7l8bp
Goodwin and Amirimani Hashimoto
•G at -722bp in Goodwin and Deletion at position -722bp G at -722bp
Amirimani in Hashimoto
Because of the high sequence homology (91%) reported by Hashimoto et al. between the 
first kb of the promoters of CYP3A4 and CYP3A7 it was difficult to obtain primers highly 
specific to CYP3A4. There was therefore a possibility that unwanted CYP3A7 promoter 
sequences could be co-amplified during PCR. Analysis following the sequencing of all 
fragments was carried out and confirmed that only the CYP3A4 promoter was amplified 
on all occasions. Hence, analysis for the presence of mutations occurred in the CYP3A4 
promoter only.
Complete sequencing of all 11 individuals over the -1086/+7 region revealed no 
reproducible mutations although occasional sequencing artefacts (i.e. one strand only) 
were obseiwed. Therefore it can be concluded that the —1086/4-7 region of the CYP3A4 
promoter sequenced from the 1 1  liver samples contained no novel mutations, or any of 
the previously identified polymorphisms (Rebbeck et ah, 1998; Sata et al, 2000).
4.2.1.2. Sequencing of the CYP3A4 exon 7.
Sequencing of the DNA from the eleven liver samples revealed wild type sequence at 
serine 222, with no cases of the published polymorphism CYP3A4'^2 (Sata et al, 2000).
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4.2.2. Analysis of the binding affinity of nuclear proteins to natural mutations in the 
CYP3A4 promoter.
Wliereas the screening of 11 phenotyped liver samples revealed no novel mutations in the 
CYP3A4 proximal promoter, screening of a large population by Dr Hossein Hamzeiy 
allowed the discovery of novel polymorphisms (Hamzeiy, 2002). A population of 101 
subjects (41 females and 60 males of mainly Caucasian or Iranian origin) was screened 
for variations to the wild type sequence in both the proximal promoter and the XREM 
region of CYP3A4 using a non-radioactive SSCP technique (Hamzeiy et a l, 2002). This 
work revealed the presence of a known variant {CYP3A4^IB) within the population but 
also allowed for the identification of 3 novel mutations (table 4.2 and figure 4.1).
To study the functional effect of these polymorphisms, DNA from these mutant 
promoters was cloned into a pSEAP plasmid and their response to classical CYP3A4 
inducers studied in a reporter gene assay (Hamzeiy et al, submitted). The drug 
concentration choice was based on preliminary experimental evidence (Hossein Hamzeiy, 
personal communication), where the compounds were found to fully induce the 
constructs without causing cytotoxicity. Typical experiments are shown in figure 4.2 and 
the data demonstrate a clear effect on the transactivation of the reporter gene constructs. 
Although all mutations affected the induction of the constructs in a statistically 
significant manner, for at least one of the four xenobiotic inducers used, CYP3A4^IB and 
CYP3A4^1F appeared to have the strongest effects. Overall, it should be noted that, 
although the statistical analysis demonstrates a difference in induction to a matched wild 
type promoter sequence, the effect of the mutations doesn’t exceed a 2.15 times increase 
in induction. Therefore, using the experimental system described in figure 4.2, the genetic 
variants appear to have a limited effect on the activation of the CYP3A4 promoter 
reporter gene constmct.
The effects of tliree of these mutations on protein binding were examined by EMSA in 
order to investigate possible mechanistic links between the altered transcription rates and 
the binding of transcription factors to the mutation sites (described in figure 4.1). Due to 
time limitation the protein binding to the CYP3A4’^15B allele was could not be 
investigated.
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Table 4.2. Novel alleles identified following screening of a population of 101 subjects
(data taken from Hamzeiy et a l, 2002)
Allele name Position from ATG start 
codon
Modification Observed incidence 
in 1 0 1  subjects
CYP3A4^1B -392 A—>G 9
CYP3A4^1E -369 T ^ A 1
CYP3A4^1F -747 C->G 17
CYP3A4V5B •Insertion between -845
and -844
•-392
•Position 485 on cDNA
ATGGAGTAG
A-^G
G ^A
1
In this section the work on mutation detection and functional analysis by transfection 
assay was carried out by Dr Hossein Hamzeiy.
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Figure 4.1. Novel CYP3A4 alleles within the context of the putative response 
elements (adapted from Hamzeiy et al, 2002)
Wild ty p e CYP3A4*1B
-3 9 2 -3 9 2
ATAG AGACAAGGGC/\AGAGAG AGGCGATT ATAGAGACAAGGGCAGGAGAGAGGCGATT
NFSE NFSE
Wild type
-369
A l AGA r IT I A I CiCCAATGGCI 
CAAT box
= = = N F —1 = = =  
===Oct-l===
CYP3A4*1E
-369
ATAC'iA 1 lA  IATGCCA ATCKK: r 
CAAT box
===Oct-l====
Wild type
-747
CTGTGTGTACAGCACCCTGGTAGGG
CYP3A4*1F
-747
CTGTGTGTACAGCACGCrGGlAGGG
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Figure 4.2. Reporter gene assay experiments in HepG2 cells demonstrating the 
effect of the novel mutants on the transcriptional activation by xenobiotics (data 
taken from Hamzeiy, 2002). HepG2 cells were transfected with the wild type 
(CYP3A4*1A) or mutation-containing pSEAP2 reporter plasmid DNA (with XREM 
insert) in the presence of pSG5-hPXRAATG. After DNA transfection, cells were exposed 
to CYP3A4 inducers at 10 pM (phénobarbital, 1 mM) and incubated for a further 60 hours 
prior to chemiluminescent SEAP assay. (DEX; dexamethasone, PB phenobarbitone, MIF: 
mifepristone, RIF: rifampicin). The results are derived from 4 experiments in which each 
transfection and exposure was performed six times (n=24). Relative inductions of 
mutation-containing plasmid constructs compared to the wild type are presented in the 
table. Differences were analysed by two-sided t-test (*, P<0.05; **, P<0.01; ***, P<0.001 
comparing mutant to wild type). The p values relate to the wild type promoter.
■  D M S O  □  PB □  RIF  
□  D E X  ■  M IF6 0 0 0 0  -
5 0 0 0 0
4 0 0 0 0
□  3 0 0 0 0
^  20000  -
10000
m UJ Ll_ COr r lO■vr Z~< < < ■5:CO CO CO <a. Q_ p. CO>- >- >- o_o O O >-0
* P<0.05, ** P<0.01, *** P<0.001. (comparing mutant to wild type allele)
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Figure 4.2. (continued)
ACTIVATION RELATIVE TO WILD TYPE
\D ru g
A lle le \^
DEX PB MIF RIF
3A4VB 1.47 *** 1.20* 2 15 *** 1.59 ***
3A4^1E 1.22* 0.95 1.12 1.10
1 62 *** 1.23 * 1.89 *** 1.57***
3A4V5B 1.36 ** 1.04 1.32* 1.32*
* P<0.05, ** P<0.01, *** P<0.001,
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All DNA oligomers, both wild type and variant tested, bound proteins from the HepG2 
nuclear extract and this was shown to be specific as the retarded complex disappeared 
with a competitor concentration of approximately 30 fold excess to that of the labelled 
probe (figure 4.3). A single non-specific complex was seen, with CYP3A ^ IF, which was 
only competed out by the presence of 1200 fold excess competitor probe (data not 
shown). All binding reactions were optimised in order to observe an effect of the 
mutations and the differences in protocol probably reflect relative difference in affinity. 
For instance the competition assay using the probe representing the CYP3A4*1B allele 
was only obseived in binding reactions containing higher levels of nuclear proteins. The 
three mutations tested seemed to affect nuclear protein binding, with CYP3A4'^IE 
causing an increase in affinity for 15 fold excess unlabelled competitor whereas 
CYP3A4^IB and CYP3A4*1F were responsible for a decrease in affinity for competitor 
concentrations of 15 and 5 to 30 fold respectively. Overall, the CYP3A4^1F allele had the 
most pronounced effect on protein binding.
In order to confirm the findings for the probe representing CYP3A4*1B an additional 
experiment was carried out where protein binding was abolished by digestion with 
proteinase K at 37°C for 20 minutes and heat dénaturation of the protein extract at 95 °C 
for 20 seconds together with the appropriate controls (data not shown)
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Figure 4.3. Effect of the CYP3A4*1B, *1E and */F alleles on HepG2 nuclear 
binding. Error bars indicate standard error of the mean (±SEM, n=3). t= non­
binding.
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4.3. Discussion.
To date only 5 variant alleles with mutations in the 5’ flanking region of CYP3A4 have 
been reported (reviewed in Lamba et a l, 2002) and these are all located between -747 
and -62bp from the transcription start. In a study of 300 samples, no mutations were 
found in the ER6 element located in the proximal promoter as well as within the SXR 
binding site located in the distal enhancer XREM (Zhang et al, 2001). This is consistent 
with another study of 101 subjects where no mutations were found in both the proximal 
ER6 and a 300bp region of the XREM (Hamzeiy, 2002). This raises the possibility that 
the ER6 or the distal SXR binding sites are so essential for CYP3A4 gene regulation by 
nuclear receptors and for general xenobiotic metabolism that any alteration at the level of 
these regions may impair sui'vival of individual carriers and therefore such variants may 
not propagate in the population.
4.3.1 Mutation detection in the promoter of CYP3A4,
The study of the -1086/+7 region of the CYP3A4 promoter, for 11 phenotyped liver 
samples exhibiting a 14.1 fold variability in CYP3A activity revealed no inter-individual 
genetic differences as determined by sequencing analysis.
There is a possibility that all or part of the phenotype variability observed may be caused 
by several factors such as the degradation of the samples or the lack of specificity of the 
method used to determine the phenotype (the hydroxylation of the probe substrate 
midazolam is also a CYP3A5 marker). Due to technical difficulties relative to antibody 
quality and probe substrate the identity assessment of the exact CYP3A can prove 
unieliable at the level of the protein content and the metabolic activity. According to a 
recent study it appears that CYP3A5 product content represented more than half of the 
hepatic CYP3 A content in a third of a Caucasian population sample and in more than half 
of an African American population sample. This indicates that the levels of this enzyme 
may have been previously underestimated (Kuehl et al, 2001). Some reports describe a 
strong inter-individual variability in CYP3A level and activity but suggest this could be 
due to the polymorphic expression of CYP3A5 (e.g. Kuehl et a l, 2001 and reviewed in 
Lamba et al, 2002). However, Western blotting analysis revealed the levels of CYP3A4 
immuno-reactive proteins varied within the samples although this did not coiTelate with
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the obseiTed enzyme activity (Nick Plant, personal communication). This highlights the 
difficulties in finding a reliable phenotypic marker to carry out phenotype-genotype 
correlation studies.
Rebbeck et al. (1998) previously reported a -290 A>G (later known as allele 
CYP3A4^1B) mutation and the population frequency for Caucasian subjects was 9.6% 
(homozygous) and 12.8% (heterozygous) on a sample of 94 patients. Another study also 
reveals a rather low frequency of the mutation in Caucasian patients (GG: 1%, AG: 6%, 
n=117) and a higher frequency in healthy African-Americans (GG: 53%, AG: 28%, 
n=116) (Paris et al, 1999). This inter-ethnic difference is in agieement with the findings 
fi'om another study (Sata et al, 2000).
In the present study 8/11 samples originated from Caucasian subjects and 3/11 from 
Afro-American subjects therefore the results observed are not inconsistent with the 
published literature. In a study using 39 liver samples exhibiting 31-fold variability in 
testosterone metabolism (CYP3A4 marker), no further mutations were found within the - 
490/+10 region of the promoter (Westlind et al, 1999).
Although the first 300bp are known to be very important in the regulation of the CYP3A4 
gene (Hashimoto et a l, 1993), this work demonstrates that other factors must explain the 
polymorphic expression of CYP3A4 since no mutations were found in spite of a 
significant variability in the CYP3A phenotype (activity and protein level by Western 
blot).
4.3.2. Mutation detection in the coding region: exon 7
The study of 11 liver samples available reveals an absence of the previously reported 
mutation (Sata et al, 2000) in exon 7. This suggests that the inter-individual differences 
in CYP3A catalytic activity observed were probably not due to mutations in the coding 
region causing the production of enzyme with a lower activity. The result is not 
surprising since the population frequency reported was very low, 2.7% (Sata et al, 2000) 
and may therefore probably not be very significant for the population as a whole.
Attempts to amplify exon 12, which was also reported to contain a mutation (Sata et al,
2000), failed because it could not be amplified using PCR, following the published
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primer sequence and reaction conditions. This is probably because one of the PCR primer 
Sata and his group used was significantly shorter than the other in the pair (only 17bp), 
indeed a longer primer allows satisfactory amplification (Hossein Hamzey, personal 
communication). Tliis mutation was only found in one subject (Sata et al, 2000)
4.3.3. Alternative explanations to inter-individnal differences in CYP gene 
expression.
4.3.3.1. The regulators.
This chapter has so far focused on how mutations in the regulatory regions of the 
CYP3A4 gene may provide a rational basis to explain inter-individual differences in 
phenotype. However, it cannot be excluded that that the genetic component of CYP3A4 
variability may be due to quantitative or qualitative variations of the regulatory proteins 
driving its expression rather than variations in the regulatory regions of this gene. For 
instance six mutations in the gene coding for SXR have been identified each with a 
frequency of less than 3% apart hom a P27S change affecting 14.9% of patients fiom 
African origin (Hustert et a l, 2001). Using functional assays, the latter authors reported 
that the frequent P27S had no effect on gene activation; however, some of the variant 
proteins did alter the response (increased or decreased) of reporter gene constructs 
containing ER6 or DR3 elements known to bind SXR suggesting that some of these 
variants may contribute to the variation in CYP3A expression. In a larger study, more 
mutants were identified including variants in the 5’ flanking region of the SXR gene 
disrupting putative transcription factor binding sites, such as for instance a C/EBP 
binding site (Zhang et al, 2001). Taken together these results demonstrate that SXR 
ligand and DNA binding activity, as well as expression levels, may be subject to inter­
individual variability, which in turn would be expected to affect target gene expression 
levels. However, a direct association between altered SXR protein and target gene 
expression would be surprising since this would imply that CYP3A4 expression (or for 
that purpose the expression of any SXR target gene) is solely dependent on SXR 
activation. As seen in chapter 5 and in the literature, CYP3A4 expression is not solely
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driven by SXR but by other factors acting in the promoter and at the level of the ER6 
(Smirlis et a l, 2001; Xie et al, 2000a) and any of these other factors may also be 
variable.
4.3.3.2. Role of epigenetics.
Another possible explanation for CYP3A variability may come fi*om the emerging area of 
epigenetics (also discussed in chapter 6). Genomic sequencing of individuals’ regulatory 
regions does not allow the identification of variation in DNA méthylation or chromatin 
structure. Clii'omatin structure can be responsive to signals following a range of post- 
translational modifications to the histone proteins which are known as the ‘histone code’ 
(Jenuwein and Allis, 2001) and in some cases deregulation in the dynamics of histone 
modifications can be related to carcinogenesis (Schneider et al, 2002).
DNA base modifications such as méthylation of cytosine ("’CpG) can also alter the levels 
of gene expression since they can affect transcription factor binding. Indeed the binding 
of the Spl protein to a DNA response element comprising methylated bases has been 
found to be reduced (Clark et al, 1997). Of particular relevance is the work of Takahashi 
and co-workers on CYPIAI expression in rabbit (Takahashi et al, 1998). They reported 
that méthylation of a sequence binding the AhR (aryl hydrocarbon receptor) transcription 
factor caused a decrease in affinity for this protein, which explains the cell type specific 
expression of the cytochrome P450 gene since the méthylation pattern was only found in 
certain cell types and was responsible for silencing of the genes.
To date there is no evidence that these mechanisms are directly responsible for inter­
individual CYP3A4 variation. It cannot be excluded, however, that within the in vivo 
situation epigenetic factors may affect CYP3A4 regulatory regions or expression of 
CYP3A4 regulatory proteins.
4.3.4. Binding of nnclear proteins to mutant CYP3A4 alleles.
Because the regions altered in the variant alleles were beyond the area (-301/+7) covered 
in the study presented in chapter 3 no data on binding site localisation was available. 
However the fact that the oligomers tested bound HepG2 nuclear proteins and that this
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binding could be removed via competition with a DNA oligomer (figure 4.3) or digestion 
with proteinase K does suggest that the sequences are representative regions where DNA 
protein interactions take place.
The CYP3A4*1B allele is located within a region known as the NFSE (Nifepidine 
specific element) originally studied because it was thought to be responsible for the 
CYP3A7ICYP3A4 transition during development, since the NFSE is only present in the 
promoter of CYP3A4 but not of CYP3A7 (Hashimoto et al, 1993). Incubation of a DNA 
probe representing the NFSE with human adult and foetal liver extracts revealed a 
DNA:protein interaction which was considered to be non-specific. Another study 
focusing on the functional effects of the mutated allele showed this region could bind 
several proteins or protein complexes present in human liver nuclear protein extracts, but 
none of these interactions was of high affinity since a high amount of protein and low 
stiingency buffer had to be used (Westlind et al, 1999). In this study, high amounts of 
protein were also required to observe a difference in competitor affinity for the wild type 
and mutant DNA oligomers but because as little as 10-fold excess unlabelled oligomer 
were necessary to remove binding the interaction is thought to be specific. Gel shift 
assays previously cairied out on this region (Hashimoto et al, 1993; Westlind et al, 
1999) used an oligomer centred on the NFSE region, however, as shown in figure 4.4 the 
oligomer design in this study differed. Analysis of the region surrounding the NFSE 
suggested the presence of 2 putative Spl sites (as determined by the Transfac database, 
figure 4.4). The oligomer used in this study was designed to incorporate these sequences 
and it may be that the protein binding was enhanced by this modification since both 
putative sites would be covered and surrounded by a flanking base.
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Figure 4.4. Alignment of the DNA oligomer sequences used to investigate protein 
binding to the NFSE region in this study (highlighting the Spl sites) and in two 
previous reports (highlighting the NFSE region) (Hashimoto et a i, 1993; Westlind et 
al, 1999).
This study: 5 ’-G AGACA AGGGC A AG AG AG AGGCG AT-3 ’
Previous studies: 5 ’-AG AG AC A AGGGC A AGAG AG AGG
It is interesting that while discussing their results Hashimoto and co-workers (Hashimoto 
et a l, 1993) refer to unpublished data showing the BTE sequence could compete out 
protein binding to the NFSE. The BTE is a GC-rich box known to bind Spl proteins in 
the promoter of the CYPl A1 gene and may act as a repressor element (Kaczynski et al, 
2002). This corroborates the hypothesis that the NFSE may bind Spl.
The variant allele which showed the greatest change in binding during the EMSA 
experiments was CYP3A4*1F. Disruption of a putative Spl site in the variant allele 
(Figure 4.1) results in a decrease in affinity for nuclear protein (Figure 4.3) whereas the 
transcription rate is increased (figure 4.2). This would suggest a repressor role for the 
transcription factor binding to this site. As described above Spl has previously been 
shown to act as a transcriptional repressor for CYP genes (CYPlAl) through binding to 
the BTE. This would provide a molecular basis for the observations described above and 
would explain the changes seen at the level of the nuclear protein binding and at the 
transcriptional level for the CYP3A4*1B and CYP3A4*1F 3\\q\qs.
Gel shift assay using either recombinant Spl protein or antibody raised against this factor 
would confirm this hypothesis.
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4.4. Conclusion.
Sequencing of the CYP3A4 proximal promoter in a panel of 11 liver samples showing 
variability in CYP3A protein levels and catalytic activity revealed no deviation from the 
wild type sequence. However, genetic variations could be detected in another study using 
a larger sample cohort. Two of these novel variants and a previously reported allele, 
which are all known to alter the response to xenobiotics in reporter gene assays, altered 
protein binding of HepG2 nuclear extracts to synthetic oligomers representing the 
mutated alleles. Analysis of these mutations in the regulatory region of CYP3A4 has 
given some insight into the mechanisms that may drive the expression of this gene. 
However, CYP3A4 inter-individual variability is not only caused by variations in the 
regulatory regions of the gene but also probably caused by variations in the quantity and 
properties (i.e. in terms of DNA binding, ligand binding) of the regulatory proteins. 
Therefore in order to discover predictors of inter-individual variability it is necessary to 
identify the factors driving hepatic CYP3A4 expression and this will be described in the 
next chapter.
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C h a p te r  5 -  E f f e c t  o f  A r t i f i c i a l  M u ta t io n s  W ith in  t h e  
CYP3A4 P r o x im a l P r o m o te r
5.1. Introduction.
Following the mapping of DNA:protein interactions with the CYP3A4 proximal promoter 
by DNase I footprinting (chapter 3) a logical step is to examine the role of the protein 
binding regions identified in the regulation of the CYP3A4 gene, both during basal and 
chemically induced gene transcription. As discussed earlier (chapter 3) there is currently 
no empirical evidence for the involvement of factors other than the proteins binding at the 
ER6 in CYP3A4 regulation. However, there does exist some circumstantial evidence that 
factors such as tissue specific tianscription factors may be involved in the regulation of 
the hepatic expression of this gene (Oui'lin et al, 1997).
The aim of the work presented in this chapter was to mutate putative protein binding sites 
and to examine the functional effect under basal and drug-induced conditions using a 
reporter gene assay. From this important infomiation on other factors involved in 
CYP3A4 expression can be determined. Four artificial mutations known to interrupt 
putative DNAiprotein sites of interaction were tested.
Firstly during routine cloning of the -301/+7 promoter fragment a T>C substitution was 
identified at -190 bp by Dr Wafaa El Sankary in our laboratory. This mutation was found 
to decrease dexamethasone by not rifampicin mediated induction of a -301/+7 construct 
of the CYP3A4 promoter. This was further investigated in the current study by the use of 
DNase 1 footprinting (see section 3.2.2.3) to characterize the protein binding at this site 
and gel shift assays to assess the effect of the mutation on protein binding.
Secondly following the DNase I footprinting on the -301/+7 region thiee sites were 
selected on the basis of the protein binding pattern and computer analysis of the DNA 
fragment. Using site directed mutagenesis, the DNA sequence in these regions was 
altered and the functional effect of the mutations was tested using a reporter gene assay.
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5.2. Results: Glucocorticoid-mediated induction of CYP3A4 is decreased 
by disruption of a protein :DNA interaction distinct from the ER6.
In this section the initial cloning work and the fimctional analysis by transfection assay 
were carried out by Dr Wafaa El Sankary (as described in El Sankary et al, 2002). 
Following amplification of the -301/+7 CYP3A4 promoter fragment by PCR and cloning 
of the product, a single base pair mutation (T>C transition, -190bp) was detected which 
was probably caused by polymerase infidelity. This mutation disrupted a putative 
HNF/C/EBPa binding site, as assessed by DNase I footprinting and bioinformatic 
analysis (chapter 3), Using a reporter gene assay in HepG2 cells it was found that 
although the rifampicin induction remained unchanged compared to the wild type 
promoter (pWT), the induction by dexamethasone and hydrocortisone was markedly 
reduced (figure 5.1) in the mutant promoter (pMUT). In order to investigate the possible 
effects of this mutation on the transcription factors binding to this site, DNase I 
footprinting was carried out using a wild type and a mutant probes representing the -  
301/+7 region of the promoter incubated in the presence of HepG2 nuclear proteins. The 
resulting protein binding pattern (figure 5.2) demonstrated that the mutation did not result 
in any qualitative change. The relative affinities of the wild type and mutant DNA 
oligomers representing the site of DNA protein interaction was next examined using 
EMSA in the presence of unlabelled competitors. The results shown in figure 5.3 
demonstrate that both fragments bind a protein present in HepG2 cell nuclear extracts and 
that its binding affinity to the wild type sequence is higher than to the mutant sequence. 
This would suggest that DNArprotein interactions are reduced in the mutant although the 
exact nature of this interaction has not yet been identified.
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Figure 5.1. A single base pair mutation alters responsiveness of the -301/+7 region 
of the CYP3A4 promoter to synthetic and endogenous steroids but not to rifampicin
(this experiment is described in El Sankary et a l, 2002).
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The wild type (pWT) and mutant (pMUT) plasmids were transfected in HepG2 cells and 
instead of measuring the ‘induction’ as described in the method section (chapter 2), the 
degree of reporter gene production was assessed using a similar measurement, the 
Specific Chemical Effect (SCE, Plant et al, 2000). The SCE allows a thorough 
examination of the reporter gene assay data by taking into account experimental variables 
such as drug-induced proliferative effects or plasmid transfection efficiency.
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Figure 5.2. The -190 T>C substitution does not alter the binding pattern of HepG2 
nuclear proteins to -301/+7 fragment of the CYP3A4 promoter.
Wild Type Mutant
G A T C  - + + + + - G A T C
DNA probes representing the -301/+7 region of the CYP3A4 promoter were prepared by
labelling at one 5’ end using following amplification by PCR from the wild type 
(pWT) and mutant (pMUT) plasmids. The probes were incubated in the presence (+) or 
absence (-) of nuclear proteins from HepG2 cells, digested with DNase I and the DNA 
was run on a denaturing polyacrylamide gel. The mutation site (arrow) disrupts a DNA 
protein interaction (black line) encompassing a putative HNF/C/EBP binding site.
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Figure 5.3. Binding of HepG2 nuclear proteins to the WT oligomer is reduced by the 
T>C -190 transition.
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The oligomers represent the site of DNA:protein interaction in the wild type (WT) and 
mutant (MUT) plasmids. Error bars indicate standard error of the mean (± S.E.M.) for 
three repeat experiments.
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5.3. Results: Mutagenesis of putative régula to ly protein binding sites.
5.3.1. Reporter gene assay optimization and technical considerations.
Preliminary experiments using a construct containing the -1078/-57 fragment of the 
CYP3A4 promoter (p3A4-CMV-cSPAP as described in El Sankary et al., 2000) and 
HepG2 cells failed because of a very low transfection efficiency. On the other hand it was 
found that HuH7 cells could be transiently transfected in a reproducible mamier using 
Fugene 6 (Roche).
The pSEAP pro2 vector with -301/+7 insert was used in the initial work but although the 
levels of alkaline phosphatase were higher than in the empty pSEAP pro2 vector the 
construct was not responsive to rifampicin. However, when a similar construct containing 
the distal enhancer XREM (pSEAP2-basic with XREM insert and —301/+7 insert) was 
transfected the levels of reporter gene could be detected and could be induced in a 
concentration-dependent manner. It was also noted that in order to be able to observe 
high levels of basal expression and a sufficient response to rifampicin, co-transfection 
with a SXR expression plasmid was necessary (data not shown). Finally it was found the 
construct could be activated by rifampicin concentration as low as 0.5 jaM (but not 0.1 
pM, as shown for instance on figure 5.4) and that the dose-response curve generally 
reaches a plateau for concentrations between 1 and 5 pM (e.g. see figure 5.4).
5.3.2. Comparison of the -301/+7 versus -1201/-61 CYP3A4 promoter fragments.
During preliminary work, the induction of the -301/+7 promoter region was compared to 
that of a longer promoter fragment (-1201/-61). Both fragments were cloned at the same 
position in a pSEAP2 promoter plasmid containing the -79727-7673 XREM fragment. It 
was found that the levels of reporter gene transcription were significantly higher for the 
short fragment (figure 5.4), for all doses of rifampicin and the DMSO treatment. 
However, the level of induction (defined as the ratio between the rifampicin induction 
and the DMSO solvent control values) were similar. This is explained by the fact that the
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-301/+7 fragment exhibited a higher basal level of SEAP expression than the -1201/-61 
fragment.
Figure 5.4. Comparison of the rifampicin induction profile for the pWT plasmid 
(with a -301/+7 insert) and a longer CYP3A4 promoter fragment (-1201/-61).
-301/+7 (pWT) -1201A614000-1
3000-
3  2000 -
1000 -
0 2 4 6 8 10
uM RIF
Both constructs contained the distal enhancer XREM. Induction for each rifampicin 
concentration was calculated as described previously (section 2.12.6) and is presented as 
the mean ± standard error of the mean (n=6). The statistical analysis is described in 
chapter 2 (*: p<0.05, **: p<0.01). This experiment was carried out in triplicate and was 
reproducible.
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5.3.3. Comparison WT versus WT*.
The WT and WT* constructs from which all the SDM plasmids are derived were tested 
using transfection assays in order to assess the possible effect of the T>C substitution at - 
193bp present in the pWT* plasmid. The results are presented in figure 5.5. Both 
promoter had very similar activation profiles and from this experiment it can be 
concluded that the mutation has very little or no detectable effect on rifampicin mediated 
reporter gene activation.
5.3.4. Site Directed Mutagenesis (SDM) procedure.
In spite of several attempts to mutate the ER6  motif in both the wild type fragment (WT) 
and the wild type fragment containing the T->-C substitution located at position -193 
(WT*), SDM experiments only resulted in one of the half site modified with a AA*^TT 
transversion within the WT* promoter. The use of a longer mutagenic primer, which 
should have improved the annealing to the plasmid template, proved unsuccessful. 
Attempts to generate ER6  mutations in the WT fragment repeatedly failed and the 
procedure was discontinued because of lack of time. The diagram in figure 5.6 describes 
the plasmids generated dui'ing the SDM experiments.
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Figure 5.5. Comparison of the rifampicin induction profile for pWT and pWT^
plasmids.
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Summary of the Imax and EC50 values generated by the regression analysis presented with 
the 95% confidence interval for the pWT and pWT* plasmids.
Plasmid Imax ECso (pM)
pWT* WT: 19.29 (13.86 to 24.73) 
WT*: 19.59 (14.73 to 24.45)
WT: 0.12 (0.16 to 0.40) 
WT*: 0.18 (0.10 to 0.46)
Induction for each rifampicin concentration was calculated as described previously 
(section 2.12.6) and is presented as the mean + standard error of the mean (n=6 ). The 
statistical analysis is described in chapter 2. This experiment was carried out in duplicate 
and was reproducible.
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Figure 5.6. Summary of the plasmids generated during the SDM experiments.
WT* WT
Putative Spl (-97bp) CTTCCAAC-»CTTTTAAC
Putative HNF3 (-188bp) TGTTTATG-»TGTGGATG
Putative C/EBPa (-127bp) TCTTTGC-»TCGAGGC
ER6 half site (-166bp) ATGAACTC-»ATGTTCTC
The circles represent the mutations and an approximation of their relative location on the 
-301/4-7 fragment. As described in the method chapter pSpl, pHNF, pCEBP were created 
from the wild type (pWT) plasmid and pSpl*, pHNF*, pCEBP* and pER6 were created 
from pWT* which contains a T>C substitution at -193bp.
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5.3.5. Effect of the mutations at the basal level in HuH7 cells.
All SDM generated mutations were tested against their respective original template (WT 
or WT*). It should be noted that the plateau values of the WT and WT* plasmid 
induction may vary between experiments. This is essentially because of inter-assay 
variations in the detection of the alkaline phosphatase (SEAP). Indeed, although sample 
levels of reporter gene levels can be reproducibly detennined the accuracy is highly 
sensitive to several exogenous factors (e.g. incubation time, temperature) and all 
experiments provide comparative rather than absolute readings of SEAP levels.
Initially the possible effect of the SDM fragments on basal reporter gene expression was 
examined. The SEAP gene production pattern was consistent for fragments generated 
from both WT (figure 5.7 panel A) and WT* (figure 5.7 panel B) once again suggesting 
the T>C mutation at position -193 was silent. The ER6, HNF and C/EBP mutants all 
exhibited a statistically significant reduced basal activity compared to control, while the 
Spl SDM plasmids (pSpl and pSpl*) showed no statistical change in basal expression 
levels.
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Figure 5.7. Effect of the mutations in pWT (A) and pWT* (B) on the basal levels of 
reporter gene expression upon transfection in HuH7 cells.
A : pWT vector.
C/3 15
HNF3 C/EBPa
B : pWT* vector
M 20
I
HNF3 C/EBPa
HuH7 cells were transfected with the mutant plasmids and the levels of reporter gene 
expression were measured 48 hours later. Differences were tested by ANOVA (*: 
p<0.05) n=6 representative experiment. The experiment was carried out in duplicate and 
was reproducible.
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5.3.6. Effect of the mutations in rifampicin treated HuH7 cells.
The experiments with transfected pER6 *, pHNF*, pHNF, pCEBP* and pCEBP were 
carried out 3 to 4 times and provided highly reproducible results. The graphs in figures 
5.8 to 5.11 mpresent the results for one representative experiment.
The pER6 * plasmid (figure 5.8) exhibited a lower Imax in response to rifampicin (95% 
Cl). The HNF mutants (figure 5.9) had a different response to rifampicin mediated gene 
activation, since the pHNF plasmid was induced to the same level as the pWT plasmid 
but the mutation in pHNF* caused a significant Imax decresase. Both pCEBP and pCEBP* 
(figure 5.10) were affected in a similar way by the mutation as the Imax in response to 
rifampicin were significantly decreased (based on the 95% Cl) to about a third of the 
value for the control plasmids. For the five SDM constructs described above the EC50 
95% confidence intervals overlapped demonstrating that there was no significant effect of 
the mutations on this variable (at p<0.05). The comparison of the SEAP levels between 
the wild type and mutant sequences for all rifampicin doses allowed identical conclusions 
apart fi'om pHNF* where the significant difference was found at the 0.5, 5 and 10 pM 
doses.
Unlike all the other constructs used, the pSpl and pSpl* plasmid transfections appeared 
to be generally less reliable since there was a high inter- and intra-experiment variability. 
The regression analysis of each individual experiment is presented in figure 5.11 and 
demonstiates the inconsistency of the results. Overall, there was no statistically 
significant effect on the Imax value of the mutants using both the 95% Cl of the values 
generated by the regression analysis and the t-test. Therefore it appears that similarly to 
what was found for the experiments on the expression at the basal level, the Spl mutation 
has no effect on the activation of the -301/+7 region of the CYP3A4 promoter.
119
Figure 5.8. Rifampicin response of the ER6 mutant construct upon transfection in
HuH7 cells.
A
B
75-1
■ pWT  ^ pER6
I  50- ** ****o3"OC
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Plasmid Imax ECso (\iM)
pER6 * WT: 45.52 (39.61 to 51.44) WT: 0.18 (0.00 to 0.35)
MUT: 15.63 (12.79 to 18.46) MUT: 0 .2 3  (-0.04 to 0 .5 0 )
A: Induction profile for the pWT* and pER6 * plasmids presented as induction (± SEM, 
n=6 ) and the statistical analysis is described in chapter 2  (**: p<0 .0 0 1 ).
B: Summary of the Imax and EC50 values generated by the regression analysis presented 
with the 95% confidence interval for the mutated plasmid (MUT : pER6 *) against the 
value for the respective wild type control (WT : pWT*).
120
Figure 5.9. Rifampicin response of the HNF mutant constructs upon transfection in
HuH7 cells.
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Plasmid Imax E C 50 (pM)
pHNF* WT: 34.69 (29.81 to 39.57) WT: 0.55 (0.21 to 0.88)
MUT: 21.93 (17.76 to 26.11) MUT: 0.36(0.01 to 0.72)
pHNF WT: 68.33 (53.83 to 82.84) WT: 0.12 (-0.13 to 0.38)
MUT: 76.98 (65.33 to 88.62) MUT: 0.35 (0.08 to 0.63)
A; Induction profile for the pWT* and pHNF* plasmids and the pWT and pHNF 
plasmids presented as induction (± SEM, n=6 ) and the statistical analysis is described in 
chapter 2 (*: p<0.05).
B: Summary of the Imax and EC50 values generated by the regression analysis presented 
with the 95% confidence interval for the mutated plasmid (MUT : pHNF* or pHNF) 
against the value for the respective wild type control (WT : pWT* or pWT).
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Figure 5.10. Rifampicin response of the C/EBP mutant constructs upon transfection
in HuH7 cells.
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Plasmid Imax ECso (pM)
p C /E B P * WT: 75.94 (63.91 to 87.97) WT: 0.47 (0.13 to 0.81)
MUT: 25.84 (21.07 to 30.61) MUT: 0.41 (0.05 to 0.78)
p C /E B P WT: 29.79 (26.03 to 35.55) WT: 0.40 (0.15 to .64)
MUT: 11.30 (10.04 to 12.55) MUT: 0.27 (0.09 to 0.45)
A: Induction profile for the pWT* and pC/EBP* plasmids and the pWT and pC/EBP 
plasmids presented as induction (± SEM, n=6 ) and the statistical analysis is described in 
chapter 2 (*: p<0.05, **: p<0.001).
B: Summary of the Imax and EC50 values generated by the regression analysis presented 
with the 95% confidence interval for the mutated plasmid (MUT : pC/EBP* or pC/EBP) 
against the value for the respective wild type control (WT : pWT* or pWT).
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Figure 5.11. Summary of the transfection experiments for the Spl* (A) and pSpl 
(B) plasmids.
A : pSpl* plasmid.
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The ECso (pM) and hnax values, and their 95% confidence interval, were calculated 
using a non-linear regression mode 1 described in section 2.12.6. The experiments were 
carried out in triplicate and were reproducible.
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Figure 5.11. (continued)
B : pSpl plasmid.
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The ECso (pM) and Imax values, and their 95% confidence interval, were calculated 
using a non-linear regression model described in section 2.12.6. The experiments were 
carried out four times and were reproducible.
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5.4. Discussion; Glucocorticoid-mediated induction of CYP3A4 is 
decreased by disruption of a protein:DNA interaction distinct from the 
ER6.
The data from the reporter gene assay (figure 5.1) and gel shift assay (figure 5.3) 
demonstrate that a single base pair mutation can alter the response of the -301/+7 
promoter fragment to hydrocortisone and dexamethasone (thought to act as GR ligands) 
but not to rifampicin (thought to be mainly a SXR ligand) and that this is probably due to 
the mutation decreasing the binding of a protein present in HepG2 nuclear extracts. 
DNase I footprinting experiments (chapter 3) suggests the factor involved may bind to a 
putative HNF3 or C/EBPa response element. This work therefore suggests that 
glucocorticoids may act at least partly through a SXR independent pathway and that the 
ER6 may not be the only region of the promoter involved in the xenobiotic response of 
the CYP3A4 promoter.
Early reports demonstrated that an alternative mechanism to the classical GR-mediated 
gene regulation (e.g. as for the tyrosine aminotransferase gene) may be operative for 
dexamethasone induction of CYP3A genes (Schuetz and Guzelian, 1984). Those results 
suggested the presence of an alternative receptor. Glucocorticoid mediated induction of 
CYP3A genes remained unexplained for several years until the discovery of SXR 
(Bertilsson et a l, 1998; Blumberg et a l, 1998; Kliewer et al, 1998) which has the ability 
to bind classical CYP3A inducers including glucocorticoids. However, in co-transfection 
experiments, GR addition was still found to have a positive effect on drug response in 
spite of the absence of any consensus GR binding sites in the proximal promoter region 
of CYP3A4 (Ogg et al, 1999). A more probable scenario to the direct binding of GR was 
then suggested by experimental data on the regulation of the level of the xenobiotic 
nuclear receptors by glucocorticoid. It was found that glucocorticoid treatment of human 
hepatocytes transcriptionally increases the levels of SXR (and CAR) gene expression at 
the mRNA and protein levels as well as the levels of the heterodimerization partner 
RXRa (Pascussi et al, 2000a; Pascussi et al, 2000b). The same group went on to 
demonstrate the relevance of this observation by showing that CYP3A4 induction in 
human hepatocytes is enhanced by glucocorticoids at low concentrations by increasing
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the levels of nuclear receptors (SXR, CAR, RXRa) and at higher concentrations by 
activating SXR (Pascussi et a l, 2001). Therefore this work demonstrates a further level 
of complexity than proposed by earlier models by showing that xenobiotic may regulate 
the levels of nuclear receptors prior to activating them tlnough binding. This suggests an 
alternative pathway and it provides some insight into possible mechanisms of CYF3A4 
gene regulation by glucocorticoids.
The fact that the mutation affects putative binding sites for HNF3 and/or C/EBPa is not 
inconsistent with earlier findings that these factors may be involved in interactions with 
GR. If no direct binding of the GR to the CYP3A4 proximal promoter takes place the 
experimental results reported here could be explained by protein-protein interactions as 
GR has been shown to interact with members of the C/EBP family to enhance 
transcription without directly binding to the DNA and instead acting via the Activation 
Function 2 (AF2) of both receptors (Boruk et a l, 1998). Alternatively the effect of the 
mutation could be due to a modification of the levels of HNF3 or C/EBPa by 
glucocorticoids in the same manner as RXR, SXR and CAR are upregulated by 
glucocorticoids in human hepatocytes (Pascussi et al, 2000a; Pascussi et al, 2000b; 
Rodrigues et al, 2003). Members of the HNF3 family (a and p) have been shown to be 
up-regulated by dexamethasone treatment in rat (Imae et al, 2000).
The nuclear protein(s) involved in the phenomenon described above have not yet been 
identified and this would be a logical next step. Initial attempts to produce recombinant 
C/EBPa and HNF3 or carry out supershift assays were unsuccessful and could not be 
completed due to time constraints.
5.5 Discussion: Mutagenesis of putative regulatory protein binding sites.
5.5,1 Reporter gene assay optimization and technical considerations.
Numerous attempts to carry out functional analysis of the CYP3A4 promoter using 
transfection assay as previously described by others in our laboratory (e.g. El Sankary et 
al, 2000; Ogg et aï., 1999) were unsuccessful in this study. The method employed here
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differs from previous methods used in our laboratory in a number of ways. First the cell 
line used (HuH7) was different to the previous hepatoma cell line used (HepG2). This 
was because the cells were found to be easier to maintain in culture (personal 
observation) and were readily transfected using Fugene 6 (instead of the previously used 
calcium phosphate method) at a sufficient level to allow for reproducible measuiements 
of reporter gene levels. Also the reporter gene construct was different to the one 
previously developed and used in our laboratory (Ogg et al, 1999). The main advantage 
of the new construct engineered by Dr Hossein Hamzeiy (Hamzeiy, 2002) is that it 
included the native distal enhancer element XREM (Goodwin et a l, 1999) suggesting 
that within the experimental set-up reported here this enhancer region may be critical for 
the induction process. Indeed in preliminary experiments, constructs containing the 
-301/+7 promoter region in the presence and absence of the XREM were found to 
produce detectable levels of reporter gene expression but plasmids with an XREM insert 
provided a stronger response to CYP3A4 inducers than those without (data not shown). It 
is worth mentioning that there appears to be a discrepancy in terms of the rifampicin 
concentrations necessary to achieve full induction in various experimental systems. In the 
present study a significant level of reporter gene activation can be achieved at a 
concentration as low as 0.5 pM and the increase peaks for rifampicin concentrations 
between 5 to 10 pM, which is not inconsistent with findings in HepG2 cells using a 
similar construct (Goodwin et a l, 1999). However, using a construct with a different 
enhancer to the XREM and the -301/+7 fr agment of CYP3A4 the concentration needed to 
reach maximum induction appeared to be higher than 100 pM (El Sankary et al, 2002) or 
higher than 20 pM with a similar construct containing the -1201/-61 region of promoter 
(Hamzeiy, 2002). The causes for this variability are unknown and are probably due to 
variations in the constructs (enhancing effect of the XREM), cell line sub-clone 
populations (which may slightly vary in the transcription factor content) or individual 
experimenter variation. The comparison of the pWT and pWT* induction profiles 
presented in figure 5.5 demonstrates that the mutation (T>C, -193bp) has no effect on the 
rifampicin activation of the -301/4-7 fragment of CYP3A4. It is possible, however, that 
the response to other inducers may be altered as it was the case for the glucocorticoid 
induction of the pMUT plasmids (see above section 5.4).
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Finally it should be noted that during preliminary experiments (not shown) the induction 
of the construct was only achieved in the presence of co-transfected SXR expression 
plasmid. This is consistent with the fact that the levels of SXR and several other nuclear 
receptors are present in HuH7 cells at lower levels than in human liver (Anna Phillips, 
University of SiUTey, personal communication).
5.5.2. Comparison of the -301/+7 fragment versus -1201/-61.
The data from this experiment show a difference in the reporter gene expression between 
the 2 constructs suggesting the presence of factors within HuH7 cells acting as CYP3A4 
repressors between -1201/-301 and/or acting as activators between -61/4-7. The ratio of 
reporter gene production for rifampicin dosed cells against the respective DMSO solvent 
control are similar between the two constructs, suggests that in the -1201/-301 and/or the 
-61/4-7 fragment additional factors interact to alter the basal level of CYP3A expression, 
but that these do not interfere with the rifampicin mediated CYP3A expression. It could 
be that because HuH7 cells exhibit a foetal phenotype with CYP3A7 expression but no 
CYP3A4 expression (Saito et a l, 2001) the regulatory regions of the CYP3A4 gene may 
interact with endogenous transcription factors repressing the promoter activity. The 
DNase I footprinting data presented in chapter 3 suggest that besides the TATA box there 
may be at least 2 sites where proteins (or protein complexes) may interact with the 
-61/4-7 region of the CYP3A4 promoter. Unfortunately the nature of the possible proteins 
binding at those sites could not be determined experimentally. There are, however, 
several possible candidate proteins including the nuclear receptor COUP-TF which is 
laiown to act as a transcriptional repressor and is also known to be present at high level in 
foetal tissues and cell lines (Qiu et al, 1994).
5.5.3. Effect of the mutations on the basal expression of reporter gene constructs in 
HuH7 cells.
In this experiment the level of reporter gene expression was measured by transfecting the 
wild type and mutated plasmids in HuH7 cells without adding any exogenous SXR 
ligands. However in this context it is probable that the co-transfected SXR may have
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been activated by endogenous cellular metabolites or steroids potentially present in the 
cell culture media. Indeed because of a large ligand-binding domain (Watkins et al, 
2001) the promiscuous PXR ligand binding domain can interact with a very wide variety 
of structurally unrelated compounds (Moore et a l, 2000). Therefore basal state will be 
defined here as the absence xenobiotic inducers and in the presence of endogenous 
activators. The results presented in figure 5.7 suggest that factors binding to the ER6 are 
involved in the basal expression of the CYP3A4 gene, within the experimental system 
used in this study. A similar effect has been previously reported, together with data 
demonstrating the importance of the other nuclear receptor binding sites located within 
the XREM region (Goodwin et a l, 1999). This is in contrast with results from 
experiments using SXR knock out mice which failed to demonstrate a down regulation of 
cyp3all gene in the untreated animals (Staudinger et al, 2001; Xie et a l, 2000b). This is 
probably because in knock out mice the product of the missing SXR gene can be replaced 
by CAR binding to the intact cyp3all regulatory regions (Smirlis et al, 2001; Xie et al, 
2000a) or because SXR in the in vivo basal state may act as a tianscriptional repressor 
due to its interaction with co-repressors (discussed in section 3.3.3). This result highlights 
the very important role of the ER6 as a c/j-acting element. The fact that the HNF and 
C/EBP SDM constructs exhibited a lower reporter gene activity in non-drug treated cells 
suggests that the proteins binding to these sites are involved in the basal expression of the 
CYP3A4 gene. This is in agreement with the fact that proteins fi'om both the HNF and 
C/EBP families are mainly expressed in the liver (Xanthopoulos et a l, 1991) and are 
involved in the tissue specific expression of several hepatic genes (Diehl, 1998; Hayashi 
et al., 1999; Lekstrom-Himes and Xanthopoulos, 1998). Hence it would not be surprising 
if these factors played a role in the tissue specific basal expression of CYP3A4 in the 
liver. The pSpl and pSpl * plasmids, however, did not display any change in the level of 
SEAP production suggesting a lack of effect of these mutations on the basal promoter 
activity. This is in contradiction with the fact the Spl is involved in the basal regulation 
of many genes (Suske, 1999) and that it was predicted to play a similar role herein. 
However, as will be discussed below, the responses of the Spl SDM constructs are 
variable suggesting a complex role.
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5.5.4. Effect of the mutations in rifampicin treated HuH7 cells.
The results generated by the reporter gene assay study following the mutagenesis of 
regions from the -301/4-7 fragment of CYP3A4 proximal promoter indicate that some of 
the mutated regions are located within important c/^-acting elements with regards to the 
rifampicin mediated induction of CYP3A4 gene expression.
As expected the pER6* plasmid which contains two base pair mutations (AA>TT, - 
166bp) within the ER6 region exhibited a lower response to rifampicin treatment than its 
wild type (pWT*) counterpart. This experiment acted as a positive control to assert that 
mutations to important regulatory elements could affect the transcriptional activation of 
the constructs generated within the experimental set-up presented here. Data from the 
literature suggest that if only one of the ER6 half sites is mutated there is still possibility 
for in vitro synthesised SXR:RXRa protein heterodimers to recognise the DNA sequence 
(Lehmann et al, 1998). Because it could not be determined whether transcription factor 
binding to this ER6 site was completely abolished, this experiment could not prove that 
the activation of a CYP3A4 reporter gene constr uct could be achieved without binding of 
proteins (SXR-RXR heterodimers in this case) to this region.
The responses of the pMUT, pWT*, pHNF and pHNF* plasmids to rifampicin raises 
interesting questions about the mechanisms of CYP3A4 gene regulation. The sequence 
variations of these plasmids are summarized in figure 5.12. Previous work demonstrated 
that the pMUT construct responds to rifampicin in the same way as a plasmid containing 
the wild type promoter but that the response to GR ligands is altered (figure 5.1). The 
similar responses to rifampicin obseiwed in the pHNF and pWT* constructs compared to 
that of the pWT plasmid were therefore consistent with the published data (El Sankary et 
a l, 2002). However, the pHNF* plasmid which contains 3 base pair mutations responded 
in a different manner as rifampicin induction was decreased.
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Figure 5.12. Representation of the locations where bases are modified in the pMUT
(El Sankary et aL, 2002) (A), pHNF (B), WT* (C) and pHNF* (D) plasmids.
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This could be because the cumulative effect of both mutations affects the protein-binding 
site in a more pronounced manner (e.g. the putative HNF3 binding site) or because the 
combination of 2 mutations (pWT* and pHNF) affects two protein-binding sites which 
disruption results in a loss of SXR mediated response. Testing the pHNF* plasmid with 
other xenobiotics (e.g. glucocorticoids) will shed light on this phenomenon. This work is 
currently undertaken in our laboratory.
The inconsistency of the responses seen for the pSpl and pSpl* plasmids as well as the 
high intra-experiment variability are unlikely to be due to problems with the plasmid 
preparations since they were re-extracted from bacterial cultures. Additionally problems 
with the plasmid transfection efficiency would have been noticed from unusual levels of 
SEAP production in the cell media prior to xenobiotic dosing (measured at ‘day 1 ’) and 
this did not appear to be the case.
The results for the Spl mutant plasmids were not significant. It was expected the 
activation profile would be disrupted since Spl is known to be involved as a repressor in 
the regulation of other CYP genes (discussed in section 4.3.4, Kaczynsld et al, 2002; 
Muangmoonchai et al, 2001). The negative result could be due to the fact that the 
nucleai* protein binding to this region is not significantly involved in the regulation of the 
CYP3A4 gene or because the mutation was not sufficient to disrupt the DNA:protein 
interaction. In order to test this hypothesis, fiirther disruption of the putative protein 
binding site by SDM would be necessary.
The most significant result was the clear reduction of the Imax observed in plasmids where 
a putative C/EBPa binding site had been mutated (pCEBP and pCEBP*). As discussed in 
chapter 3, previous reports demonstrate that the -169/+11 region of the CYP3A4 
promoter as well as the -350/-311 and -628/-608 of the CYP3A1 promoter can be up 
regulated by co-transfection of a C/EBPa expression plasmid (Omiin et al, 1997; 
Rodrigues et a l, 2003). In a functional study of the CYP3A5 proximal promoter it was 
reported that a member of the Nuclear Factor-Y (NF-Y) family bound to a CAAT box 
(Iwano et al, 2001). Therefore care should be taken in interpreting the computer analysis 
of the -301/+7 with the Transfac database. Indeed although data from the literature 
strongly suggests that the CAAT box binding factor is C/EBPa this has not been
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demonstrated in this report and further work is required in order to determine the exact 
nature of the factor binding at this location.
In this attempt to identify factors involved in the regulation of the CYP3A4 gene the exact 
nature of the mechanisms involved in the altered activation of the constructs caused by 
the mutations remains to be tested. Indeed it is possible that altered binding of the factors 
described above may cause the effect seen without affecting the binding to the ER6 but it 
could also be that the changes seen are due to changes in the binding at the ER6 site 
caused by modifications of the protein-protein interactions within the promoter fi agment. 
The former hypothesis is consistent with the interactions described in the mechanisms of 
CYP3A5 gene regulation (Iwano et al, 2001) where members of the Sp and NF-Y 
families act synergistically to activate reporter gene constructs. The latter hypothesis 
would fit with the model of interactions described in a study of the PECK gene promoter 
(Stafford et a l, 2001) where binding of the GR is enhanced by the presence of 
‘accessory’ transcription factors (HNF3 and COUP-TF) binding in the flanking region of 
the GRE.
Due to lack of time it was not possible to further identify the factors binding to the 
mutated sites and attempts to generate in vitro transcribed proteins were unsuccesful. In 
spite of this uncertainty it should be noted that any effect of the mutations on the reporter 
gene construct basal activity and activation strongly suggests that in this proximal 
promoter context and in this HuH7 cellular enviromnent the affected region is involved in 
the transcriptional activity.
Also due to time limitation a study of the effect of the mutations on HepG2 and HuH7 
nuclear protein binding could not be optimised. The data suggested binding to the 
response elements thought to be involved, however, quantification of differential affinity 
of the proteins could not be made. Therefore there is theoretically a possibility that the 
alterations generated by mutagenesis may have enhanced nuclear protein binding or may 
have created novel protein binding sites.
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5.6. Conclusion.
The work described in this section confirms some of the hypotheses generated by the 
DNase I footprinting mapping experiment described in chapter 3. Using site directed 
mutagenesis and reporter gene assays the role of c/^-acting elements other than the ER6, 
including a putative HNF3 and C/EBPa, has been demonstrated for the first time. The 
exact nature of the mechanisms and the identity of the transcription factors involved 
remain to be investigated. These findings demonstrate that the molecular mechanisms 
driving the expression of the CYP3A4 gene are more complex than initially thought, as 
they are likely to results from the integration of xenobiotic-, hormone- and tissue-specific 
signals.
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C h a p t e r  6 -  D is c u s s io n
6.1. Introduction.
Following years of investigation into the molecular mechanisms of the CYP3A4 gene 
regulation, the cloning of the SXR provided answers to several enigmas such as the wide 
range of compounds capable of inducing this important drug-metabolizing enzyme or the 
fact that several of these inducers had apparent contradictory therapeutic effects (i.e. 
glucocorticoids and antiglucocorticoids) (Bertilsson et a l, 1998; Blumberg et al, 1998; 
Kliewer et a l, 1998). The discovery of this receptor also raised questions and for instance 
there was a need to investigate the role of other transcription factors in CYP3A4 basal 
expression and activation. Indeed the interaction with other regulators is likely to play a 
role in modulating this response, since SXR is a good xenobiotic sensor (Jones et al,
2000) but its very promiscuity causes problems with the fine tuning of the target gene 
response. The present study was aimed at investigating the transcriptional regulation of 
the CYP3A4 gene in the light of these recent advances, focusing on the proximal 
promoter region. Although, due to teclinical problems and time restrictions, the identity 
of the regulatory factors contributing to the induction process is not fully understood, a 
DNase I footprinting mapping study coupled with functional assays of transcription 
strongly suggest that factors others than SXR acting at the ER6 can influence the basal 
level of expression as well as the degree of induction of an heterologous reporter gene 
construct by rifampicin. The cw-acting elements involved are putative binding sites for 
members of the HNF and C/EBP families. Additionally a study of the effect of naturally 
occuring functional mutations on the binding of nuclear proteins to DNA oligomers 
suggested that further regions are likely to be involved in the hepatic regulation of the 
CYP3A4 gene and that the most likely transcription factor candidate is Spl.
This chapter describes how these findings may have potential implications on the current 
understanding of the hepatic CYP3A4 gene regulation by pathophysiological and 
environmental signals other than xenobiotics and on the understanding of inter-individual
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variability in CYP3A4 expression and drug-activation. This section will be concluded by 
a discussion on how recent discoveries in the field of eukaryotic gene regulation could be 
applied to the study of this important gene.
6.2. Liver specific transcription factors and CYP3A4 gene expression.
Although this work does not provide unequivocal evidence for the identity of specific 
factors, it demonstrates that regions in the CYP3A4 proximal promoter can bind 
transcription factor(s) present in hepatic cell lines and that alterations in their binding 
sites can impact on the basal and rifampicin induced expression of this gene. Together 
with recent evidence published in the literature (e.g. Huss and Kasper, 2000; Jover et al, 
2001; Ourlin et al, 1997; Rodrigues et al, 2003) this work suggests that members of the 
C/EBP and HNF family possibly contribute to CYP3A4 gene expression.
A study of the rat CYP3A23 gene promoter indicates that a functional HNF4 binding site 
is located between bases -85 to -110 (from the transcription start site) (Huss and Kasper, 
1998). Although this site is not necessary for the expression and induction of CYP3A23, 
the presence of the HNF4 liver specific transcription factor is required in order to achieve 
full induction of the gene (Huss and Kasper, 1998; Huss and Kasper, 2000). In a human 
hepatocyte model, adenovirus mediated transfection of the HNF4 gene demonstrated the 
role of this factor in the maintenance of CYP3A4 gene expression (Jover et al, 2001). 
Two studies point towards a role of C/EBPa in the regulation of the CYP3A4 and 
CYP3A1 genes. Using co-transfection experiments, the expression of reporter genes was 
increased by C/EBPa expression plasmids (Ourlin et al, 1997; Rodrigues et al, 2003). 
Additionally, this transcription factor was found to interact in vitro with CYP3A1 
regulatory sequences (Rodrigues et aï., 2003).
The transfection assay data reported in chapter 5 unequivocally demonstrate that a 
transcription factor interacting with a binding site for C/EBPa in the CYP3A4 proximal 
promoter impacts on both the basal and rifampicin induced expression of the gene. 
Additionally an HNF3 response element is also involved in at least the basal expression 
of an heterologous -301/+7 construct of the CYP3A4 proximal promoter.
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This section highlights that besides their involvement in sustaining the tissue-specific 
expression of the CYP3A4 gene, liver specific transcription factors are probably involved 
in mediating gene expression in response to pathological states and might be important 
variables to explain the polymorphic liver specific expression of the CYP3A4 gene.
6.2.1. Liver specific transcription factors and inflammation.
Several reports describe a change in P450 levels or activity following infection or 
inflammatory reaction (reviewed in Morgan, 1997). For instance, CYP3A4 expression has 
been reported to be decreased by interleukin 6 (IL6) exposure in human hepatocytes 
(Muntane-Relat et al, 1995). This phenomenon could be due, at least partly, to an altered 
expression of CAR and PXR, since IL6 has been reported to cause a decrease in the level 
of the nuclear receptors in human hepatocytes (Pascussi et al., 2000c). This obseiwation 
was also made in mice injected with bacterial lipopolysaccharides, responsible for 
inducing acute inflammation, where Cyp2bl0 and Cyp3a mRNA levels were rapidly 
decreased in parallel with the mRNA levels of CAR, PXR and RXRa (Beigneux et al,
2002). This would suggest a mechanistic link between pathological states and 
inflammation-induced reduction of P450’s. There is, however, conflicting evidence 
supporting which liver specific transcription factors may transduce the effect of the 
signaling molecules produced during inflammation or infection and result in decreased 
CYP gene expression. As discussed earlier in section 3.3.4.2 there is a possibility that the 
effects of nitric oxide (NO) may be mediated by HNF4. Also, a member of the C/EBP 
family (C/EBPP) is known to be involved in the response to IL6 (Lekstrom-Himes and 
Xanthopoulos, 1998). Therefore it cannot be excluded that members of the C/EBP family 
can directly alter CYP3A4 expression by acting at the promoter level. Indeed it has been 
reported that IL 6 causes an increase in the levels of a low molecular form of C/EBP(3 
(C/EBPp-LIP), which reduces the activating effect of C/EBPa and has a repressive effect 
on CYP3A4 expression levels in human hepatocytes (Jover et al, 2002).
It could be that both mechanisms are involved in the response to inflammation. However, 
in order to reconcile the two models it may be hypothesized that liver specific
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transcription factors mediate the effect of inflammation mediators and then impact the 
level of the liver expressed CAR, SXR and RXRa, which in turn have an effect on the 
levels of the target gene CYP3A4. This hypothesis remains to be tested.
In conclusion this work provides a possible mechanistic link between certain pathologies 
and their effect on CYP3A4 gene expression. Knowledge of the involvement of liver 
specific transcription factors in CYP3A4 regulation may provide valuable mechanistic 
clues to explain these observations and help design treatments and compounds with a 
view to avoid drug-drug interactions and adjust doses of therapeutic drugs as the 
metabolism of CYP3A4 substrates and/or inducers may be altered in patients suffering 
from infection or inflammatory reactions.
6.2.2. Liver specific transcription factors and inter-individual variability in drug 
metabolism.
The mutation screening of 11 human liver samples with a 14.1-fold variability in CYP3A 
activity (phenotype) revealed that the first kilobase of proximal promoter contained no 
mutations (as discussed in chapter 4). Although the study of a larger population sample 
(101 subjects) revealed that 28 individuals contained mutations in the CYP3A4 regulatory 
region (Hamzeiy et al, 2002), it is possible that the inter-individual variability in drug 
metabolism displayed in the population may also be due to variability in the levels of 
regulatory proteins or epigenetic features such as DNA méthylation (see section 4.3.3 and 
below). In addition to qualitative and quantitative variations in the factors binding at the 
ER6 (SXR and CAR), there is evidence that the expression of liver specific transcription 
factors may vary because of genetic or environmental factors.
6.2.2.1. Mutations in liver specific transcription factors.
Some hepatic transcription factors are loiovwi to contain mutations in their exon, intron 
and promoter regions. For instance a total of 65 mutations have been reported for the 
HNF la  coding region, as well as 6 promoter variants (Ellard, 2000). Some of these 
mutations are thought to be associated with the occurrence of certain forms of diabetes.
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the maturity onset diabetes of the young (MODY). Another gene which mutations are 
linked to MODY is tliat coding for HNF4a (Schrem et al, 2002), where various 
mutations have been discovered that were found to disrupt various domains of the nuclear 
receptor. In addition to members of the HNF family, there is a report of mutations in the 
gene coding for C/EBPa (Gombart et al, 2002). However, because these 12 mutations 
were detected in tumour tissue, it is not clear whether these may be present in healthy 
tissue or within a healthy population.
Although no work so far has revealed an association between mutations in liver specific 
transcription factors and CYP gene expression, it can be hypothesized that genetic 
variability in these hepatic regulators may result in variability in the expression level of 
their target genes (namely CYP3A4).
6.22.2. Variability in the parameters which regulate liver specific transcription factor 
expression.
Besides genetic alterations which may affect expression and protein function between 
individuals, endocrine and environmental factors can possibly alter the expression levels 
of liver specific transcription factors. For instance in a study of human liver samples 
taken by biopsy, the mRNA and protein levels of C/EBPa and p were shown to vary 
between patients (which suggests polymorphic expression or the influence of 
environmental factors) and their levels were found to be greatly affected by plating in 
primary cultures suggesting an influence of stress and cell proliferation signals in 
regulating the levels of expression (Ferrini et a l, 2001). In a study of HNF3 family 
member mRNA expression in rat liver (Imae et a l, 2000) it was reported that a low 
protein diet increased HNF3y, dexamethasone treatment increased HNF3a and p and that 
diabetic animals exhibited an increased HNF3p and y expression which was reversed 
upon insulin injection. An enhancer element in the HNF4a regulatory region allows 
transcriptional regulation of the gene by glucocorticoids (Bailly et a l, 2001). C/EBPa 
has also been shown to be affected by synthetic glucocorticoids, since it is up regulated 
following dexamethasone treatment in rat hepatocytes (Rodrigues et al, 2003). Taken
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together these results suggest that the hormonal status may alter the levels of liver 
transcription factors thereby possibly affecting the CYP3A4-mediated drug metabolism.
A recent study suggests that xenobiotics may also alter hepatic transcription factor 
content. Treatment of rat primaiy hepatocytes with the polychlorinated biphenyl (PCB) 
mixture Aroclor 1254 resulted in an increase in mRNA for C/EBPa and members of the 
HNFl and 4 families (Borlak et al, 2002). These changes had an effect on the secretion 
of albumin, which was raised concomitantly and which is a known target for these 
transcriptional regulators. Additionally, because the transcriptional regulation of some of 
these factors is influenced by synthetic steroids, it is possible that inter-individual 
variations in steroid metabolism and in the levels of plasma steroids (which in turn may 
be linked to the environment and ageing) may impact upon transcription factor levels and 
the expression of downstream target genes. There is substantial evidence that HNF4a is 
involved in the regulation of several other liver specific transcription factors (Hayashi et 
al, 1999; Sclirem et al, 2002), as well in the regulation of other nuclear receptors such as 
SXR (Li et a l, 2000). Therefore modifications in the regulatory networks formed by 
these factors could possibly alter the CYP3A4 phenotype.
In conclusion, since CYP3A4 expression is likely to be driven partly by liver specific 
trancription factors (C/EBPa and HNF family members), variability in the functionality 
or expression of these regulators (tlu'ough genetic or environmental factors) is likely to 
result in variability in the expression of the CYP3A4 gene.
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6.3. Role of epigenetics on gene regulation.
In cell nuclei the DNA is associated with histone proteins and forms chromatin fibers. 
These fibers are formed by nucleosome units which consist of 146bp of DNA wrapped 
around an octamer formed by 2 of each core histone proteins (H2A, H2B, H3, H4) 
(Zhang and Reinberg, 2001). This chromatin template undergoes structural modifications 
associated with various processes such as cell division, DNA replication and repair as 
well as gene regulation (Zhang and Reinberg, 2001). The core histone proteins consist of 
a globular C-terminal around which the DNA is wrapped and a N-terminal tail protruding 
outward from the nucleosome unit. The histone tails may undergo covalent post- 
transcriptional modifications (acétylation, méthylation, ubiquitination, phosphorylation) 
by specific enzymes, which are part of multi-protein complexes recruited to various 
regions of the genome following intra- and extra-cellular signals (Jenuwein and Allis,
2001). It has been suggested that these modifications form an histone code (Jenuwein and 
Allis, 2001; Turner, 2002) and depending on the nature and the position of the group 
added, these histone tails establish which area of the chromatin are transcriptionally 
active (euchromatin) or transcriptionally repressed (heterochromatin). For instance 
acétylation of the lysine 9 residue and méthylation of the arginine 3 residue on the tail of 
histone 4 are associated with gene activation, whereas méthylation of lysine 9 on the H3 
tail is associated with transcriptional repression (Berger, 2002).
Histone modifying enzymes are part of multiprotein complexes which are specifically 
recruited to promoters prior to transcription initiation. For instance the histone 
methyltransferase PRMTl has been shown to physically interact with the transcription 
factor Ying Yang 1 (YYl), as part of a complex which binds to a YYl activated 
promoter, and methylate the arginine 4 residue on the histone H4 tail (Rezai-Zadeh et al,
2003). This modification resulted in an increased transcription of the target gene. As 
mentioned in the introduction chapter (section 1.4.2), nuclear receptors are capable of 
interactions with other proteins (coregulators), bringing an additional level of complexity 
to the regulation of target genes (McKenna and O'Malley, 2002). SXR is known to recruit 
SRC-1 (Lehmann et al, 1998) and SMRT (Takeshita et al, 2002), which act respectively 
as coactivator and corepressor. Some of these coregulator proteins (e.g. SRC-1) possess
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the ability to acetylate histories (Jenster, 1998) thereby modifying the clii'omatin stmcture 
to make it more accessible for the transcription machinery.
Attempts to stimulate the genomic transcription of CYP3A4 in HuH7 and HepG2 cells 
(which express CYP3A4 at very low levels), using over-expression of SXR in order to 
overcome the low expression of the regulatory protein, have been unsuccessful (Anna 
Pliilips and Nick Plant, personal communication). This observation lends support to the 
hypothesis that chromatin structure may be an important factor in CYP gene regulation. 
There is clearly a scope for further work on the histone modifying enzymes involved in 
CYP3A gene regulation in vivo. For instance since post-translational modifications of 
histone tails may have a role in cellular memory processes and in the long-term activation 
or repression of genomic regions (Jenuwein and Allis, 2001; Turner, 2002), it is possible 
that such mechanisms may explain the variations in drug metabolism enzymes observed 
during development (Lacroix et a l, 1997). The study of the histone modifications and 
nucleosomal structure at the CYP3A locus may provide insight into the ontogeny of 
CYP3A gene expression {CYP3A4 Vs CYP3A7) as well as possible phenotype alterations 
in CYP genes occurring during disease and xenobiotic exposure.
6.4. Conclusion.
This work demonstrates that the ER6 is not the only c/5-acting element involved in the 
transcriptional activation of the CYP3A4 gene. Mutations affecting putative protein 
binding sites which are response elements for a variety of factors can alter the binding of 
nuclear proteins and/or the in vitro response of the proximal promoter in reporter gene 
assays. This finding demonstrates that the molecular mechanisms of the CYP3A4 gene 
expression are far more elaborate than originally anticipated, since there are several 
layers of complexity in the regulation process. The diagram in figure 6.1 presents a model 
that summarises the factors involved in the regulation of this important hepatic drug 
metabolism enzyme, in the light of the results presented in this thesis and in the recent 
literature. It appears that questions relating to the transcriptional regulation of the 
CYP3A4 gene in the human liver are in fact addressing wider issues such as the 
regulatory networks formed by xenobiotic and tissue specific transcription factors.
142
Recent advances in genetic and molecular biology techniques (e.g. transgenic technology 
and DNA microarrays) will undoubtedly contribute towards a more complete 
understanding of this system and while allowing scientists to uncover fascinating 
biological mechanisms, they will eventually allow the design of safer drugs and therapy 
designs.
Figure 6.1. Summary of the mechanisms involved in the hepatic regulation of the 
CYP3A4 gene. The xenobiotic and liver specific transcriptions factors regulate the 
expression of the CYP3A4 gene. Both the CYP3A4 genes and its regulators are subject to 
the effect of epigenetic mechanisms. The various gene regulation events and protagonists 
are influenced by a variety of exogenous factors.
Transcription Regulators:
liver specific (HNF and 
C/EBP families) and 
xenobiotic transcription 
factors (CAR and SXR)
cm Form a network of inter­regulated genes
Epigenetics:
chromatin 
structure and DNA 
méthylation
Environment: Diet, Drugs, 
Hormones, Pathology
CM CYP3A4 gene
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6.5. Future directions.
Following this study of the transcriptional mechanisms of the CYP3A4 gene regulation, it 
would be interesting to identify the transcription factors binding to the c/5-acting 
elements identified here. This could be done by a number of complementary approaches 
including reporter gene assay experiments with co-transfection of expression plasmids for 
factors thought to be interacting with the regulatory region as well as DNArprotein 
interaction studies using recombinant proteins and/or antibodies specific to the protein 
bound to the labeled DNA oligomer.
Once the involvement of those transcription factors has been established monitoring their 
levels (as well as that of any other factor known to be involved in the regulation of CYP 
genes or xenobiotic nuclear receptors) under various experimental treatments as well as 
in liver tissue samples from several individuals would provide insight into the 
mechanisms of drug-drug interaction and inter-individual variability in drug metabolism. 
This could be done alongside the measurement of several other target genes for instance 
as part of a gene array experiment (RNA levels) or a proteomics experiment 
(measurement of global changes in protein levels)
Because there is evidence from this work and the literature that SXR may bind 
unliganded to the CYP3A4 promoter and repress transcription and also interacts with a 
variety of coactivators, it would be interesting to investigate the in vivo associations 
formed between the nuclear receptor and other nuclear proteins. This could be done by 
analyzing the proteins present in complexes found in liver extracts which would have 
been immunoprecipitated.
Finally, as discussed above, the study of the Tiistone code’ in place at the nucleosomal 
structure of the CYP3A locus may provide insight into the ontogenic, basal and 
xenobiotic induced regulation of the CYP3A4 gene.
144
7. B ib l io g r a p h y .
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. (2002). 
Molecular Biology of the Cell, 4th edition. Garland Science.
Ando, Y., Tateishl, T., Selddo, Y., Yamamoto, T., Satoh, T., Hasegawa, Y., 
Kobayashi, S., Katsumata, Y., Shimokata, K., and Salto, H. (1999). Re: Modification 
of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 [letter]. 
Journal of the National Cancer Institute 91, 1587-1590.
Aranda, A., and Pascual, A. (2001). Nuclear hormone receptors and gene expression. 
Physiological Reviews 81, 1269-1304.
Baes, M., Gulick, T., Choi, H. S., Martinoli, M. G., Simha, D., and Moore, D. D.
(1994). A new orphan member of the nuclear hormone receptor superfamily that interacts 
with a subset of retinoic acid response elements. Molecular and Cellular Biology 14, 
1544-1551.
Bailly, A., Torres-Padilla, M. E., Tinel, A. P., and Weiss, M. C. (2001). An enliancer 
element 6kb upstream of the mouse HNF4al promoter is activated by glucocorticoids and 
liver-enriched transcription factors. Nucleic Acids Research 29, 3495-3505.
Ball, S. E., Scatina, J., Kao, J., Perron, G. M., Fruncillo, R., Mayer, P., Weiniyb, I., 
Guida, M., Hopldns, P. J., Warner, N., and Hall, J. (1999). Population distribution and 
effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. 
Clinical Pharmacology and Therapeutics 66, 288-294.
Baiwick, J. L., Quattrochi, L. €., Mills, A. S., Potenza, C., Tukey, R. H., and 
Guzelian, P. S. (1996). Trans-species gene transfer for analysis of glucocorticoid- 
inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit 
CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. Molecular 
Pharmacology JO, 10-16.
Beigneux, A. P., Moser, A. H., Shigenaga, J. K., Grunfeld, €., and Feingold, K. R.
(2002). Reduction in cytoclirome P-450 enzyme expression is associated with repression 
of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver
145
during the acute phase response. Biochemical and Biophysical Research Communications 
293, 145-149.
Berger, S. L. (2002). Histone modifications in transcriptional regulation. Current 
Opinion in Genetics and Development 12, 142-148.
Bertilsson, G., Berkenstam, A., and Blomquist, P. (2001). Functionally conserved 
xenobiotic responsive enhancer in cytochrome P450 3A7. Biophysical and Biochemical 
Research Communication 280, 139-144,
Bertilsson, G., Heidricli, J., Svensson, K., Asman, M., Jendeberg, L., Sydow- 
Backman, M., Ohlsson, R., Postlind, H., Blomquist, P., and Berkenstam, A. (1998). 
Identification of a human nuclear receptor defines a new signaling pathway for CYP3A 
induction. Proceedings of the National Academy of Sciences of the United States of 
America PJ, 12208-12213.
Blumberg, B., Sabbagh, W. J., Juguilon, H., Bolado, J. J., van Meter, C. M., Ong, E.
S., and Evans, R. M. (1998). SXR, a novel steroid and xenobiotic-sensing nuclear 
receptor. Genes and Development 12, 3195-3205.
Bonifer, C. (1999). Long-distance chromatin mechanisms controlling tissue-specific 
gene locus activation. Gene 238, 277-289.
Borlak, J., Dangers, M., and Thum, T. (2002). Aroclor 1254 modulates gene 
expression of nuclear transcription factors: implications for albumin gene transcription 
and protein synthesis in rat hepatocyte cultures. Toxicology and Applied Pharmacology 
181, 79-88.
Boruk, M., Savory, J. G., and Hache, R. J. (1998). AF-2-dependent potentiation of 
CCAAT enhancer binding protein beta-mediated transcriptional activation by 
glucocorticoid receptor. Molecular Endocrinology, 12, 1749-1763.
Buratowski, S. (1994). The basics of basal transcription by RNA polymerase II. Cell 77, 
1-3.
Calleja, C , Pascussi, J. M., Maui, J. C., Maurel, P., and Vilarem, M. J. (1998). The 
antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid 
receptor. Nature Medicine 4, 92-96.
146
Chen, D., Lepar, G., and Kemper, B. (1994). A transcriptional regulatory element 
common to a large family of hepatic cytoclirome P450 genes is a functional binding site 
of the orphan receptor HNF-4. Journal of Biological Chemistry 269, 5420-5427. 
Cholerton, S., Daly, A. K., and Idle, J. R. (1992). The role of individual human 
cytochromes P450 in drug metabolism and clinical response. Trends in Pharmacological 
Sciences 13, 434-439.
Claris, S. J., Harrison, J., and Molloy, P. L. (1997). Spl binding is inliibited by 
(m)Cp(m)CpG méthylation. Gene 195, 67-71.
Daly, A. K., Fairbrother, K. S., and Smart, J. (1998). Recent advances in 
understanding the molecular basis of polymorphisms in genes encoding cytoclir ome P450 
enzymes. Toxicology Letters 102-103, 143-147.
Darlington, G. (1999). Molecular mechanisms of liver development and différenciation. 
Current Opinion in Cell Biology 11, 678-682.
Deng, W. P., and Nickoloff, J. A. (1992). Site-directed mutagenesis of virtually any 
plasmid by eliminating a unique site. Analytical Biochemistry 200, 81-88.
Denison, M. S., and Whitlock, J. P. (1995). Xenobiotic-inducible transcription of 
cytochrome P450 genes. Journal of Biological Chemistry 270, 18175-18178.
Diehl, A. M. (1998). Roles of CCAAT/enhancer-binding proteins in regulation of liver 
regenerative growth. Journal of Biological Chemistry 273, 30843-30846.
Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983). Accurate transcription 
initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. 
Nucleic Acids Research 11, 1475-1489.
Domanski, T., Finta, C., Halpert, J., and Zaphiropoulos, P. (2001). cDNA cloning 
and initial characterization of CYP3A43, a novel human cytochrome P450. Molecular 
Pharmacology 59, 386-392.
Drocourt, L., Ourlin, J. C., Pascussi, J. M., Maurel, P., and Vilarem, M. J. (2002). 
Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor 
pathway in primary human hepatocytes. Journal of Biological Chemistry 277, 25125- 
25132.
Eldns, S., Stresser, D. M., and Williams, J. A. (2003). In vitro and pharmacophore 
insights into CYP3A enzymes. Trends in Pharmacological Sciences 24, 161-166.
147
El Sankaiy, W. (2000) Molecular Mechanisms of CYP3A4 Gene Regulation, PliD 
Thesis, University of Surrey.
El Sankaiy, W., Bombail, V., Gibson, G. G., and Plant, N. (2002). Glucocorticoid- 
Mediated Induction of CYP3A4 is Decreased by Disruption of a Protein; DNA 
Interaction Distinct from the Pregnane X Receptor Response Element. Drug Metabolism 
and Disposition 30, 1029-1034.
El Sankaiy, W., Gibson, G. G., Ayrton, A., and Plant, N. (2001). Use of a reporter 
gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug 
Metabolism and Disposition 29, 1499-1504.
El Sankaiy, W., Plant, N. J., Gibson, G. G., and Moore, D. J. (2000). Regulation of 
the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and 
pregnane X receptors. Drug Metabolism and Disposition 28, 493-496.
Ellard, S. (2000). Hepatocyte nuclear factor 1 alpha (HNF-la) mutations in maturity- 
onset diabetes of the young. Human mutation 16, 377-385.
Felix, C. A., Walker, A. H., Lange, B. J., Williams, T. M., Winick, N. J., Cheung, N. 
K., Lovett, B. D., Nowell, P. C., Blair, I. A., and Rebbeck, T. R. (1998). Association of 
CYP3A4 genotype with treatment-related leukemia. Proceedings of the National 
Academy of Sciences of the United States of America 95, 13176-13181.
Ferrini, J. B., Rodrigues, E., Dulic, V., Pichard-Gareia, L., Fabre, J. M., Blanc, P., 
and Maurel, P. (2001). Expression and DNA binding activity of C/EBPa and C/EBPp in 
human liver and differenciated primary hepatocytes. Journal of Hepatology 35, 170-177. 
Finta, C., and Zaphiropoulos, P. (2000). The human cytochrome P450 3A locus, Gene 
evolution by captur e of downstream exons. Gene 260, 13-23.
Fujii-Kuriyama, Y., Imataka, H., Sogawa, K., Yasumoto, K., and Kikuchi, Y.
(1992). Regulation of CYPlAl expression. Faseb Journal 6, 706-710.
Garabedian, M. J., Labaer, J., Liu, W.-H., and Thomas, J. R. (1993). Analysis of DNA- 
protein interactions. In Gene Transcription a Practical Approach, B. D. Hames, and S. G. 
Higgins, eds. (Oxford University Press), pp. 243-293.
Gellner, K., Eiselt, R., Hustert, E., Arnold, H., Koch, I., Haberl, M., Deglmann, C. 
J., Biirlc, O., Buntefuss, D., Escher, S., et al. (2001). Genomic organization of the
148
human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 
11, 111- 121.
Gibson, G. G., Plant, N. J., Swales, K. E., Ayrton, A., and El Sankary, W. (2002). 
Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction 
mechanisms, species differences and interindividual variation in man. Xenobiotica 22, 
165-206.
Gibson, G. G., and Skett, P. (1994). Introduction to Drug Metabolism, second edition, 
Stanley Thornes Publishers Ltd.
Gombart, A. F,, Hofmann, W. K., Kawano, S., Takeuchi, S., Krug, U., Kwok, S. H., 
Larsen, R. J., Asou, H., Miller, C. W., Hoelzer, D., and Koeffler, H. P. (2002). 
Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein 
alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 99, 1332-1340. 
Gonzalez, F. J., Liu, S. Y., and Yano, M. (1993). Regulation of cytoclii'ome P450 
genes: molecular mechanisms. Pharmacogenetics S, 51-57.
Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., 
Gelboin, H. V., Hardwick, J. P., and Meyer, U. A. (1988). Characterization of the 
common genetic defect in humans deficient in debrisoquine metabolism. Nature 331, 
442-446.
Goodwin, B., Hodgson, E., Costa, D. J., Robertson, G. R., and Liddle, C. (2002). 
Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane 
receptor. Molecular Pharmacology 62, 359-365.
Goodwin, B., Hodgson, E., and Liddle, C. (1999). The orphan human pregnane X 
receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal 
enliancer module. Molecular Pharmacology 56, 1329-1339.
Guengerich, F. P. (1999). Cytochiome P-450 3A4: regulation and role in drug 
metabolism. Annual Review of Pharmacology and Toxicology 39, 1-17.
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Ben et, L. Z., Paine, M. F., 
Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., and Wrighton, S. A.
(1999). Molecular and physical mechanisms of first-pass extraction. Drug Metabolism 
and Disposition 27, 161-166.
149
Hamzeiy, H. (2002) Identification and functional analysis of inherited variations in the 
CYP3A4 gene, PhD thesis. University of Surrey, Guildford.
Hamzeiy, H., Vahdati-Mashhadiaii, N., Edwards, H. J., and Goldfarb, P. S. (2002). 
Mutation analysis of the human CYP3 A4 gene 5' regulatory region: population screening 
using non-radioactive SSCP. Mutation Research 500, 103-110.
Hara, H., and Adachi, T. (2002). Contribution of hepatocyte nuclear factor-4 to down- 
regulation of CYP2D6 gene expression by nitric oxide. Molecular Pharmacology 61, 
194-200.
Hara, H., Yasiinami, Y., and Adachi, T. (2002). Alteration of cellular phosphorylation 
state affects vitamin D receptor-mediated CYP3A4 mRNA induction in Caco-2 cells. 
Biochemical and Biophysical Research Communications 296, 182-188.
Hashimoto, H., Toide, K., Kitamnra, R., Fujita, M., Tagawa, S., Itoh, S., and 
Kamataki, T. (1993). Gene structure of CYP3A4, an adult-specific form of cytochiome 
P450 in human livers, and its transcriptional control. European Journal of Biochemistry 
218, 585-595.
Hayashi, Y., Wang, W., Ninomiya, T., Nagano, H., Ohta, K., and Itoh, H. (1999). 
Liver enriched transcription factors and differentiation of hepatocellular carcinoma. 52, 
19-24.
He, K., Woolf, T. F., and Hollenberg, P. F. (1999). Mechanism-based inactivation of 
cytochiome P-450-3A4 by mifepristone (RU486). Journal of Pharmacology and 
Experimental Therapeutics 288, 791-797.
Herr, A. S., Woehnik, G. M., Rosenhagen, M. C., Holsboer, F., and Rein, T. (2000). 
Rifampicin is not an activator of glucocorticoid receptor. Molecular Pharmacology 57, 
732-737.
Honkakoski, P., and Negishi, M. (2000). Regulation of cytochrome P450 (CYP) genes 
by nuclear receptors. Biochemical Journal 347, 321-337.
Huss, J. M., and Kasper, C. B. (1998). Nuclear receptor involvement in the regulation 
of rat cytochrome P450 3A23 expression. Journal of Biological Chemistry 273, 16155- 
16162.
150
Huss, J. M., and Kasper, C. B. (2000). Two-stage glucocorticoid induction of 
CYP3A23 tiii'ough both the glucocorticoid and pregnane X receptors. Molecular 
Pharmacology 58, 48-57.
Huss, J. M., Wang, S. I,, Astrom, A., McQuiddy, P., and Kasper, C. B. (1996). 
Dexamethasone responsiveness of a major glucocorticoid-inducible CYP3A gene is 
mediated by elements unrelated to a glucocorticoid receptor binding motif. Proceedings 
of the National Academy of Sciences of the United States of America 93, 4666-4670. 
Hustert, E., Zibat, A., Presecan-Siedel, E., Eiselt, R., Mueller, R., Fuss, C., Brehm,
I., Brinkmann, U., Eichelbaum, M., Wojnowski, L., and Burk, O. (2001). Natural 
protein variants of pregnane X receptor with altered transactivation activity toward 
CYP3A4. Drug Metabolism and Disposition 29, 1454-1459.
Hutchinson, M. J., and Allen, J. M. (1997). Improved efficiency of two-primer 
mutagenesis. BioMedNet Technical Tips Online, http://research.bmn.com/tto/.
Imae, M., Inoue, Y., Fu, Z., Kato, H., and Noguchi, T. (2000). Gene expression of the 
thi-ee members of hepatocyte nuclear factor-3 is differentially regulated by nutritional and 
hormonal factors. The Journal of Endocrinology 167, Rl-5.
Ingelman-Sundberg, M. (2002). Polymorphism of cytoclirome P450 and xenobiotic 
toxicity. Toxicology 181-182, 447-452.
Iwano, S., Saito, T., Takahashi, Y., Fujita, K., and Kamatald, T. (2001). Cooperative 
regulation of CYP3A5 gene transcription by NF-Y and Sp family members. Biochemical 
and Biophysical Research Communications 286, 55-60.
Jaffuel, D., Demoly, P., Gougat, C., Mautino, G., Bousquet, J., and Mathieu, M.
(1999). Rifampicin is not an activator of the glucocorticoid receptor in A549 human 
alveolar cells. Molecular Pharmacology 55, 841-846.
Jenster, G. (1998). Coactivators and corepressors as mediators of nuclear receptor 
fimction: An update. Molecular and Cellular Endocrinology 143, 1-7.
Jenuwein, T., and Allis, C. D. (2001). Translating the histone code. Science 293, 1074- 
1080.
Jones, S. A., Moore, L. B., Shenk, J. L., Wisely, G. B., Hamilton, G. A., McKee, D. 
D., Tomkinson, N. C. O., LeCluyse, E. L., Lambert, M. H., Willson, T. M., et ah
151
(2000). The pregnane x receptor: A promiscuous xenobiotic receptor that has diverged 
during evolution. Molecular Endocrinology 14, 27-39.
Jover, R., Bort, R., Gomez-Lechon, M. J., and Castell, J. V. (2001). Cytochrome P450 
regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using 
adenovirus-mediated antisense targeting. Hepatology 33, 668-675.
Jover, R., Bort, R., Gomez-Lechon, M. J., and Castell, J. V. (2002). Down-regulation 
of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and 
transcription factors involved. The FASEB Journal 16, 1799-1801.
Kaczynski, J. A., Conley, A. A., Fernandez-Zapico, M., Delgado, S. M., Zhang, J. S., 
and Urrutia, R. (2002). Functional analysis of basic transcription element (BTE)- 
binding protein (BTEB) 3 and BTEB4, a novel Spl-like protein, reveals a subfamily of 
transcriptional repressors for the BTE site of the cytochrome P4501A1 gene promoter. 
The Biochemical Joiumal 366, 873-882.
Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S.
A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterstrom, R. H., et al. (1998). An 
orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. 
Cell 92, 73-82.
Kliewer, S. A., Umesono, K., Mangelsdoif, D. J., and Evans, R. M. (1992). Retinoid 
X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin 
D3 signalling. Nature 355, 446-449.
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., 
Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001). Sequence diversity in CYP3A 
promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. 
Nature Genetics 27, 383-391.
Lacroix, D., Sonnier, M., Moncion, A., Cheron, G., and Crested, T. (1997). 
Expression of CYP3A in the human liver - Evidence that the shift between CYP3A7 and 
CYP3A4 occurs immediately after birth. European Journal of Biochemistry 247, 625- 
634.
Lamba, J. K., Lin, Y. S., Schnetz, E. G., and Thummel, K. E. (2002). Genetic 
contribution to variable human CYP3A-mediated metabolism. Advances in Drug 
Delivery Review. 54, 1271-1294.
152
Latclimaii, D. S. (1998). Gene Regulation: a eukaryotic perspective., Third edition edn, 
Stanley Thornes publishers Ltd).
LeCIair, K. P., Blanar, M. A., and Sharp, P. A. (1992). The p50 subunit of NF-kappa 
B associates with the NF-IL6 transcription factor. Proceedings of the National Academy 
of Sciences of the United States of America 89, 8145-8149.
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., and 
Kliewer, S. A. (1998). The human orphan nuclear receptor PXR is activated by 
compounds that regulate CYP3A4 gene expression and cause drug interactions. Journal 
of Clinical Investigation 102, 1016-1023.
Lekstrom-Himes, J., and Xanthopoulos, K. G. (1998). Biological role of the 
CCAAT/enliancer-binding protein family of transcription factors. Journal of Biological 
Chemistry 273, 28545-28548.
Lewis, D. F., Watson, E., and Lake, B. G. (1998). Evolution of the cytochrome P450 
superfamily: sequence alignments and pharmacogenetics. Mutation Research 410, 245- 
270.
Li, A. P., Kaminski, D. L., and Rasmussen, A. (1995). Substi*ates of human hepatic 
cytochiome P450 3A4. Toxicology 104, 1-8.
Li, J., Ning, G., and Duncan, S. A. (2000). Mammalian hepatocyte differentiation 
requires the transcription factor HNF-4alpha. Genes and Development 14, 464-474.
Lin, Y. S., Dowling, A. L., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J., 
Schuetz, E, G., and Thummel, K. E. (2002). Co-regulation of CYP3A4 and CYP3A5 
and contribution to hepatic and intestinal midazolam metabolism. Molecular 
Pharmacology 62, 162-172.
Lu, A. Y., Somogyi, A., West, S., Kuntzman, R., and Conney, A. H. (1972). 
Pregnenolone-16 -carbonitrile: a new type of inducer of drug-metabolizing enzymes. 
Archives of Biochemistiy and Biophysics 152, 457-462.
Lund, A. H., Duch, M., and Pedersen, F. S. (1996). Increased cloning efficiency by 
temperature-cycle ligation. Nucleic Acids Research 24, 800-801.
Maglich, J. M., Stoltz, C. M., Goodwin, B., Hawkins-Brown, D., Moore, J. T., and 
Kliewer, S. (2002). Nuclear pregnane X receptor and constitutive androstane receptor
153
regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. 
Molecular Pharmacology 62, 638-646.
Maldshima, M., Lu, T. T., Xie, W., Whitfield, G. K., Domoto, H., Evans, R. M., 
Haussier, M. R., and Mangelsdorf, D. J. (2002). Vitamin D receptor as an intestinal 
bile acid sensor. Science 296, 1313-1316.
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., 
Blumberg, B., Kastner, P., Marie, M., Chambon, P., et al. (1995). The nuclear receptor 
superfamily: the second decade. Cell 83, 835-839.
McKenna, N. J., and O’Malley, B. W. (2002). Combinatorial control of gene expression 
by nuclear receptors and coregulators. Cell 108,465-474.
McKinnon, R. A., Burgess, W. M., Hall, P. M., Roberts-Tliomson, S. J., Gonzalez, F. 
J., and McManus, M. E. (1995). Characterisation of CYP3A gene subfamily expression 
in human gastrointestinal tissues. Gut 36, 259-267.
Mimura, J., and Fujii-Kuriyama, Y. (2003). Functional role of AliR in the expression 
of toxic effets by TCDD. Biochimica et Biophysica Acta 1619, 263-268.
Moore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J.
B., Goodwin, B., Liddle, C., Blanchard, S. G., Willson, T. M., et al. (2000). Orphan 
nuclear receptors constitutive androstane receptor and pregnane X receptor share 
xenobiotic and steroid ligands. Journal of Biological Chemistry 275, 15122-15127. 
Morgan, E. T. (1997). Regulation of cytochromes P450 during inflammation and 
infection. Drug Metabolism Reviews 29, 1129-1188.
Muangmoonchai, R., Smirlis, D., Wong, S. C., Edwards, M., Phillips, I. R., and 
Shephard, E. A. (2001). Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is 
mediated by the oiphan nuclear receptor constitutive androstane receptor (CAR) and 
requires steroid co-activator 1 (SRC-1) and the transcription factor Spl. Biochemical 
Journal 355, 71-78.
Muntane-Relat, J., Ourlin, J. C., Domergue, J., and Maurel, P. (1995). Differential 
effects of cytokines on the inducible expression of CYPlAl, CYP1A2, and CYP3A4 in 
human hepatocytes in primary culture. Hepatology 22, 1143-1153.
Nebert, D. W., and Russell, D. W. (2002). Clinical importance of the cytochromes 
P450. The Lancet 360, 1155-1162.
154
Nelson, D. R. (1999). Cytochrome P450 and the individuality of species. Archives of 
Biochemistry and Biophysics 369, 1-10.
Nelson, D. R., Kamataki, T., Waxman, D, J., Guengerich, F. P., Estabrook, R. W., 
Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O. et aU (1993). 
The P450 superfamily: update on new sequences, gene mapping, accession numbers, 
early trivial names of enzymes, and nomenclature. DNA and Cell Biology 12, 1-51. 
Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, 
D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996). 
P450 superfamily: update on new sequences, gene mapping, accession numbers and 
nomenclature. Phaimacogenetics 6, 1-42.
Nuclear Receptor Nomenclature Committee (1999). A unified nomenclature system 
for the nuclear receptor superfamily [letter]. Cell 97, 161-163.
Ogg, M. S., Williams, J. M., Tarbit, M., Goldfarb, P. S., Gray, T. J., and Gibson, G.
G. (1999). A reporter gene assay to assess the molecular mechanisms of xenobiotic- 
dependent induction of the human CYP3A4 gene in vitro. Xenobiotica 29, 269-279. 
Ourlin, J. C., Jounaidi, Y., Maurel, P., and Vilarem, M. J. (1997). Role of the liver- 
emiched transcription factors C/EBP alpha and DBP in the expression of human 
CYP3A4 and CYP3A7. Journal of Hepatology 26, 54-62.
Ozdemir, V., Kalow, W., Tang, B. K., Paterson, A. D., Walker, S. E., Endrenyi, L., 
and Kashuba, A. D. M. (2000). Evaluation of the genetic component of variability in 
CYP3A4 activity: a repeated drug administration method. Pharmacogenetics, 10, 373- 
388.
Paris, P. L., Kupelian, P. A., Hall, J, M., Williams, T. L., Levin, H., Klein, E. A., 
Casey, G., and Witte, J. S. (1999). Association between a CYP3A4 genetic variant and 
clinical presentation in African-American prostate cancer patients. Cancer Epidemiology, 
Biomarkers and Prevention 8 ,901-905.
Parker, R. (1974). Chapter 20: Cerenkov counting and other special topics. In Liquid 
Scintillation Counting, M. Crook, and P. Johnson, eds. (London, Heyden), pp. 237-251. 
Pascussi, J., Gerbal-Chaloiii, S., Fabre, J., Maurel, P., and MJ, V. (2000a). 
Dexamethasone enhances Constitutive Androstane Receptor expression in human
155
hepatocytes: Consequences on cytochrome P450 gene regulation. Molecular
Pharmacology 55, 1441-1450.
Pascussi, J. M., Drocourt, L., Fabre, J. M., Maurel, P., and Vilarem, M. J. (2000b). 
Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in 
human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor 
activators. Molecular Pharmacology 58, 361-372.
Pascussi, J. M., Drocourt, L., Gerbal-Chaloin, S., Fabre, J. M., Maurel, P., and 
Vilarem, M. J. (2001). Dual effect of dexamethasone on CYP3A4 gene expression in 
human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. 
European Journal of Biochemistry 268, 6346-6358.
Pascussi, J. M., Gerbal-Chaloin, S., Pichard-Garcia, L., Daujat, M., Fabre, J. M., 
Maurel, P., and Vilarem, M. J. (2000c). Interleukin-6 negatively regulates the 
expression of pregnane X receptor and constitutively activated receptor in primary human 
hepatocytes. Biochemical and Biophysical Research Communications 274, 707-713. 
Pascussi, J. M., Jounaidi, Y., Drocourt, L., Domergue, J., Balabaud, C., Maurel, P., 
and Vilarem, M. J. (1999). Evidence for the presence of a functional pregnane X 
receptor response element in the CYP3A7 promoter gene. Biochemical and Biophysical 
Research Communications 260, 377-381.
Pichard, L., Fabre, I., Fabre, G., Domergue, J., Saint Aubert, B., Mourad, G., and 
Maurel, P. (1990). Cyclosporin A drug interactions. Screening for inducers and 
inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human 
hepatocytes and in liver microsomes. Drug Metabolism and Disposition 18, 595-606. 
Plant, N. J., and Gibson, G. G. (2003). Evaluation of the toxicological relevance of 
CYP3A4 induction. Cunent Opinion in Drug Discovery and Development 6, 50-56.
Plant, N, J., Ogg, M., Crowder, M., and Gibson, G. G. (2000). Control and statistical 
analysis of in vitro reporter gene assays. Analytical Biochemistry 278, 170-174.
Qiu, Y., Tsai, S. Y., and Tsai, M. J. (1994). COUP-TF, an oiphan member of the 
steroid/thyroid hormone receptor superfamily. Trends in Endocrinology and Metabolism 
5, 234-239.
Quattrochi, L. €., and Guzelian, P. S. (2001). CYP3A regulation: from pharmacology 
to nuclear receptors. Drug Metabolism and Disposition 29, 615-622.
156
Quattrochi, L. C., Mills, A. S., Baiwick, J. L., Yockey, C., and Guzelian, P. S.
(1995). A novel cw-acting element in a liver cytochiome P450 3A gene confers 
synergistic induction of glucocorticoids and antiglucocorticoids. Journal of Biological 
Chemistry 270, 28917-28923.
Rae, J. M., Johnson, M. D., Lippman, M. E., and Flocldiart, D. A. (2001). Rifampin 
is a selective, pleitropic inducer of drug metabolism genes in human hepatocytes: studies 
with cDNA and oligonucleotides expression arrays. The Journal of Pharmacology and 
Experimental Therapeutics 299, 849-857.
Rebbecl(, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J., and Malkowicz, S. B.
(1998). Modification of clinical presentation of prostate tumors by a novel genetic variant 
in CYP3A4 [published eiTatum appears in J Natl Cancer Inst 1999 Jun 16;91(12):1082]. 
Journal of the National Cancer Institute 90, 1225-1229.
Rezai-Zadeh, N., Zhang, X., Namour, F., Fejer, G., Wen, Y. D., Yao, Y. L., Gyory,
I., Wright, K., and Seto, E. (2003). Tai'geted recruitment of a histone H4-specific 
methyltransferase by the transcription factor YYl. Genes and Development 17, 1019- 
1029.
Rivory, L., Qin, H., Clarke, S., Eris, J., Duggin, G., Ray, E., Trent, R., and Bishop,
J. (2000). Frequency of cytochrome P-450 3A4 variant genotype in transplant population 
and lack of association with cyclosporin clearance. European Journal of Clinical 
Pharmacology 56, 395-398.
Rodrigues, E., Vilarem, M. J., Ribeiro, V., Maurel, P., and Lechner, M. C. (2003). 
Two CCAAT/enhancer binding protein sites in the cytochrome P4503A1 locus. Euiopean 
Jouiml of Biochemistry 270, 556-564.
Rodriguez-Antona, C., Donato, M. T., Boobis, A., Edwards, R. J., Watts, P. S., 
Castell, J. V., and Gomez-Lechon, M. J. (2002). Cytoclirome P450 expression in 
human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower 
expression in cultured cells. Xenobiotica 32, 505-520.
Saito, T., Takahashi, Y., Hashimoto, H., and Kamataki, T. (2001). Novel 
Transcriptional Regulation of the Human CYP3A7 Gene by Spl and Sp3 through 
Nuclear Factor kappa B-like Element. Journal of Biological Chemistry 276, 38010- 
38022.
157
Sata, F., Sapone, A., Elizondo, G., Stocker, P., Miller, V. P., Zheng, W., Raunio, H., 
Crespi, C. L., and Gonzalez, F. J. (2000). CYP3A4 allelic variants with amino acid 
substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic 
activity. Clinical Pharmacology and Therapeutics 67,48-56.
Schmiedlin-Ren, P., Thummel, K. E., Fisher, J. M., Paine, M. F., Lown, K. S., and 
Watkins, P. B. (1997). Expression of enzymatically active CYP3A4 by Caco-2 cells 
grown on extracellular matiix-coated permeable supports in the presence of 1 alpha,25- 
dihydroxyvitamin D3. Molecular Pharmacology 51, 741-754.
Schmiedlin-Ren, P., Thummel, K. E., Fisher, J. M., Paine, M. F., and Watldns, P. B.
(2001). Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line- 
specific and is unlikely to involve pregnane X receptor. Drug Metabolism and 
Disposition: the Biological Fate of Chemicals 29, 1446-1453.
Schneider, R., Bannister, A. J., and Kouzarides, T. (2002). Unsafe SETs: histone 
lysine methyltransferases and cancer. Trends in Biochemical Sciences 27, 396-402. 
Schrem, H., Klempnauer, J., and Borlak, J. (2002). Liver-emiched transcription 
factors in liver function and development. Part I: the hepatocyte nuclear factor network 
and liver-specific gene expression. Pharmacological Reviews 54, 129-158.
Schuetz, E. G., and Guzelian, P. S. (1984). Induction of cytochrome P-450 by 
glucocorticoids in rat liver. II. Evidence that glucocorticoids regulate induction of 
cytochrome P-450 by a nonclassical receptor mechanism. Journal of Biological 
Chemistry 259, 2007-2012.
Schuetz, E. G., Schmid, W., Schütz, G., Brimer, C., Yasuda, K., Kamatald, T., 
Bornheim, L., Myles, K., and Cole, T, J. (2000). The glucocorticoid receptor is 
essential for induction of cytochrome P-4502B by steroids but not for drug or steroid 
induction of CYP3A or P-450 reductase in mouse liver. Drug Metabolism and 
Disposition 28, 268-278.
Schuetz, E. G., Schuetz, J. D., Strom, S. C., Thompson, M. T., Fisher, R, A., 
Molowa, D. T., Li, D., and Guzelian, P. S. (1993). Regulation of human liver 
cytochrome P450 in family 3 A in primary and continuous cultures of human hepatocytes. 
Hepatology 18, 1254-1262.
158
Shoii, M., Grogan, J., Mancewicz, J. A., Krausz, K. W., Gonzalez, F. J., Gelboin, H. 
V., and Korzelova, K. R. (1994). Activation of CYP3A4: evidence for the simultaneous 
binding of two substrates in a cytocluome P450 active site. Biochemistiy 33, 6450-6455. 
Smirlis, D., Muangmoonchai, R., Edwards, M., Phillips, I. R., and Shephard, E. A.
(2001). Orphan receptor promiscuity in the induction of cytocliromes p450 by 
xenobiotics. Journal of Biological Chemistry 276, 12822-12826.
Stafford, J. M., Wilkinson, J. C., Beechem, J. M., and Granner, D. K. (2001). 
Accessory factors facilitate the binding of glucocorticoid receptor to the 
phosphoenolpyruvate carboxykinase gene promoter. The Journal of Biological Chemistry 
276,39885-39891.
Staudinger, J. L., Goodwin, B., Jones, S. A., Hawldns-Brown, D., MacKenzie, K. I., 
LaTour, A., Liu, Y., Klaassen, C. D., Brown, K. K., Reinhard, J., et al. (2001). The 
nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. 
Proceedings of the National Academy of Sciences of the United States of America 98, 
3369-3374.
Stephens, T. D., Bunde, C. J., and Fillmore, B. J. (2000). Mechanism of action in 
thalidomide teratogenesis. Biochemical Pharmacology 59, 1489-1499.
Stoscheck, C. M. (1990). Quantitation of Proteins. Methods in Enzymology 182, 50-68. 
Sudarsanam, P., and Winston, F. (2000). The SWI/SNF family, nucleosome 
remodeling complexes and transcriptional control. Trends in Genetics 16, 345-351. 
Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakosld, P., and Negishi, M. (1999). The 
repressed nuclear receptor CAR responds to phénobarbital in activating the human 
CYP2B6 gene. Journal of Biological Chemistry 274, 6043-6046.
Surapiireddi, S., Yu, S., Bu, H., Hashimoto, T., Yeldandi, A. V., Kashireddy, P., 
Cherkaoui-Malki, M., Qi, C., Zhu, Y. J., Rao, M. S., and Reddy, J. K. (2002). 
Identification of a transcriptionally active peroxisome proliferator-activated receptor 
alpha -interacting cofactor complex in rat liver and characterization of PRIC285 as a 
coactivator. Proceedings of the National Academy of Sciences of the United States of 
America P9, 11836-11841.
Suske, G. (1999). The Sp-family of transcription factors. Gene 238, 291-300.
159
Synold, T. W., Dussault, I., and Forman, B. M. (2001). The orphan nuclear receptor 
SXR coordinately regulates drug metabolism and efflux. Nature Medicine 7, 584-590. 
Takahashi, Y., Suzuki, C., and Kainatald, T. (1998). Silencing of CYPlAl expression 
in rabbits by DNA méthylation. Biochemical and Biophysical Research Communications 
247, 383-386.
Takeshita, A., Taguchi, M., Koibuclii, N., and Ozawa, Y. (2002). Putative role of the 
oiphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of 
CYP3A4 inhibition by xenobiotics. The Journal of Biological Chemisti-y 277, 32453- 
32458.
Taylor, M. N. P., and Reide, P. J. W. (1998). Pharmacology, Mosby).
Telhada, M. B., Pereira, T. M., and Lechner, M. C. (1992). Effect of dexamethasone 
and phénobarbital on run-on transcription rate and CYP3A mRNA concentration in rat 
liver: changes during development. Archives of Biochemistry and Biophysics 298, 715- 
725.
Thummei, K, E., Brimer, C., Yasuda, K., Thottassery, J., Senn, T., Lin, Y., Ishizulm,
H., Kharasch, E., Schuetz, J., and Schuetz, E. (2001). Transcriptional control of 
intestinal cytochrome P-4503A by 1 alpha,25-dihydroxy vitamin D3. Molecular 
Pharmacology 60, 1399-1406.
Tirona, R. G., Lee, W., Leake, B. F., Lan, L. B., Brimer Cline, C., Lamba, V., 
Parviz, F., Duncan, S. A., Inoue, Y., Gonzalez, F. J., et al. (2003). The orphan nuclear 
receptor HNF4a determines PXR- and CAR- mediated xenobiotic induction of CYP3A4. 
Nature Medicine 9 ,220-224.
Tjian, R., and Maniatis, T. (1994). Transcriptional activation: a complex puzzle with 
few easy pieces. Cell 77, 5-8.
Turner, B. M. (2002). Cellular memory and the histone code. Cell 111, 285-291. 
von Moltke, L. L., Tran, T. H., Cotreau, M. M., and Greenblatt, D. J. (2000). 
Unusually low clearance of two CYP3A substrates, alprazolam and trazodone, in a 
volunteer subject with wild-type CYP3A4 promoter region. Journal of Clinical 
Pharmacology 40, 200-204.
160
Vosseii, C., and Erard, M. (2002). Down-regulation of nuclear receptor DNA-binding 
activity by nitric oxide - HNF4 as a possible model system. Medical Science Monitor 8, 
271-220.
Wan, Y. J., An, D., Cai, Y., Repa, J. J., Hung-Po Chen, T., Flores, M., Postic, C., 
Magnuson, M. A., Chen, J., Chien, K. R., et al. (2000). Hepatocyte-specific mutation 
establishes retinoid X receptor alpha as a heterodimeric integrator of multiple 
physiological processes in the liver. Molecular and Cellular Biology 20,4436-4444. 
Wang, N. D., Finegold, M. J., Bradley, A., On, C. N., Abdelsayed, S. V., Wilde, M. 
D., Taylor, L. R., Wilson, D. R., and Darlington, G. J. (1995). Impaired energy 
homeostasis in C/EBP alpha knockout mice. Science 269, 1108-1112.
Watkins, P. B., Wrighton, S. A., Maurel, P., Schuetz, E. G., Mendez-Picon, G., 
Parker, G. A., and Guzelian, P. S. (1985). Identification of an inducible form of 
cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences of 
the United States of America 82, 6310-6314.
Watkins, R. E., Maglich, J. M., Moore, L. B., Wisely, B., Noble, S. M., Davis-Searles, 
P., Lambert, M. H., Kliewer, S., and Redinbo, M. R. (2003). 2.1 A crystal structure of 
human PXR in complex with the Saint John's Wort compound hyperforin. Biochemistry 
42, 1430-1438.
Watldns, R. E., Wisely, G. B., Moore, L. B., Collins, J. L., Lambert, M. H., 
Williams, S. P., Willson, T. M., Kliewer, S. A., and Redinbo, M. R. (2001). The 
human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. 
Science 292, 2329-2333.
Waxman, D. J. (1999). P450 gene induction by structurally diverse xenochemicals: 
central role of nuclear receptors CAR, PXR, and PPAR. Archives of Biochemistry and 
Biophysics 369, 11-23.
Wei, P., Zhang, J., Egan-Hafley, M., Liang, S., and Moore, D. D. (2000). The nuclear 
receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 407, 
920-923.
Westlind, A., Lofberg, L., Tindbei-g, N., Andersson, T. B., and Ingelman-Sundberg,
M. (1999). Interindividual differences in hepatic expression of CYP3A4: relationship to
161
genetic polymorphism in the 5 -upstream regulatory region. Biochemical and Biophysical 
Research Communications 239, 201-205.
Williams, J. A., Cheneiy, R. J., Berkliout, T. A., and Hawlcsworth, G. M. (1997). 
Induction of cytochrome P450 3A by the antiglucocorticoid mifepristone and a novel 
hypocholesterolaemic drug. Drug Metabolism and Disposition 23, 757-761.
Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eclistein, J., Ruterbories, 
K., Hamman, M. A., Hall, S. D., and Wrighton, S. A. (2002). Comparative Metabolic 
Capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metabolism and Disposition: the 
Biological Fate of Chemicals 30, 883-891.
Wrighton, S. A., and Stevens, J. C. (1992). The human hepatic cytochromes P450 
involved in drug metabolism. Critical Reviews in Toxicology 22, 1-21.
Xanthopoulos, K. G., Prezioso, V. R., Chen, W. S., Sladek, F. M., Cortese, R., and 
Darnell, J. E. (1991). The different tissue transcription patterns of genes for HNF-1, 
C/EBP, HNF-3, and HNF-4, protein factors that govern liver-specific transcription. 
Proceedings of the National Academy of Sciences of the United States of America S8, 
3807-3811.
Xie, W., Barwick, J., Simon, C., Pierce, A., Safe, S., Blumberg, B., Guzelian, P., and 
Evans, R. (2000a). Reciprocal activation of Xenobiotic response genes by nuclear 
receptors SXR/PXR and CAR. Genes and Development 14, 3014-3023.
Xie, W., Baiivick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., 
Neuschwander-Tetri, B. A., Brunt, E. M., Guzelian, P. S., and Evans, R. M. (2000b). 
Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406, 
435-439.
Xie, W., Radominska-Pandya, A., Shi, ¥., Simon, C. M., Nelson, M. C., Ong, E. S., 
Waxman, D. J., and Evans, R. M. (2001). An essential role for nuclear receptors 
SXR/PXR in detoxification of cholestatic bile acids. Proceedings of the National 
Academy of Sciences of the United States of America 98, 3375-3380.
Zhang, J., Kuehl, P., Green, E. D., Touchman, J. W., Watkins, P. B., Daly, A., Hall, 
S. D., Maurel, P., Relling, M., Brimer, C., et al. (2001). The human pregnane X 
receptor: genomic structure and identification and functional characterization of natural 
allelic variants. Pharmacogenetics 11, 555-572.
162
Zhang, Y., and Reinberg, D. (2001). Transcription regulation by histone méthylation: 
interplay between different covalent modifications of the core histone tails. Genes and 
Development 15, 2343-2360.
163
